PFE


Line plots across dimensions of each concept
Line plots across concepts
Tables

Table of contents



us-gaap:CommonStockValue
us-gaap:StatementEquityComponents
us-gaap:SharesIssued

us-gaap:CommonStockSharesIssued

us-gaap:PreferredStockSharesIssued

us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

us-gaap:WeightedAverageNumberOfSharesOutstandingBasic

us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

us-gaap:EarningsPerShareBasic
us-gaap:Restatement

us-gaap:EarningsPerShareDiluted
us-gaap:Restatement

us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
us-gaap:Restatement

us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
us-gaap:Restatement

us-gaap:ComprehensiveIncomeNetOfTax

us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest

us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest

us-gaap:CostOfGoodsAndServicesSold
us-gaap:EquityMethodInvestmentNonconsolidatedInvestee
us-gaap:CostOfRevenue
us-gaap:LongtermDebtType
us-gaap:GainsLossesOnExtinguishmentOfDebt
us-gaap:EquityMethodInvestmentNonconsolidatedInvestee
us-gaap:GrossProfit

us-gaap:IncomeLossFromContinuingOperations

us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
pfe:OtherSegmentReconcilingItems, us-gaap:ConsolidationItems
us-gaap:ConsolidationItems
us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments
us-gaap:Restatement

us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

us-gaap:IncomeTaxExpenseBenefit
us-gaap:Restatement

us-gaap:IncomeTaxesPaidNet

us-gaap:InterestExpense

us-gaap:InterestPaidNet

us-gaap:NetIncomeLoss
us-gaap:EquityMethodInvestmentNonconsolidatedInvestee
us-gaap:Restatement

us-gaap:NetIncomeLossAttributableToNoncontrollingInterest

us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic

us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted

us-gaap:OtherComprehensiveIncomeLossNetOfTax
us-gaap:StatementEquityComponents

us-gaap:OtherNonoperatingIncomeExpense
us-gaap:Restatement

us-gaap:ProfitLoss
us-gaap:EquityMethodInvestmentNonconsolidatedInvestee
us-gaap:Restatement
us-gaap:StatementEquityComponents

us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ConsolidationItems
us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments
us-gaap:Currency, us-gaap:StatementGeographical
us-gaap:ProductOrService
us-gaap:ProductOrService, us-gaap:ReportingUnit
us-gaap:ProductOrService, us-gaap:ReportingUnit, us-gaap:StatementBusinessSegments
us-gaap:ProductOrService, us-gaap:StatementBusinessSegments
us-gaap:ReportingUnit
us-gaap:ReportingUnit, us-gaap:StatementBusinessSegments
us-gaap:StatementBusinessSegments
us-gaap:StatementGeographical
us-gaap:EquityMethodInvestmentNonconsolidatedInvestee
us-gaap:Revenues

us-gaap:SellingGeneralAndAdministrativeExpense

us-gaap:Assets
us-gaap:EquityMethodInvestmentNonconsolidatedInvestee
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:FairValueByMeasurementFrequency
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

us-gaap:Liabilities
us-gaap:EquityMethodInvestmentNonconsolidatedInvestee
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

us-gaap:LiabilitiesAndStockholdersEquity

us-gaap:StockholdersEquity
us-gaap:EquityMethodInvestmentNonconsolidatedInvestee
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:EquityMethodInvestmentNonconsolidatedInvestee
us-gaap:StatementEquityComponents

us-gaap:AssetsCurrent
us-gaap:EquityMethodInvestmentNonconsolidatedInvestee
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

us-gaap:CashAndCashEquivalentsAtCarryingValue

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

us-gaap:ShortTermInvestments

us-gaap:AccountsReceivableNetCurrent

us-gaap:InventoryNet

us-gaap:OtherAssetsCurrent
us-gaap:EquityMethodInvestmentNonconsolidatedInvestee
us-gaap:AssetsNoncurrent
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

us-gaap:PropertyPlantAndEquipmentGross
us-gaap:PropertyPlantAndEquipmentByType

us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
us-gaap:FiniteLivedIntangibleAssetsByMajorClass
us-gaap:AmortizationOfIntangibleAssets

us-gaap:PropertyPlantAndEquipmentNet
us-gaap:StatementGeographical

us-gaap:LongTermInvestments

us-gaap:Goodwill
us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments

us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
us-gaap:IndefiniteLivedIntangibleAssetsByMajorClass

us-gaap:IntangibleAssetsNetExcludingGoodwill

us-gaap:FiniteLivedIntangibleAssetsNet
us-gaap:FiniteLivedIntangibleAssetsByMajorClass

us-gaap:OperatingLeaseRightOfUseAsset

us-gaap:OtherAssetsNoncurrent
us-gaap:BalanceSheetLocation, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:BalanceSheetLocation, us-gaap:FairValueByMeasurementFrequency
us-gaap:Restatement

us-gaap:EquitySecuritiesFvNi
us-gaap:BalanceSheetLocation, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:BalanceSheetLocation, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument
us-gaap:BalanceSheetLocation, us-gaap:FairValueByMeasurementFrequency
us-gaap:BalanceSheetLocation, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

us-gaap:AccountsPayableCurrent

us-gaap:ContractWithCustomerLiabilityCurrent
us-gaap:MajorCustomers, us-gaap:ProductOrService

us-gaap:DebtCurrent

us-gaap:DividendsPayableCurrent

us-gaap:LiabilitiesCurrent
us-gaap:EquityMethodInvestmentNonconsolidatedInvestee
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

us-gaap:LongTermDebtCurrent
us-gaap:LongtermDebtType

us-gaap:OperatingLeaseLiabilityCurrent

us-gaap:OtherLiabilitiesCurrent
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement

us-gaap:TaxesPayableCurrent
us-gaap:EquityMethodInvestmentNonconsolidatedInvestee
us-gaap:LiabilitiesNoncurrent
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

us-gaap:LongTermDebt
us-gaap:DebtInstrument, us-gaap:LongtermDebtType
us-gaap:DerivativeInstrumentRisk
us-gaap:LongtermDebtType

us-gaap:LongTermDebtNoncurrent
us-gaap:LongtermDebtType

us-gaap:DeferredIncomeTaxLiabilitiesNet
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType

us-gaap:MinorityInterest
us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

us-gaap:OtherLiabilitiesNoncurrent

us-gaap:OperatingLeaseLiabilityNoncurrent

us-gaap:OperatingLeaseLiability

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue

us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

us-gaap:StockholdersEquity
us-gaap:EquityMethodInvestmentNonconsolidatedInvestee
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:EquityMethodInvestmentNonconsolidatedInvestee
us-gaap:StatementEquityComponents

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
us-gaap:EquityMethodInvestmentNonconsolidatedInvestee
us-gaap:StatementEquityComponents

us-gaap:CommonStockValue

us-gaap:AdditionalPaidInCapital

us-gaap:RetainedEarningsAccumulatedDeficit
us-gaap:DisposalGroupClassification, us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperations
us-gaap:Restatement

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
us-gaap:Restatement

us-gaap:TreasuryStockValue

us-gaap:MinorityInterest
us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
us-gaap:StatementEquityComponents

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

us-gaap:DeferredIncomeTaxExpenseBenefit
us-gaap:Restatement

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetIncomeLoss
us-gaap:EquityMethodInvestmentNonconsolidatedInvestee
us-gaap:Restatement

us-gaap:ProfitLoss
us-gaap:EquityMethodInvestmentNonconsolidatedInvestee
us-gaap:Restatement
us-gaap:StatementEquityComponents

us-gaap:ShareBasedCompensation

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:ProceedsFromIssuanceOfLongTermDebt
dei:LegalEntity, us-gaap:ConsolidatedEntities

us-gaap:RepaymentsOfLongTermDebt

us-gaap:EffectiveIncomeTaxRateContinuingOperations

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

us-gaap:DeferredTaxLiabilities
us-gaap:BalanceSheetLocation

us-gaap:DeferredTaxAssetsNet

us-gaap:UnrecognizedTaxBenefits
us-gaap:BalanceSheetLocation

us-gaap:DeferredTaxAssetsValuationAllowance

pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction

pfe:AssetWriteOffsAndAssetImpairmentCharges

pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
pfe:CollaborativeArrangementMilestonePaymentUponCommercializing
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
pfe:CollaborativeArrangementUpfrontAndMilestonePayments

pfe:DeconsolidationGainLossAmountNetOfCashConveyed

pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax

pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization
us-gaap:DisposalGroupClassification
pfe:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:IncomeStatementLocation
pfe:EquityMethodInvestmentExcessBasisAmortizationAndWriteOff
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName
pfe:EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation

pfe:ImplementationCosts
us-gaap:IncomeStatementLocation

pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights

pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic

pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted

pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization

pfe:InterestPaidReceivedInterestRateHedges

pfe:InterestReceivedInterestRateHedges
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:TypeOfArrangement
pfe:InvestmentOwnershipPercentage
us-gaap:CounterpartyName, us-gaap:FiniteLivedIntangibleAssetsByMajorClass
pfe:LicensingArrangementValueOfSharesPurchased
us-gaap:CounterpartyName, us-gaap:FiniteLivedIntangibleAssetsByMajorClass, us-gaap:SubsequentEventType
us-gaap:DisposalGroupClassification, us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperations
pfe:OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax
us-gaap:DerivativeInstrumentRisk, us-gaap:HedgingDesignation
pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
us-gaap:IncomeStatementLocation
pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax

pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax
us-gaap:IncomeStatementLocation
pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax

pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax

pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax

pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax

pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax

pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
us-gaap:Restatement

pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
us-gaap:Restatement

pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax

pfe:OtherNonoperatingIncomeExpenseNet
us-gaap:StatementScenario, us-gaap:SubsequentEventType
pfe:PaymentForRepatriationTax
us-gaap:SubsequentEventType
us-gaap:CounterpartyName
pfe:PaymentPursuantToTermsOfSeparationAgreementFinancingActivities

pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess

pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
us-gaap:RestructuringCostAndReserve

pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
us-gaap:Restatement

pfe:PercentageChangeInRevenue
us-gaap:StatementGeographical
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
pfe:PrepaymentsandPaymentstoCollaborators
us-gaap:CounterpartyName, us-gaap:FiniteLivedIntangibleAssetsByMajorClass
pfe:ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage

pfe:RestructuringAssetImpairmentCharges

pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts

pfe:RestructuringChargesAndAcquisitionRelatedCosts
us-gaap:RestructuringCostAndReserve, us-gaap:RestructuringPlan
pfe:RestructuringandRelatedCostNoncashChargesPercentage
us-gaap:StatementEquityComponents
pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock

pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
us-gaap:StatementEquityComponents

us-gaap:AssetImpairmentCharges
us-gaap:BusinessAcquisition
us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1

us-gaap:BusinessCombinationIntegrationRelatedCosts
us-gaap:BusinessAcquisition
us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles
us-gaap:BusinessAcquisition, us-gaap:FiniteLivedIntangibleAssetsByMajorClass

us-gaap:BusinessExitCosts1
us-gaap:DisposalGroupClassification, us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperations
us-gaap:CashDivestedFromDeconsolidation

us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
us-gaap:DerivativeInstrumentRisk, us-gaap:HedgingDesignation, us-gaap:IncomeStatementLocation
us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
us-gaap:DerivativeInstrumentRisk, us-gaap:HedgingDesignation, us-gaap:IncomeStatementLocation
us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1

us-gaap:CommonStockDividendsPerShareDeclared
us-gaap:MajorCustomers, us-gaap:ProductOrService, us-gaap:ConcentrationRiskByBenchmark, us-gaap:ConcentrationRiskByType
us-gaap:ConcentrationRiskPercentage1
us-gaap:ProductOrService, us-gaap:ConcentrationRiskByBenchmark, us-gaap:ConcentrationRiskByType
us-gaap:MajorCustomers, us-gaap:ProductOrService
us-gaap:ContractWithCustomerLiabilityRevenueRecognized

us-gaap:DeconsolidationGainOrLossAmount
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType

us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax

us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanContributionsByEmployer
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanInterestCost
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:IncomeStatementLocation
us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanServiceCost
us-gaap:RetirementPlanType
us-gaap:IncomeStatementLocation
us-gaap:DerivativeGainLossOnDerivativeNet
us-gaap:DerivativeInstrumentRisk, us-gaap:HedgingDesignation, us-gaap:IncomeStatementLocation
us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
us-gaap:DisposalGroupClassification
us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
us-gaap:DisposalGroupClassification
us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
us-gaap:DisposalGroupClassification
us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
us-gaap:DisposalGroupClassification
us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
us-gaap:DisposalGroupClassification
us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
us-gaap:DisposalGroupClassification
us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue

us-gaap:DividendsCommonStockCash
us-gaap:StatementEquityComponents

us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName
us-gaap:EquityMethodInvestmentDividendsOrDistributions

us-gaap:EquitySecuritiesFvNiGainLoss
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName

us-gaap:EquitySecuritiesFvNiRealizedGainLoss

us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName
us-gaap:BusinessAcquisition, us-gaap:FiniteLivedIntangibleAssetsByMajorClass
us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:FiniteLivedIntangibleAssetsByMajorClass
us-gaap:ProductOrService, us-gaap:FiniteLivedIntangibleAssetsByMajorClass
dei:LegalEntity, us-gaap:ConsolidatedEntities
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax

us-gaap:GainLossOnDispositionOfAssets1

us-gaap:GainLossRelatedToLitigationSettlement
us-gaap:ProductOrService

us-gaap:GoodwillForeignCurrencyTranslationGainLoss

us-gaap:GoodwillPurchaseAccountingAdjustments

us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit

us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill

us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
us-gaap:DisposalGroupClassification
us-gaap:Restatement

us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName
us-gaap:IncomeLossFromEquityMethodInvestments
us-gaap:MajorCustomers, us-gaap:ProductOrService, us-gaap:SubsequentEventType
us-gaap:IncreaseDecreaseInContractWithCustomerLiability

us-gaap:IncreaseDecreaseInOperatingCapital
us-gaap:BusinessAcquisition, us-gaap:IndefiniteLivedIntangibleAssetsByMajorClass
us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
us-gaap:ProductOrService, us-gaap:IndefiniteLivedIntangibleAssetsByMajorClass

us-gaap:InterestRevenueExpenseNet
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName
us-gaap:InvestmentIncomeDividend

us-gaap:InvestmentIncomeInterest

us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent

us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax

us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest

us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax

us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax

us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax

us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax

us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax

us-gaap:OtherComprehensiveIncomeLossBeforeTax

us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax

us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax

us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
us-gaap:DerivativeInstrumentRisk, us-gaap:HedgingDesignation

us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax

us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
us-gaap:DerivativeInstrumentRisk, us-gaap:HedgingDesignation, us-gaap:IncomeStatementLocation

us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
us-gaap:DerivativeInstrumentRisk, us-gaap:DerivativeInstrumentsGainLossByHedgingRelationship, us-gaap:HedgingDesignation, us-gaap:IncomeStatementLocation
us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
us-gaap:DerivativeInstrumentRisk, us-gaap:DerivativeInstrumentsGainLossByHedgingRelationship, us-gaap:HedgingDesignation
us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax

us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
us-gaap:Restatement
us-gaap:DisposalGroupClassification, us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperations
us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax

us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
us-gaap:DerivativeInstrumentRisk, us-gaap:HedgingDesignation
us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
us-gaap:StatementEquityComponents
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect

us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
us-gaap:Restatement

us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax

us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax

us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
us-gaap:Restatement

us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax
us-gaap:DisposalGroupClassification, us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperations
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax

us-gaap:OtherComprehensiveIncomeLossTax
us-gaap:Restatement

us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax

us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax

us-gaap:OtherNoncashIncomeExpense

us-gaap:PaymentsForProceedsFromOtherInvestingActivities

us-gaap:PaymentsOfOrdinaryDividends

us-gaap:PaymentsToAcquireIntangibleAssets

us-gaap:PaymentsToAcquireMarketableSecurities

us-gaap:PaymentsToAcquireShortTermInvestments
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
us-gaap:ProceedsFromCollaborators

us-gaap:ProceedsFromPaymentsForOtherFinancingActivities

us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess

us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments

us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments

us-gaap:ProceedsFromShortTermDebt

us-gaap:ProceedsFromStockOptionsExercised

us-gaap:RepaymentsOfShortTermDebt
us-gaap:RestructuringPlan
us-gaap:RestructuringAndRelatedCostIncurredCost

us-gaap:RestructuringCharges
us-gaap:ConsolidationItems
us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments
us-gaap:RestructuringCostAndReserve

us-gaap:RestructuringReserveAcceleratedDepreciation
us-gaap:IncomeStatementLocation

us-gaap:RoyaltyIncomeNonoperating

us-gaap:SeveranceCosts1
us-gaap:StatementEquityComponents
us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation

us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
us-gaap:StatementEquityComponents

us-gaap:StockholdersEquityOther
us-gaap:StatementEquityComponents

us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
us-gaap:BalanceSheetLocation
pfe:AccruedRebates
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:TypeOfArrangement
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
pfe:CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
pfe:CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo
us-gaap:LongtermDebtType
pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting

pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain

pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss

pfe:DebtSecuritiesAmortizedCostBasis

pfe:DebtSecuritiesMaturitiesAfterYearFiveFairValue

pfe:DebtSecuritiesMaturitiesNextTwelveMonthsFairValue

pfe:DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue

pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits
us-gaap:BalanceSheetLocation

pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
us-gaap:Restatement

pfe:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards

pfe:DeferredTaxAssetsStateandLocalTaxesAdjustments

pfe:DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves

pfe:DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits

pfe:DerivativeNetReceivablePositionAggregateFairValue

pfe:EquitySecuritiesFVNINoncurrent
us-gaap:FairValueByMeasurementFrequency
pfe:EquitySecuritiesFVNIRestrictedNoncurrent

pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount

pfe:HeldToMaturityCashEquivalents
us-gaap:FinancialInstrument
pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue

pfe:IntangibleAssetsFairValueDisclosure
us-gaap:FairValueByFairValueHierarchyLevel
us-gaap:ConsolidationItems, us-gaap:FiniteLivedIntangibleAssetsByMajorClass, us-gaap:StatementBusinessSegments
pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
us-gaap:ConsolidationItems, us-gaap:FiniteLivedIntangibleAssetsByMajorClass, us-gaap:Subsegments
us-gaap:ConsolidationItems, us-gaap:IndefiniteLivedIntangibleAssetsByMajorClass, us-gaap:StatementBusinessSegments
us-gaap:ConsolidationItems, us-gaap:IndefiniteLivedIntangibleAssetsByMajorClass, us-gaap:Subsegments
us-gaap:CreditFacility
pfe:LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear

pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting
us-gaap:BalanceSheetLocation, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
us-gaap:BalanceSheetLocation, us-gaap:FairValueByMeasurementFrequency
us-gaap:BalanceSheetLocation
pfe:OtherAccruals

pfe:OtherTaxAssetsCurrent

pfe:PrivateEquityInvestments

pfe:RebatesAndDiscountsAccrual
us-gaap:BalanceSheetLocation

pfe:RebatesAndOtherSalesRelatedAccruals
us-gaap:BalanceSheetLocation
us-gaap:AwardType
pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice
us-gaap:AwardType
pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest
us-gaap:AwardType
pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber
us-gaap:AwardType
pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice
us-gaap:AwardType
pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice
us-gaap:AwardType
pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice
us-gaap:AwardType
pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares

pfe:ShorttermDebtGross
us-gaap:BalanceSheetLocation, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
us-gaap:BalanceSheetLocation, us-gaap:FairValueByMeasurementFrequency

pfe:UnrecognizedTaxBenefitsExcludingInterest

us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent

us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
us-gaap:DisposalGroupClassification
us-gaap:FinancialInstrument
us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
us-gaap:FinancialInstrument
us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
us-gaap:FinancialInstrument
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
us-gaap:FinancialInstrument
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
us-gaap:FinancialInstrument
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue

us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent

us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

us-gaap:BusinessCombinationContingentConsiderationLiability

us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent

us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent

us-gaap:CollateralAlreadyPostedAggregateFairValue

us-gaap:CommercialPaper
us-gaap:DebtInstrument, us-gaap:LongtermDebtType
us-gaap:DebtInstrumentCarryingAmount
us-gaap:LongtermDebtType

us-gaap:DebtInstrumentInterestRateEffectivePercentage
dei:LegalEntity, us-gaap:ConsolidatedEntities
us-gaap:ConsolidatedEntities
us-gaap:LongtermDebtType
us-gaap:DebtInstrument, us-gaap:LongtermDebtType
us-gaap:DebtInstrumentRepurchaseAmount

us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
us-gaap:LongtermDebtType

us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity
us-gaap:DebtInstrument, us-gaap:LongtermDebtType
us-gaap:DebtWeightedAverageInterestRate
us-gaap:LongtermDebtType

us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible

us-gaap:DeferredIncomeTaxLiabilities

us-gaap:DeferredTaxAssetsEquityMethodInvestments

us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets

us-gaap:DeferredTaxAssetsGross

us-gaap:DeferredTaxAssetsInventory

us-gaap:DeferredTaxAssetsOther

us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment

us-gaap:DeferredTaxAssetsTaxDeferredExpense

us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits

us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges

us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts

us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets

us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates

us-gaap:DeferredTaxLiabilitiesOther

us-gaap:DeferredTaxLiabilitiesPrepaidExpenses

us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment

us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings

us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
us-gaap:Restatement
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanBenefitObligation
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanFundedStatusOfPlan
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1
us-gaap:DefinedBenefitPlanByPlanAssetCategories, us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
us-gaap:DefinedBenefitPlanByPlanAssetCategories, us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType

us-gaap:DerivativeAssets
us-gaap:DerivativeInstrumentRisk, us-gaap:HedgingDesignation
us-gaap:HedgingDesignation
us-gaap:BalanceSheetLocation, us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:DerivativeAssetsCurrent
us-gaap:BalanceSheetLocation, us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByMeasurementFrequency
us-gaap:BalanceSheetLocation, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:BalanceSheetLocation, us-gaap:FairValueByMeasurementFrequency
us-gaap:BalanceSheetLocation, us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:DerivativeAssetsNoncurrent
us-gaap:BalanceSheetLocation, us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByMeasurementFrequency
us-gaap:BalanceSheetLocation, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:BalanceSheetLocation, us-gaap:FairValueByMeasurementFrequency

us-gaap:DerivativeLiabilities
us-gaap:BalanceSheetLocation, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:BalanceSheetLocation, us-gaap:FairValueByMeasurementFrequency
us-gaap:DerivativeInstrumentRisk, us-gaap:HedgingDesignation
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:FairValueByMeasurementFrequency
us-gaap:HedgingDesignation
us-gaap:BalanceSheetLocation, us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:DerivativeLiabilitiesCurrent
us-gaap:BalanceSheetLocation, us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByMeasurementFrequency
us-gaap:BalanceSheetLocation, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:BalanceSheetLocation, us-gaap:FairValueByMeasurementFrequency
us-gaap:BalanceSheetLocation, us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:DerivativeLiabilitiesNoncurrent
us-gaap:BalanceSheetLocation, us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByMeasurementFrequency
us-gaap:BalanceSheetLocation, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:BalanceSheetLocation, us-gaap:FairValueByMeasurementFrequency

us-gaap:DerivativeNetLiabilityPositionAggregateFairValue
pfe:HedgedItem, us-gaap:DerivativeInstrumentRisk, us-gaap:HedgingDesignation
us-gaap:DerivativeNotionalAmount
us-gaap:DerivativeInstrumentRisk, us-gaap:HedgingDesignation
us-gaap:CounterpartyName, us-gaap:DisposalGroupClassification, us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperations
us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
us-gaap:DisposalGroupClassification
us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
us-gaap:DisposalGroupClassification
us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets

us-gaap:EmployeeRelatedLiabilitiesCurrent
us-gaap:AwardType
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
us-gaap:AwardType
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName
us-gaap:EquityMethodInvestmentOwnershipPercentage

us-gaap:EquityMethodInvestments
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName

us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount

us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
us-gaap:FiniteLivedIntangibleAssetsByMajorClass

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FiniteLivedIntangibleAssetsByMajorClass
us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure
us-gaap:FiniteLivedIntangibleAssetsByMajorClass

us-gaap:FiniteLivedIntangibleAssetsGross
us-gaap:CounterpartyName, us-gaap:FiniteLivedIntangibleAssetsByMajorClass, us-gaap:TypeOfArrangement
us-gaap:FiniteLivedIntangibleAssetsByMajorClass

us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months
us-gaap:BalanceSheetLocation
us-gaap:HedgedAssetFairValueHedge
us-gaap:BalanceSheetLocation
us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
us-gaap:BalanceSheetLocation
us-gaap:HedgedLiabilityFairValueHedge
us-gaap:BalanceSheetLocation
us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
us-gaap:FinancialInstrument
us-gaap:HeldToMaturitySecurities

us-gaap:HeldToMaturitySecuritiesCurrent
us-gaap:FinancialInstrument
us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
us-gaap:FinancialInstrument
us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
us-gaap:FinancialInstrument
us-gaap:HeldToMaturitySecuritiesFairValue

us-gaap:HeldToMaturitySecuritiesNoncurrent
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:IndefiniteLivedIntangibleAssetsByMajorClass
us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure
us-gaap:IndefiniteLivedIntangibleAssetsByMajorClass

us-gaap:IntangibleAssetsGrossExcludingGoodwill

us-gaap:InventoryFinishedGoodsNetOfReserves

us-gaap:InventoryNoncurrent

us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves

us-gaap:InventoryWorkInProcessNetOfReserves

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths

us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
us-gaap:BalanceSheetLocation, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
us-gaap:BalanceSheetLocation, us-gaap:FairValueByMeasurementFrequency
us-gaap:CreditFacility
us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
us-gaap:CreditFacility, us-gaap:ShortTermDebtType
us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementBasis
us-gaap:LongTermDebtFairValue
us-gaap:FairValueByMeasurementBasis
dei:LegalEntity, us-gaap:Ownership
us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
dei:LegalEntity, us-gaap:Ownership, us-gaap:StatementScenario, us-gaap:SubsequentEventType
us-gaap:Ownership
us-gaap:MinorityInterestOwnershipPercentageByParent
us-gaap:Ownership, us-gaap:StatementScenario, us-gaap:SubsequentEventType
us-gaap:CounterpartyName
us-gaap:NontradeReceivablesCurrent

us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
us-gaap:LongtermDebtType
us-gaap:OtherLongTermDebt

us-gaap:OtherLongTermInvestments

us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent

us-gaap:OtherShortTermBorrowings

us-gaap:OtherShortTermInvestments
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType
us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanType

us-gaap:RestrictedInvestmentsCurrent
us-gaap:RestructuringPlan
us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
us-gaap:RestructuringCostAndReserve, us-gaap:RestructuringPlan
us-gaap:RestructuringAndRelatedCostExpectedCost1
us-gaap:RestructuringPlan

us-gaap:RestructuringReserve
us-gaap:BalanceSheetLocation
us-gaap:RestructuringCostAndReserve

us-gaap:SecuritiesReceivedAsCollateral
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
us-gaap:AwardType
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
us-gaap:ShortTermDebtType
us-gaap:ShortTermDebtWeightedAverageInterestRate

us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

us-gaap:TreasuryStockShares

us-gaap:UndistributedEarningsOfForeignSubsidiaries

us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
us-gaap:BalanceSheetLocation

Plots across concepts


IncomeStatement
Other Comprehensive Income Loss Net Of Tax
Expenses
Interest Expense
Balance Sheet
Operating Lease Right Of Use Asset
Assets
Derivative Assets
Current Assets
Cash And Cash Equivalents At Carrying Value
NonCurrent Assets
Operating Lease Right Of Use Asset
PropertyPlantAndEquipmentNet
Property Plant And Equipment Net
Liabilities
Derivative Liabilities
Current Liabilities
Operating Lease Liability Current
Noncurrent Liabilities
Minority Interest
Stockholders Equity
Accumulated Other Comprehensive Income Loss Net Of Tax
Per Share
Common Stock Dividends Per Share Declared
CashFlow
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInOperatingActivities
Share Based Compensation
NetCashProvidedByUsedInInvestingActivities
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInFinancingActivities
Proceeds From Issuance Of Long Term Debt
Shares
Treasury Stock Shares
OperatingLeaseLiability
Operating Lease Liability Current
LesseeOperatingLeaseLiabilityPaymentsDue
Lessee Operating Lease Liability Undiscounted Excess Amount
FiniteLivedIntangibleAssets
Finite Lived Intangible Assets Net
InventoryNet
Inventory Finished Goods Net Of Reserves
AccountsReceivable
Allowance For Doubtful Accounts Receivable Current

Tables

  2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
us-gaap:CommonStockValue ██████▇▇▇▇▇▆▆▆▆▆▆▆▅▅▅▅▅▅▄▄▄▄▄▄▃▃▃▂▂▂▂▂▁▁▁▁472.0472.0470.0470.0470.0470.0468.0468.0468.0468.0467.0466.0465.0465.0464.0463.0463.0463.0461.0461.0461.0460.0459.0459.0458.0458.0455.0455.0454.0454.0453.0452.0451.0450.0448.0447.0447.0446.0445.0445.0445.0444.0NANANA
 us-gaap:SharesIssued us-gaap:StatementEquityComponents us-gaap:CommonStock██▆▆▆▆▅▅▅▄▃▃▂▂▁9450.09445.09407.09397.09394.09393.09369.09366.09363.09358.09332.09326.09303.09299.09275.0NANANA9230.0NANANA9178.0NANANA9110.0NANANA9051.0NANANA8956.0NANANA8902.0NANANANANANA
 us-gaap:SharesIssued us-gaap:StatementEquityComponents us-gaap:TreasuryStock███████▁▁██▁▁█▇3851.03851.03840.03840.03840.03841.03835.0-3835.0-3801.03801.03615.0-3484.0-3438.03437.03296.0NANANA3160.0NANANA3003.0NANANA-2819.0NANANA2652.0NANANA-1680.0NANANA-1327.0NANANANANANA
us-gaap:CommonStockSharesIssued NANA9407.0NANANA9369.0NANANA9332.0NANANA9275.0NANANA9230.0NANANA9178.0NANANA9110.0NANANA9051.0NANANA8956.0NANANA8902.0NANANANANANA
us-gaap:PreferredStockSharesIssued NANA0.0NANANA0.000431NANANA0.000478NANANA0.000524NANANA0.000597NANANA0.000649NANANA0.000717NANANA0.000829NANANA0.000967NANANA0.001112NANANANANANA
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding █▁5678.05662.0NA5633.05619.05613.0NA5649.05672.05750.0NA5986.05952.06057.0NA6041.06037.06092.0NA6138.06137.06214.0NA6243.06243.06292.0NA6403.06444.06476.0NA6656.07117.07269.0NA7508.07537.07598.0NA7810.07935.08035.08057.08072.08101.0
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic █▁5598.05584.0NA5557.05554.05545.0NA5545.05562.05635.0NA5875.05866.05957.0NA5951.05958.06006.0NA6066.06068.06150.0NA6168.06159.06203.0NA6330.06368.06389.0NA6581.07042.07187.0NA7436.07476.07537.0NA7770.07875.07982.08027.08046.08061.0
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount █▁5.02.0NA7.06.03.0NA3.01.0NANANANANANANANANANANANANANANANANANANA44.043.0NA43.044.097.0NA180.0216.0223.0NA342.0280.0290.0419.0427.0366.0
us-gaap:EarningsPerShareBasic ▄▄▂▂▃▃▁▆▄▃▁▄▃▃█▃▃▃▂▂▂▃▁▂▃▂▂▃▃▂▃▂█▂▄▃▃▂▂▃▂▂▂▂▂0.990.870.109999999999999880.390.620.61-0.060000000000000051.380.910.69-0.060000000000000050.70.660.62.05999999999999960.480.520.520.13999999999999990.220.330.49-0.0200000000000000180.350.430.380.199999999999999960.420.460.360.430000000000000160.392.00.380.85999999999999990.430.440.240.189999999999999950.480.330.280.110.310.25
 us-gaap:EarningsPerShareBasic us-gaap:Restatement pfe:ScenarioPreviousAccountingPrinciple█▁0.980.85NANA0.620.61NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:EarningsPerShareDiluted ▄▄▂▂▃▃▁▆▄▃▁▃▃▃█▃▃▃▂▂▂▃▁▂▃▂▂▃▃▂▃▂█▂▄▃▃▂▂▃▂▂▂▂▂0.980.860.109999999999999880.390.610.61-0.049999999999999821.360.890.68-0.049999999999999820.690.650.592.03000000000000020.470.510.510.13999999999999990.210.330.49-0.0299999999999998050.340.420.380.189999999999999950.420.450.360.419999999999999930.391.980.380.84999999999999990.430.430.240.189999999999999950.480.330.280.110.310.25
 us-gaap:EarningsPerShareDiluted us-gaap:Restatement pfe:ScenarioPreviousAccountingPrinciple█▁0.970.84NANA0.610.61NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare ▅▅▁▃▄▄▂▆▅▄▂▄▄▄█▃▄▄▂▃▃▃▂▃▃▃▃▃▃▃▃▃▄▃▃▃▃▃▃▃▃▃▂▃▃9.9e-078.7e-07-3.600000000000001e-073.9e-076.2e-076.1e-07-6.000000000000005e-081.38e-069.100000000000001e-076.9e-07-6.000000000000005e-087e-076.6e-076e-072.0599999999999998e-064.8e-075.2e-075.2e-071.399999999999999e-072.2e-073.3e-074.9e-07-2.0000000000000017e-083.4000000000000003e-074.3e-073.8e-071.9999999999999996e-074.2e-074.6000000000000004e-073.5e-074.0999999999999994e-073.9e-075.1e-073.8e-071.9999999999999996e-074.2e-074.3e-072.4e-071.9000000000000006e-073.1e-073.3e-072.8e-071.1e-073e-072.5e-07
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare ▅▅▁▃▄▄▂▆▅▄▂▄▄▄█▃▄▄▂▃▃▃▂▃▃▃▃▃▃▃▃▃▄▃▃▃▃▃▃▃▃▃▂▃▃9.8e-078.6e-07-3.600000000000001e-073.9e-076.1e-076.1e-07-4.999999999999982e-081.3600000000000001e-068.900000000000001e-076.800000000000001e-07-5.999999999999984e-086.9e-076.5e-075.9e-072.03e-064.6999999999999995e-075.1e-075.1e-071.399999999999999e-072.2e-073.3e-074.9e-07-2.9999999999999805e-083.4000000000000003e-074.2e-073.8e-071.8999999999999995e-074.2e-074.5000000000000003e-073.5e-073.9999999999999993e-073.9e-075e-073.8e-071.9999999999999996e-074.1e-074.2e-072.4e-072.0000000000000007e-073.1e-073.3e-072.8e-071.1e-073e-072.5e-07
  2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
 Cost Ratio us-gaap:EquityMethodInvestmentNonconsolidatedInvestee pfe:ConsumerHealthcareJVNANA3096.0NANANA3188.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 Cost Ratio us-gaap:EquityMethodInvestmentNonconsolidatedInvestee pfe:GSKConsumerHealthcareNANANA3102.0NANANA2161.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 EBT Margin us-gaap:ConsolidationItems us-gaap:OperatingSegmentsNANANA12131.011801.012028.012689.012303.012402.012259.013977.013298.013466.012001.013703.013168.012896.012779.013628.013045.013147.013005.013541.012087.011853.010864.0NANANANANANANANANANANANANANANANANANANA
 EBT Margin us-gaap:ConsolidationItems,us-gaap:StatementBusinessSegments us-gaap:OperatingSegments,pfe:BiopharmaSegmentNANANA10215.09795.010007.010532.010108.09595.09185.09821.09422.09434.08881.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 EBT Margin us-gaap:ConsolidationItems,us-gaap:StatementBusinessSegments us-gaap:OperatingSegments,pfe:UpjohnSegmentNANANA1916.02006.02022.02156.02195.02807.03075.03182.03036.03147.03120.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 Gross Margin us-gaap:EquityMethodInvestmentNonconsolidatedInvestee pfe:ConsumerHealthcareJVNANA3096.0NANANA3188.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 Gross Margin us-gaap:EquityMethodInvestmentNonconsolidatedInvestee pfe:GSKConsumerHealthcareNANANA3102.0NANANA2161.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 Margin from Continuing Operations us-gaap:EquityMethodInvestmentNonconsolidatedInvestee pfe:ConsumerHealthcareJVNANA3096.0NANANA3188.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 Margin from Continuing Operations us-gaap:EquityMethodInvestmentNonconsolidatedInvestee pfe:GSKConsumerHealthcareNANANA3102.0NANANA2161.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 Net profit Margin us-gaap:EquityMethodInvestmentNonconsolidatedInvestee pfe:ConsumerHealthcareJVNANA3096.0NANANA3188.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 Net profit Margin us-gaap:EquityMethodInvestmentNonconsolidatedInvestee pfe:GSKConsumerHealthcareNANANA3102.0NANANA2161.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
  2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
  2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
us-gaap:ComprehensiveIncomeNetOfTax ▄▄▃▃▄▃▂▅▄▄▂▄▄▄▇▄▄▄▁▃▃▃▂▃▃▃▁▃▃▃▅▃█▃▅▄▂▃▁▄▄▄▃▂▂5469.05523.01653.02763.03312.01911.0-176.07415.04434.04236.0-1252.03700.03270.03480.012117.03857.03486.03563.0-1963.01997.02647.03019.0-523.01481.02663.01134.0-2621.02351.03150.02210.05653.02672.013785.02548.06015.03563.0867.02301.0-1474.03480.03712.03602.01574.010.0-468.0
us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest █▆▆▆▅▆▆▄▆▅▆▅▅▆▇▇▆▇▆▅▇▆▅▅▆▄▆▅█▆▆▂▇▆▇▆▄▆▁▆▆▇▆█▄28.010.011.011.0-4.09.010.0-6.012.01.011.00.0-4.010.014.019.013.015.04.00.021.04.00.02.08.0-10.04.01.024.07.09.0-32.018.012.018.05.0-10.08.0-40.07.012.016.05.028.0-10.0
us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest ▄▄▃▃▄▃▂▅▄▄▂▄▄▄▇▄▄▄▁▃▃▃▂▃▃▃▁▃▃▃▅▃█▃▅▄▂▃▁▄▄▄▃▂▂5498.05533.01665.02774.03307.01920.0-166.07409.04446.04237.0-1241.03700.03266.03490.012132.03876.03499.03579.0-1959.01997.02668.03022.0-523.01483.02670.01124.0-2617.02352.03174.02217.05662.02640.013803.02560.06033.03568.0857.02309.0-1512.03487.03724.03618.01579.038.0-478.0
us-gaap:CostOfGoodsAndServicesSold █▄▁▂▂▂▂▂▂▂▃▃▃▂▃▃▂7049.04211.01504.02529.02281.02378.02608.02602.02576.02433.03075.02694.02916.02563.03256.02844.02660.0NANANANANANANANANANANANA2045.02794.02287.02242.02652.03172.02665.02752.02974.03908.03679.03805.03693.03790.03684.04202.0
 us-gaap:CostOfRevenue us-gaap:EquityMethodInvestmentNonconsolidatedInvestee pfe:ConsumerHealthcareJVNANA1188.0NANANA1811.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:CostOfRevenue us-gaap:EquityMethodInvestmentNonconsolidatedInvestee pfe:GSKConsumerHealthcareNANANA1173.0NANANA803.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:GainsLossesOnExtinguishmentOfDebt us-gaap:LongtermDebtType us-gaap:SeniorNotesNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:GrossProfit us-gaap:EquityMethodInvestmentNonconsolidatedInvestee pfe:ConsumerHealthcareJVNANA1908.0NANANA1377.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:GrossProfit us-gaap:EquityMethodInvestmentNonconsolidatedInvestee pfe:GSKConsumerHealthcareNANANA1929.0NANANA1358.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:IncomeLossFromContinuingOperations ▅▄▁▃▄▄▂▆▄▄▂▄▄▄█▃▃▄▂▃▃▃▂▃▃▃▃▃▃▃▃▃▄▃▃▄▄▃▃▃▃▃▂▃▃5539.04868.0-2037.02194.03426.03401.0-337.07676.05046.03884.0-394.04103.03872.03562.012274.02840.03071.03121.0843.01320.02019.03016.0-169.02122.02626.02371.01249.02669.02912.02256.02626.02582.03565.02738.01484.03104.03187.01794.01482.02423.02580.02212.0851.02444.02005.0
us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity NANANA8.08.09.010.04.010.06.011.08.07.09.015.018.05.09.06.00.016.09.03.09.09.06.07.06.09.09.05.06.010.0NA6.06.07.0NANANANANANANANA
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest ▆▅▁▃▄▄▂█▅▅▂▅▅▅▃▄▄▄▃▃▄▄▂▄▄▄▃▄▄▄▄▄▅▄▃▄▅▄▄▄▄▄▃▄6609.05683.0-2517.02176.03953.03885.0-1508.010727.04141.04323.0-946.04177.04527.04127.0954.03585.03815.03951.0776.01604.02410.03561.0-354.02697.03539.03082.01803.03587.04003.02847.03061.03573.05357.03921.02170.02991.04484.02553.02293.03669.03682.03118.01414.03926.0NA
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest ▅▄▁▃▄▄▂▆▄▄▂▄▄▄█▃▃▄▂▃▃▃▂▃▃▃▃▃▃▃▃▃▄▃▃▄▄▃▃▃▃▃▂▃▃5565.04877.0-2025.02202.03434.03410.0-327.07680.05056.03889.0-383.04111.03879.03571.012289.02858.03077.03130.0849.01320.02035.03026.0-166.02130.02635.02376.01257.02676.02921.02265.02631.02588.03575.02761.01490.03110.03194.01803.01493.02434.02588.02224.0856.02454.02014.0
us-gaap:IncomeTaxExpenseBenefit ▇▇▆▇▇▇▆█▆▇▆▇▇▇▁▇▇▇▆▇▇▇▆▇▇▇▇▇▇▇▇▇▇▇▇▆▇▇▇▇▇▇▇▇▇1043.0805.0-491.0-26.0519.0475.0-1182.03047.0-915.0433.0-564.066.0648.0556.0-11336.0727.0739.0821.0-71.0284.0375.0535.0-188.0567.0905.0706.0545.0911.01082.0582.0430.0985.01782.01160.0680.0-119.01290.0750.0800.01235.01094.0894.0558.01472.01135.0
us-gaap:IncomeTaxesPaidNet ▇▃▄▅▅▂▅▃█▂█▃▅▂▅▂▄▂▅▂▃▃▅▂▄▃▃▃▃▃▅▃▄▃▃▄▄▃▆▄▄▁▂1794.0394.0708.01155.01051.0239.01028.0500.01901.0235.01989.0469.0940.0257.01065.0303.0926.0195.01091.0319.0593.0518.0969.0290.0752.0372.0616.0416.0532.0536.01075.0494.0751.0554.0535.0768.0676.0451.01399.0802.0871.0-134.0208.0NA10547.0
us-gaap:InterestExpense ▂▃▁▅▄▄▅▅▄▄▄▂▃▂▃▂▂▂▂▂▂▂▃▁▁▂▃▃▃▂▃▃▃▄▄▄▄▄▄▅▅▆▅▄█316.0336.0271.0416.0372.0390.0416.0409.0389.0361.0370.0310.0326.0310.0330.0320.0312.0309.0297.0291.0292.0306.0335.0278.0278.0309.0353.0343.0343.0321.0347.0340.0356.0391.0373.0382.0379.0390.0396.0423.0404.0458.0427.0389.0522.0
us-gaap:InterestPaidNet ▄▅▄▄▅▅▄▅▅▄▄▂▅▃▅▂█▂▃▃▆▄▁▂▇▃▂▃▇▄▂▄█▅▂▅█▆▂▆██353.0445.0344.0387.0438.0472.0341.0437.0424.0385.0343.0244.0465.0259.0417.0220.0665.0216.0274.0274.0521.0382.0140.0248.0582.0332.0221.0333.0635.0361.0217.0409.0670.0433.0198.0481.0686.0508.0213.0535.0650.0687.0NANANA
us-gaap:NetIncomeLoss ▄▄▁▂▃▃▁▅▄▃▁▃▃▃▇▃▃▃▂▂▂▃▁▂▂▂▂▂▃▂▂▂█▃▄▃▃▂▂▃▂▂▂▂▂5563.04877.0594.02194.03426.03401.0-336.07680.05046.03884.0-393.04114.03872.03561.012274.02840.03073.03121.0860.01320.02019.03016.0-172.02130.02626.02376.01228.02666.02912.02329.02568.02590.014095.02750.06315.03208.03253.01794.01439.03738.02610.02222.0866.02475.02026.0
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest ▆▃▃▂▂▃▃▂▃▂▃▂▂▃▄▄▂▃▂▁▄▃▂▃▃▂▂▂▃▃▂▃█▄▂▂▂▃▃▃▂▃▂▃▃26.09.011.08.08.09.010.04.010.06.011.08.07.09.015.018.05.09.06.00.016.09.03.09.09.06.07.06.09.09.06.09.039.015.06.06.07.09.011.011.08.012.05.010.09.0
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic ▄▄▁▂▃▃▁▅▄▃▁▃▃▃▇▃▃▃▂▂▂▃▁▂▂▂▂▂▃▂▂▂█▃▄▃▃▂▂▃▂▂▂▂▂5563.04877.0595.02194.03426.03401.0-337.07680.05045.03883.0-394.04114.03871.03560.012274.02839.03073.03121.0859.01319.02019.03016.0-172.02130.02626.02375.01228.02666.02911.02329.02568.02593.014099.02742.06314.03207.03253.01794.01438.03738.02610.02222.0865.02474.02025.0
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted ▄▄▁▂▃▃▁▅▄▃▁▃▃▃▇▃▃▃▂▂▂▃▁▂▂▂▂▂▃▂▂▂█▃▄▃▃▂▂▃▂▂▂▂▂5563.04877.0594.02194.03426.03401.0-336.07680.05046.03884.0-393.04114.03872.03561.012274.02840.03073.03121.0859.01320.02019.03016.0-171.02130.02626.02376.01227.02666.02912.02329.02569.02593.014099.02742.06315.03208.03253.01794.01439.03738.02610.02222.0866.02475.02026.0
us-gaap:OtherComprehensiveIncomeLossNetOfTax ▅▆▆▅▅▃▅▅▄▅▄▄▄▅▅▆▅▅▂▆▆▅▅▄▅▄▁▅▅▅█▅▅▅▅▅▂▅▂▅▆-92.0647.01059.0572.0-127.0-1490.0160.0-275.0-610.0348.0-859.0-422.0-613.0-80.0-158.01018.0421.0449.0-2825.0678.0633.0-4.0-354.0-656.035.0-1257.0-3853.0-320.0253.0-121.03088.041.0-331.0-205.0-288.0354.0-2403.0506.0-2962.0-262.01106.0NANANANA
 us-gaap:OtherComprehensiveIncomeLossNetOfTax us-gaap:StatementEquityComponents us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCredit▄▄-33.0-33.0NANANANANANANANANANANANANANANANANANANANANANANANA445.0NANANANANANANANANANANANANANANANANANA
 us-gaap:OtherComprehensiveIncomeLossNetOfTax us-gaap:StatementEquityComponents us-gaap:AccumulatedGainLossNetCashFlowHedgeParent▁█-220.0380.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:OtherComprehensiveIncomeLossNetOfTax us-gaap:StatementEquityComponents us-gaap:AccumulatedNetUnrealizedInvestmentGainLoss█▁105.0-142.0NANANANANANANANANANANANANANANANANANANANANANANANA-143.0NANANANANANANANANANANANANANANANANANA
 us-gaap:OtherComprehensiveIncomeLossNetOfTax us-gaap:StatementEquityComponents us-gaap:AccumulatedOtherComprehensiveIncome▅▇█▇▅▁▆▄▃▆▃▄▃▅-94.0646.01059.0569.0-115.0-1490.0160.0-265.0-613.0353.0-859.0-414.0-602.0-81.0NANANANANANANANANANANANA-3849.0NANANANANANANANANANANANANANANANANANA
 us-gaap:OtherComprehensiveIncomeLossNetOfTax us-gaap:StatementEquityComponents us-gaap:AccumulatedTranslationAdjustment▁█53.0442.0NANANANANANANANANANANANANANANANANANANANANANANANA-1744.0NANANANANANANANANANANANANANANANANANA
 us-gaap:OtherComprehensiveIncomeLossNetOfTax us-gaap:StatementEquityComponents us-gaap:NoncontrollingInterest█▇▇█▁▇▇▂█▅▇▂▁▇2.01.00.03.0-12.00.00.0-9.03.0-4.00.0-9.0-11.01.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:OtherComprehensiveIncomeLossNetOfTax us-gaap:StatementEquityComponents us-gaap:Parent▅▇█▇▅▁▆▄▃▆▃▄▃▅-94.0646.01059.0569.0-115.0-1490.0160.0-265.0-613.0353.0-859.0-414.0-602.0-81.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:OtherNonoperatingIncomeExpense ██▆▄█▆▁▆▆▆▁▇▇▇▄▆▆▆▅▄▅▆▃▅▆▆▆▆▆▅▇▇▆▆▆▆▆▆▆▆▆▆▆▆▆998.01004.0-162.0-1148.0862.0-221.0-3041.0-319.0-126.0-92.0-3259.0414.0551.0178.0-1331.0-51.066.01.0-840.0-1417.0-1068.0-330.0-2190.0-661.0-55.046.0-344.0-94.053.0-623.0556.0120.0-29.0-128.0-2.0-32.039.0-206.0-98.0-105.025.01.0-3.0-18.0-52.0
us-gaap:ProfitLoss ▄▄▁▂▃▃▁▅▄▃▁▃▃▃▇▃▃▃▂▂▂▃▁▂▂▂▂▂▃▂▂▂█▃▄▃▃▂▂▃▂▂▂▂▂5589.04886.0606.02202.03434.03410.0-326.07684.05056.03889.0-383.04122.03879.03570.012289.02858.03078.03130.0866.01319.02035.03026.0-169.02139.02635.02381.01236.02672.02921.02338.02574.02599.014134.02765.06321.03214.03260.01803.01450.03749.02618.02234.0871.02485.02035.0
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost ▅▃█▄▄▂▆▄▂▂▅▃▂▂▄▂▂▂▅▂▂▂▄▂▂▂█▂▂▁▂▁▁▂▄▃▂▃▅▄▄▃▄▄▄2459.02014.03189.02360.02132.01724.02823.02283.01842.01703.02457.02008.01797.01743.02311.01859.01780.01708.02512.01881.01748.01731.02348.01722.01734.01885.03209.01802.01759.01623.01811.01627.01530.01800.02136.01981.01699.02072.02596.02188.02237.02091.02188.02181.02221.0
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax █▆▁▄▄▄▅▅▅▅▅▅▅▅▅▅▅▅▅▅▅▅▅▄▄▄▅▄▅▄▅▅▅▅▄▅▆▆▇▇▇▇▆▇▇18977.014582.05947.012131.011801.012028.012688.012680.013264.013118.013977.013298.013466.012906.013703.013168.012896.012779.013628.013045.013147.013005.014047.012087.011853.010864.013118.012361.012773.011353.013558.012643.012973.013500.010739.013976.015057.015405.016746.017193.016984.016502.015995.017132.016576.0
 us-gaap:Revenues us-gaap:EquityMethodInvestmentNonconsolidatedInvestee pfe:ConsumerHealthcareJVNANA3096.0NANANA3188.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:Revenues us-gaap:EquityMethodInvestmentNonconsolidatedInvestee pfe:GSKConsumerHealthcareNANANA3102.0NANANA2161.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:SellingGeneralAndAdministrativeExpense ▂▁▁▂▂▁▅▂▃▃▄▃▃▃▆▃▃▃▆▃▃▃▇▃▃▂▄▃▃▂▅▃▃▃▇▄▄▅█▆▇▆▆▆▅2928.02783.02696.03016.03030.02873.04240.03260.03511.03339.04007.03494.03542.03412.04551.03500.03425.03308.04423.03559.03471.03385.05048.03270.03386.03104.03981.03556.03520.03040.04152.03395.03591.03585.04815.03847.03977.04133.05371.04621.04973.04503.04599.04774.04403.0
  2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
  2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
us-gaap:Assets ▄▂▁▅▅▃▃▄▁▁▂▃▃▃▄▄▃▃▄▅▄▂▃▄▂▂▄▄▄▄▄▅▅▇▆▆▆▆▇███169920.0158818.0154229.0178983.0177934.0166336.0167489.0170446.0156199.0155421.0159000.0167838.0165000.0164612.0172000.0172151.0168558.0168784.0171615.0178430.0170658.0162929.0167460.0170867.0160878.0160640.0169274.0171362.0172612.0171808.0172101.0175521.0179335.0187398.0185798.0182603.0182842.0185683.0188002.0196132.0195899.0194956.0NANANA
us-gaap:Liabilities ▄▁▁██▄▅▅▃▃▃▃▂▂▄▇▇▇▇█▆▄▅▅▂▂▃▂▃▂▃▃▄▅▅▄▅▄▅▅▆▅99605.089953.090756.0113487.0113370.0100998.0104042.0105051.096274.096263.095664.096174.094856.094071.0100141.0111041.0109863.0110038.0111776.0114829.0107592.099582.0102463.0103743.093698.093053.097652.093057.095656.093740.095481.097167.0100358.0104571.0104120.0100488.0102881.0102006.0105381.0105602.0106936.0104423.0NANANA
us-gaap:LiabilitiesAndStockholdersEquity ▄▂▁▅▅▃▃▄▁▁▂▃▃▃▄▄▃▃▄▅▄▂▃▄▂▂▄▄▄▄▄▅▅▇▆▆▆▆▇███169920.0158818.0154229.0178983.0177934.0166336.0167489.0170446.0156199.0155421.0159422.0167838.0164980.0164612.0171797.0172151.0168558.0168784.0171615.0178430.0170658.0162929.0167460.0170867.0160878.0160640.0169274.0171362.0172612.0171808.0172101.0175521.0179335.0187398.0185798.0182603.0182842.0185683.0188002.0196132.0195899.0194956.0NANANA
us-gaap:StockholdersEquity ▄▃▂▃▂▂▂▂▁▁▂▄▄▄▄▂▁▁▁▂▂▂▂▃▃▃▄▅▅▅▅▅▅▆▆▆▆▆▆███70042.068620.063238.065259.064336.065026.063143.065103.059568.058806.063407.071319.069778.070184.071308.060770.058368.058435.059544.063306.062769.063068.064720.066838.066894.067304.071301.077988.076633.077769.076307.077969.078547.082250.081260.081703.079547.083256.082190.090047.088481.090067.0NANANA
  2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
us-gaap:AssetsCurrent ▅▂▁▄▄▁▁▁▄▄▅▃▂▁▃▃▂▂▂▂▃▃▃▄▅▅▆▆▇▆▆▇▇█▇▆▇▆▆█▇▇48814.039533.035067.047739.046424.034738.032803.033459.047073.045290.049926.041583.037303.034835.041141.040291.036385.035878.038949.038501.043845.041298.043804.045001.051715.049443.057702.056987.058287.057793.056244.059500.061435.064763.061415.057127.058765.054863.057728.062732.060484.058244.0NANANA
us-gaap:CashAndCashEquivalentsAtCarryingValue ▂▂▂▂▂▂▁▂▂▂▁▃▂▂▁▂▂▃▂▂▃▂▃▃▃▃▃▂▃▃▂▂▂▂█▄▃▃▃▃▃▁▂▂▂2372.01768.01784.01587.01801.02151.01305.02785.01784.01937.01139.03559.02704.02302.01342.02779.02585.04057.02595.02094.03411.02561.03641.03099.03670.03563.03343.02437.03406.02862.02183.02052.02436.02134.010389.04506.03031.02934.03539.03706.03096.0730.02176.01877.01759.0
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents ▄▂▂▂▂▃▁▅▂▃▁▇▅▄▁▅▄█▄2418.01809.01825.01627.01845.02196.01350.02846.01837.02018.01225.03658.02811.02416.01431.02858.02661.04131.02666.0NANANA3707.0NANANANANANANANANANANANANANANANANANANANANANA
us-gaap:ShortTermInvestments ▄▂▂▅▅▁▂▁▂▂▄▃▂▂▄▃▂▂▃▃▄▄▄▄▆▆█▇▇▇▇█▇█▅▄▅▅▅▆▅▅19328.011899.010437.020325.020993.08199.08525.06302.011128.09682.017694.013680.010727.09119.018650.014146.011748.010503.015255.012277.017531.016882.019649.017559.026586.024145.032779.031009.030648.031019.030225.031627.031275.033212.022319.018462.021275.021038.023219.025257.022388.023279.0NANANA
us-gaap:AccountsReceivableNetCurrent ▃▃▁▃▂▃▂▂▃▂▁▃▃▂▁▃▂▂▁▃▂▂▁▂▂▂▂▃▃▂▂▄▄▅▅▅▅▇▆██▇10587.09864.07930.010012.09128.09881.08724.09439.09793.09599.08025.010024.09873.09452.08221.010002.09476.08892.08225.09836.09138.09033.08176.09535.08951.08920.08669.09955.010388.09399.09357.011371.011523.012735.012378.012523.012882.014182.013608.015749.015192.015182.0NANANA
us-gaap:InventoryNet ▇▆▆█▇▆▆▆▆▆▅▆▆▆▅▅▅▄▃▅▅▅▅▅▁▁▁▂▂▂▂▃▂▄▄▅▄▄▅▆▇▆8948.08493.08046.09295.08564.08423.08283.08222.08233.08029.07508.08184.08074.08148.07578.07925.07584.07415.06783.07507.07614.07578.07513.07678.05796.05786.05663.06355.06249.06066.06166.06482.06282.07035.07063.07516.07001.07189.07769.08426.08597.08467.0NANANA
us-gaap:OtherAssetsCurrent ▇█▆▃▃▄▃▄▃▃▃▃▂▂▂▂▁▂▂▄▅▃▂▂▃▄▄▃▄▆▆3818.04091.03438.02519.02513.02737.02600.02954.02535.02567.02461.02450.02343.02126.02289.02158.01877.02218.02249.02843.03023.02355.02163.02248.02449.02815.02750.02545.02727.03473.03613.0NANANA3567.0NANANANANANANANANANA
  2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
 us-gaap:AssetsNoncurrent us-gaap:EquityMethodInvestmentNonconsolidatedInvestee pfe:GSKConsumerHealthcareNANANA38361.0NANANA38575.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:AssetsNoncurrent us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName,us-gaap:EquityMethodInvestmentNonconsolidatedInvestee pfe:ViivHealthcareLimited,pfe:ViivHealthcareLimitedNANA3381.0NANANA3437.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:PropertyPlantAndEquipmentGross NANA28711.0NANANA30756.0NANANA29977.0NANANA30037.0NANANA28125.0NANANA27268.0NANANA24988.0NANANA25678.0NANANA27882.0NANANA30522.0NANANANANANA
 us-gaap:PropertyPlantAndEquipmentGross us-gaap:PropertyPlantAndEquipmentByType us-gaap:BuildingNANA9022.0NANANA10068.0NANANA9920.0NANANA10254.0NANANA9810.0NANANA9604.0NANANA9355.0NANANA10055.0NANANANANANANANANANANANANANA
 us-gaap:PropertyPlantAndEquipmentGross us-gaap:PropertyPlantAndEquipmentByType us-gaap:ConstructionInProgressNANA3552.0NANANA2960.0NANANA2992.0NANANA2680.0NANANA2127.0NANANA1791.0NANANA1271.0NANANA1102.0NANANANANANANANANANANANANANA
 us-gaap:PropertyPlantAndEquipmentGross us-gaap:PropertyPlantAndEquipmentByType us-gaap:FurnitureAndFixturesNANA4541.0NANANA4930.0NANANA4693.0NANANA4661.0NANANA4410.0NANANA4351.0NANANA4162.0NANANA3914.0NANANANANANANANANANANANANANA
 us-gaap:PropertyPlantAndEquipmentGross us-gaap:PropertyPlantAndEquipmentByType us-gaap:LandNANA444.0NANANA516.0NANANA500.0NANANA540.0NANANA530.0NANANA588.0NANANA529.0NANANA557.0NANANANANANANANANANANANANANA
 us-gaap:PropertyPlantAndEquipmentGross us-gaap:PropertyPlantAndEquipmentByType us-gaap:MachineryAndEquipmentNANA11153.0NANANA12281.0NANANA11871.0NANANA11902.0NANANA11248.0NANANA10933.0NANANA9671.0NANANA10050.0NANANANANANANANANANANANANANA
us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment ▅▄▄▇██▇▇▇▆▇██▇▆▆▅▄▄▄▃▂▁15328.015105.014812.016636.016889.016929.016789.016728.016389.016158.016591.017078.016844.016665.016172.015906.015506.015050.014807.014838.014637.014002.013502.0NANANA13226.0NANANA13281.0NANANA13421.0NANANA13584.0NANANANANANA
us-gaap:PropertyPlantAndEquipmentNet ▄▃▃▄▄▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▁▁▁▂▂▂▂▂▂▃▄▄▄▆▆▇▇█14224.014011.013900.014403.014113.014040.013967.013701.013521.013467.013385.014036.013919.013971.013865.013505.013386.013238.013318.013284.013609.013584.013766.013695.011432.011527.011762.012032.012179.012347.012397.012359.012443.013950.014461.014606.014756.016192.016938.017721.018281.018833.0NANANA
us-gaap:LongTermInvestments ███▇▇▇▁▁▁▁▁▂▂▃▃▃▃▃▃▄▅▅▆▆▇▇▇▇▇▆▆▆▆▆▅▅▄▄▄20942.020228.020262.019008.018720.018220.03014.02723.02905.02859.02767.06444.06595.06945.07015.07311.07008.07346.07116.09507.013124.014146.015999.016233.017650.018289.017518.018451.017168.015822.016406.015731.016107.015392.014149.013429.010548.010632.09814.0NANANANANANA
us-gaap:Goodwill ▄▄▄█▇▇██▅▆▆▆▆▇▆▇▆▆▆▇▄▄▄▃▁▁▁▁▁▁▁▁▁▂▂▂▂▂▂▂▂▂49867.049791.049577.059902.058449.058502.058653.058665.053352.053487.053411.055614.055836.056393.055952.056078.055014.054656.054449.056281.050600.048558.048242.047217.041571.041854.042069.042724.042661.042467.042519.042400.042431.043752.044672.044370.044568.045252.045067.045409.045107.044853.0NANANA
us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill ▁▁▁▂▃▄▄▄▁▁▁▄▅▅▅▅▅▅██▅▃▃▃▃▃▃▃▃▃▃▃▃▃▃▄▄▅▅▆▆▆4535.04535.04575.05785.07032.08982.08983.09023.03954.04076.04165.09294.012090.012153.012179.012229.012315.012418.016984.017487.012631.08072.08192.08522.07642.07640.07660.07805.07703.07692.07827.07876.08065.08324.08586.08972.09026.011445.011296.013695.013724.013952.0NANANA
us-gaap:IntangibleAssetsNetExcludingGoodwill ▁▁▁▂▂▃▃▄▂▃▃▅▅▆▆▆▆▇▇▇▅▄▄▅▂▃▃▃▃▃▄▄▄▅▅▅▆▇▇▇██27323.027974.028471.030927.033541.034464.035370.038995.033024.034039.035211.045306.046584.047690.048741.049721.051348.052427.052648.054238.043056.039602.040356.043297.033424.034334.035166.036374.037360.038122.039385.040549.041776.044109.046013.047209.048399.052801.053833.055597.057059.058497.0NANANA
us-gaap:FiniteLivedIntangibleAssetsNet ▁▁▁▂▂▂▂▃▃▃▄▅▅▅▅▆▆▇▅▅▃▄▄▅▂▂▃▃▃▃▄▄▅▅▆▆▆▇▇▇██22789.023439.023896.025142.026509.025482.026387.029972.029070.029963.031045.036012.034494.035537.036562.037492.039033.040009.035664.036750.030425.031530.032165.034775.025782.026694.027506.028570.029657.030430.031558.032673.033711.035785.037427.038237.039373.041356.042537.041902.043335.044545.0NANANA
us-gaap:OperatingLeaseRightOfUseAsset NANA1393.0NANANA1313.01306.01273.01280.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:OtherAssetsNoncurrent █▅▅▄▄▄▅▆▄▄▁▁▁▁▂▂▂▂▂▅▅▄▃▃▃▃▃▂▃▃▃6056.04744.04569.04355.04327.04166.04450.04920.04388.04333.02799.02980.02896.02896.03227.03388.03466.03329.03323.04759.04618.04003.03499.03911.03635.03716.03513.03421.03574.03759.03596.0NANANA3233.0NANANANANANANANANANA
us-gaap:EquitySecuritiesFvNi ▂▁▁██▃▁▁▃▂▂▁▁2284.01427.0567.012273.013033.04190.0705.01054.04753.01597.01600.01213.01332.0NA2150.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
  2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
us-gaap:AccountsPayableCurrent ▇▆▇▇▆▆▇▆▆▇█▇▇▆█▅▅▅█▅▄▄▅▄▃▃▅▄▄▂▄▂▁▄▇▄▄▄▆▆▅▆4327.04064.04309.04141.03872.03972.04220.03942.04002.04156.04674.04297.04196.03879.04656.03480.03439.03393.04536.03476.03261.03125.03620.03294.02930.02724.03440.02973.02990.02546.03234.02287.01978.03279.04264.02967.03165.03091.03836.03765.03698.03750.0NANANA
us-gaap:ContractWithCustomerLiabilityCurrent █▃▁4291.02052.01113.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:DebtCurrent ▂▂▁▆▆███▅▄▄▃▅▄▅▄▄▄▅▆▇▅▅▅▄▃▂▂▂▄▃▂▂▄▃▄▄▂▂▂▃▃3888.04352.02703.013363.013084.016007.016195.016617.010507.09410.08831.07385.011583.09010.09953.09448.09514.07680.010688.013633.013724.011546.010160.09818.08394.06555.05141.05389.05561.09319.06027.04738.05214.08896.06424.07774.07703.05526.04018.05637.05988.06093.0NANANA
us-gaap:DividendsPayableCurrent 2184.0NA2162.02112.02111.00.02104.01992.01991.00.02047.01963.01980.00.02029.01909.01904.00.01944.01821.01820.00.01852.01728.01726.00.01711.00.01650.01.01663.01.01685.05.01734.01.01826.01.01796.0NANANANANANA
us-gaap:LiabilitiesCurrent ▇▄▃▇▆▇██▆▅▆▅▆▄▅▄▄▃▆▇▆▅▅▄▃▁▂▁▂▃▂▁▂▄▅▅▅▄▄▄▅▅35664.026652.025920.034154.032723.033890.037304.036974.032030.029423.031858.029013.032156.027365.030427.028217.027182.024864.031115.034759.032099.028735.029399.027845.024143.020222.021631.019920.021938.024790.023366.020373.023450.027543.028619.029131.030798.027094.028069.027856.030471.029171.0NANANA
us-gaap:LongTermDebtCurrent ▆▆▄▄▃▁▃▄▄██▇▇█▆▅▅▆▇3687.03676.02002.02149.01481.0337.01462.02431.02139.04471.04776.04255.04262.04763.03546.03072.03072.03292.04225.0NANANA3720.0NANANA3011.0NANANA2060.0NANANA2449.0NANANA6.0NANANANANANA
us-gaap:OperatingLeaseLiabilityCurrent NANA321.0NANANA276.0281.0263.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:OtherLiabilitiesCurrent █▅▄▃▂▃▃▂▂▃▃▃▂▃▃▃▂▃▃▄▃▃▃▂▁▁▂▁▂▃▂17217.012798.012640.010683.010168.010515.011083.010160.010110.010276.010753.010490.010125.010950.011115.010446.010148.011143.011023.012623.011053.011419.010990.09672.08390.08320.09024.08824.09346.010315.09951.0NANANA13812.0NANANANANANANANANANA
us-gaap:TaxesPayableCurrent ▅▄▃▄▄▃▃▅▄▅▄█▇▅▁▃▁▂▁▃▂▂▁▃▃▃▁▂▂▂▂▂▂▃▃▅▆▅▃▆▅▆1742.01401.01049.01430.01445.01150.0980.01892.01536.01849.01265.02781.02481.01614.0477.01003.0552.0790.0437.01158.0647.0920.0418.01178.01057.0944.0531.0892.0760.0851.0678.0802.0904.01158.01010.01788.02098.01930.01013.02215.01849.01958.0NANANA
  2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
 us-gaap:LiabilitiesNoncurrent us-gaap:EquityMethodInvestmentNonconsolidatedInvestee pfe:GSKConsumerHealthcareNANANA5330.0NANANA5536.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LiabilitiesNoncurrent us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName,us-gaap:EquityMethodInvestmentNonconsolidatedInvestee pfe:ViivHealthcareLimited,pfe:ViivHealthcareLimitedNANA6370.0NANANA5860.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:LongTermDebt NANA4000.0NANANANANANANANANANANANA34503.034191.036330.031398.030437.030457.0NA28818.0NANANA31541.031666.032267.0NANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument,us-gaap:LongtermDebtType pfe:SeniorUnsecuredDebtDue2043,us-gaap:UnsecuredDebtNANA1800.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument,us-gaap:LongtermDebtType pfe:SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030,us-gaap:SeniorNotesNANA1000.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument,us-gaap:LongtermDebtType pfe:SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040,us-gaap:SeniorNotesNANA1000.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument,us-gaap:LongtermDebtType pfe:SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050,us-gaap:SeniorNotesNANA1250.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument,us-gaap:LongtermDebtType pfe:SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025,us-gaap:SeniorNotesNANA750.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DerivativeInstrumentRisk pfe:ForeignCurrencyDebt▁▁█881.0872.02100.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DerivativeInstrumentRisk pfe:ForeignCurrencyLongTermDebtNANA2100.02000.02000.01900.02000.01900.02000.02000.03200.03200.03200.03300.04800.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:LongtermDebtType us-gaap:UnsecuredDebtNANANA1800.01800.01800.01800.01800.01800.01800.01800.01800.01800.01900.01900.02000.01900.01900.01900.0NANANA28818.0NANANA31541.04500.04500.0NA30462.0NANANANANANANANANANANANANANA
us-gaap:LongTermDebtNoncurrent ▄▄▄██▄▄▄▄▄▃▃▂▃▃▃▃▄▂▂▂▁▂▂▁▂▂▂▃▁▂▂▂▂▂▂▂▃▃▄▄▄35354.035347.037133.049785.050529.036281.035955.036044.036168.035733.032909.033652.028935.031831.033538.034503.034191.036330.031398.030437.030457.027824.028818.029079.026729.029370.031541.031666.032267.027649.030462.031812.031532.031481.031036.031083.030868.033543.034931.035399.035723.035308.0NANANA
us-gaap:DeferredIncomeTaxLiabilitiesNet ▁▁▁▁▂▂▂▂▁▁▁▂▂▂▁████4161.04355.04063.04542.05409.05268.05578.06724.03180.03591.03700.05512.05743.05967.03900.030411.030879.030857.030753.0NANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent us-gaap:RetirementPlanSponsorLocation,us-gaap:RetirementPlanTaxStatus,us-gaap:RetirementPlanType country:US,us-gaap:NonqualifiedPlan,us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitNANA1239.0NANANA1162.0NANANA1113.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent us-gaap:RetirementPlanSponsorLocation,us-gaap:RetirementPlanTaxStatus,us-gaap:RetirementPlanType country:US,us-gaap:QualifiedPlan,us-gaap:PensionPlansDefinedBenefitNANA845.0NANANA1949.0NANANA2088.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent us-gaap:RetirementPlanSponsorLocation,us-gaap:RetirementPlanType us-gaap:ForeignPlan,us-gaap:PensionPlansDefinedBenefitNANA2681.0NANANA2526.0NANANA2111.0NANANA2172.0NANANA2279.0NANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent us-gaap:RetirementPlanType us-gaap:OtherPostretirementBenefitPlansDefinedBenefitNANA645.0NANANA1124.0NANANA1371.0NANANA1504.0NANANA1766.0NANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:MinorityInterest ▂▁▁▁▁▃▃▂▄▃▃▃▃▄▃▃▃▃▂▂▂▂▂▂▂▂▃▃▃▂▃▄▅█▅▅▅▅▅▆▆▆273.0245.0235.0236.0228.0312.0303.0293.0357.0352.0351.0346.0346.0358.0348.0340.0326.0311.0296.0294.0297.0279.0278.0286.0286.0283.0321.0317.0323.0299.0313.0385.0430.0577.0418.0412.0414.0421.0431.0483.0482.0466.0NANANA
us-gaap:OtherLiabilitiesNoncurrent █▅▅▆▆▆▅▅▄▅▄▅▄▃▄▅▅▆▅▄▃▃▃▂▃▃▂▁▁▁▂▁▃▃▂▃▄▃▄▅▂▂8228.06677.06669.06851.06812.06812.06317.06381.06183.06346.05850.06367.05947.05644.06149.06388.06440.06918.06337.06059.05518.05180.05257.04987.05310.05644.04883.04266.04238.04416.04767.04515.05231.05138.04939.05261.05836.05119.06199.06239.04932.04970.0NANANA
us-gaap:OperatingLeaseLiabilityNoncurrent NANA1114.0NANANA1048.01037.01026.01043.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
  2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
us-gaap:StockholdersEquity ▄▃▂▃▂▂▂▂▁▁▂▄▄▄▄▂▁▁▁▂▂▂▂▃▃▃▄▅▅▅▅▅▅▆▆▆▆▆▆███70042.068620.063238.065259.064336.065026.063143.065103.059568.058806.063407.071319.069778.070184.071308.060770.058368.058435.059544.063306.062769.063068.064720.066838.066894.067304.071301.077988.076633.077769.076307.077969.078547.082250.081260.081703.079547.083256.082190.090047.088481.090067.0NANANA
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest ▄▃▂▂▂▂▂▂▁▁▂▄▄▄▄▂▁▁▁▂▂▂▂▃▃▃▄▅▅▅▅▅▅▆▆▆▆▆▆███70315.068865.063473.065495.064564.065338.063447.065396.059924.059158.063758.071664.070124.070541.071656.061110.058694.058746.059840.063601.063066.063347.064998.067124.067180.067587.071622.078305.076956.078068.076620.078354.078977.082827.081678.082115.079961.083677.082621.090530.088963.090533.0NANANA
us-gaap:CommonStockValue ██████▇▇▇▇▇▆▆▆▆▆▆▆▅▅▅▅▅▅▄▄▄▄▄▄▃▃▃▂▂▂▂▂▁▁▁▁472.0472.0470.0470.0470.0470.0468.0468.0468.0468.0467.0466.0465.0465.0464.0463.0463.0463.0461.0461.0461.0460.0459.0459.0458.0458.0455.0455.0454.0454.0453.0452.0451.0450.0448.0447.0447.0446.0445.0445.0445.0444.0NANANA
us-gaap:AdditionalPaidInCapital ████▇▇▇▇▇▇▇▇▆▆▆▆▆▆▅▅▅▅▅▅▅▄▄▄▄▄▃▃▃▃▂▂▁▁▁▁▁▁89336.089002.088674.088161.087886.087680.087428.087099.086963.086635.086253.085828.084898.084599.084278.083827.083373.083111.082685.082534.082138.081443.081016.080763.080407.080004.078977.078498.078208.077849.077283.076756.076412.075778.072608.072317.072027.071786.071423.071235.071095.070925.0NANANA
us-gaap:RetainedEarningsAccumulatedDeficit ▇▇▇█████▇▇▇▇▇▇▆▅▅▅▄▅▅▅▄▅▅▅▄▅▄▄▄▄▄▃▂▂▁▁▁▁▁▁96346.095158.096770.0100284.0100203.0101000.097670.0100113.094440.093388.089554.091995.089860.089961.085291.075043.074107.074847.071774.072846.073350.074971.071993.074019.073620.074471.072176.074292.071627.072028.069732.070381.067628.056972.054240.051256.047904.048124.046210.048121.044320.044926.0NANANA
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax ▆▆▂▁▁▁▂▂▂▂▂▃▃▃▃▃▃▃▂▄▃▃▃▃▄▄▄▇▇▇▇▅▅▅▅▅▅▆▆██▇-4758.0-4664.0-11688.0-12676.0-13246.0-13131.0-11640.0-11801.0-11535.0-10923.0-11275.0-10417.0-10003.0-9402.0-9321.0-9164.0-10181.0-10594.0-11036.0-8214.0-8891.0-9520.0-9522.0-9170.0-8521.0-8557.0-7316.0-3467.0-3152.0-3390.0-3271.0-6383.0-6465.0-6155.0-5953.0-5653.0-6008.0-3622.0-4129.0-1211.0-952.0-2056.0NANANA
 us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax us-gaap:Restatement pfe:ScenarioChangeInAccountingPrincipleAdjustment▁▁█-168.0-141.06378.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax us-gaap:Restatement pfe:ScenarioPreviousAccountingPrinciple██▁-4589.0-4523.0-11688.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:TreasuryStockValue ██████████▇▇▇▇▆▆▆▆▆▆▆▆▅▅▅▅▅▅▅▅▅▄▄▃▂▂▂▂▂▁▁▁111356.0111349.0110988.0110980.0110978.0111010.0110801.0110795.0110786.0110781.0101610.096574.095463.095460.089425.089421.089416.089414.084364.084346.084313.084313.079252.079259.079098.079100.073021.071820.070535.069204.067923.063272.059515.044832.040121.036703.034863.033519.031801.028586.026471.024215.0NANANA
us-gaap:MinorityInterest ▂▁▁▁▁▃▃▂▄▃▃▃▃▄▃▃▃▃▂▂▂▂▂▂▂▂▃▃▃▂▃▄▅█▅▅▅▅▅▆▆▆273.0245.0235.0236.0228.0312.0303.0293.0357.0352.0351.0346.0346.0358.0348.0340.0326.0311.0296.0294.0297.0279.0278.0286.0286.0283.0321.0317.0323.0299.0313.0385.0430.0577.0418.0412.0414.0421.0431.0483.0482.0466.0NANANA
us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders NANA10.01.080.00.01.0-2.08.00.05.00.07.00.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders us-gaap:StatementEquityComponents us-gaap:NoncontrollingInterestNANA10.01.080.0NA1.0-2.08.00.05.00.07.00.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
  2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
us-gaap:NetCashProvidedByUsedInOperatingActivities █▄▄▂▃▃▃▄▂▂▄▄▃▂▅▄▃▂▄▄▃▂▄▄▃▁▄▃▃▂▄▄▃▂▄▄▃▂▄▃▄▄▅11299.04538.05625.02090.03555.03133.03769.04510.02611.01698.04738.05259.03847.01983.06742.04887.03252.01589.05972.04699.03579.01651.04713.05024.04090.0685.05398.04463.04087.02935.05786.05908.03830.02241.05256.05003.04021.02774.05261.04439.05898.04642.06683.0NA-6360.0
us-gaap:NetCashProvidedByUsedInInvestingActivities ▃▄█▅▁▅▄▃▄▇▅▄▅█▄▄▄▆▄▄▄▆▄▃▄▇▅▄▅▅▅▅▅▂▇▅▅▅▅▅▅▅▄-8137.0-1747.08330.0481.0-13011.0-71.0-2833.0-6760.0-1902.07550.0-764.0-2904.0-1474.09667.0-4779.0-2996.0-1738.04772.0-3107.0-4381.0-4678.04355.0-2224.0-5243.0-2105.06592.0-1514.0-2535.0-1507.0-98.080.0-611.0836.0-10930.06837.0-247.0-887.0451.0899.0215.0361.0725.0-3880.0NA9394.0
us-gaap:NetCashProvidedByUsedInFinancingActivities ▄▄▁▄█▅▄▆▅▃▃▅▅▂▄▅▄▄▅▅▆▃▅▅▅▃▄▄▅▅▃▃▄▅▃▄▄▄▃▄▄▃▄-2557.0-2807.0-13787.0-2821.09159.0-2200.0-2440.03273.0-851.0-8467.0-6407.0-1406.0-1908.0-10720.0-3385.0-1728.0-3001.0-4921.0-2228.0-1624.01945.0-7014.0-1109.0-267.0-1875.0-6982.0-2926.0-2887.0-2040.0-2133.0-5744.0-5631.0-4034.0434.0-6233.0-3291.0-2968.0-3507.0-6250.0-4035.0-3918.0-6404.0-2523.0NA-3211.0
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect ▆▅▆▅▅▇▃▇▅▇▁▇▆▇▃▆▃█608.0-15.0198.0-218.0-351.0846.0-1495.01008.0-180.0792.0-2432.0846.0396.0985.0-1428.0198.0-1470.01465.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
  2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
us-gaap:DeferredIncomeTaxExpenseBenefit ▅▅▄▄▅▅▃█▅▅▃▄▄▅▁▅▅▅▆▃▅▅▅▅▅▅▄▅▆▅▅▅▅▆▆▅▅▄▄▅▆▅▄-152.0199.0-871.0-668.0-38.0109.0-1453.02227.0-100.0-60.0-1231.0-474.0-794.0294.0-2651.0-79.0282.038.0635.0-1325.0194.0-204.0145.018.0-142.0-41.0-446.0-87.0508.0345.059.0413.0327.0927.0642.0217.0284.0-404.0-429.0188.0625.0-120.0-333.0NA840.0
 us-gaap:DeferredIncomeTaxExpenseBenefit us-gaap:Restatement pfe:ScenarioChangeInAccountingPrincipleAdjustment▁█19.032.0NANA26.04.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:DeferredIncomeTaxExpenseBenefit us-gaap:Restatement pfe:ScenarioPreviousAccountingPrinciple▁█-171.0167.0NANA-74.077.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:NetCashProvidedByUsedInOperatingActivities █▄▄▂▃▃▃▄▂▂▄▄▃▂▅▄▃▂▄▄▃▂▄▄▃▁▄▃▃▂▄▄▃▂▄▄▃▂▄▃▄▄▅11299.04538.05625.02090.03555.03133.03769.04510.02611.01698.04738.05259.03847.01983.06742.04887.03252.01589.05972.04699.03579.01651.04713.05024.04090.0685.05398.04463.04087.02935.05786.05908.03830.02241.05256.05003.04021.02774.05261.04439.05898.04642.06683.0NA-6360.0
us-gaap:NetIncomeLoss ▄▄▁▂▃▃▁▅▄▃▁▃▃▃▇▃▃▃▂▂▂▃▁▂▂▂▂▂▃▂▂▂█▃▄▃▃▂▂▃▂▂▂▂▂5563.04877.0594.02194.03426.03401.0-336.07680.05046.03884.0-393.04114.03872.03561.012274.02840.03073.03121.0860.01320.02019.03016.0-172.02130.02626.02376.01228.02666.02912.02329.02568.02590.014095.02750.06315.03208.03253.01794.01439.03738.02610.02222.0866.02475.02026.0
us-gaap:ProfitLoss ▄▄▁▂▃▃▁▅▄▃▁▃▃▃▇▃▃▃▂▂▂▃▁▂▂▂▂▂▃▂▂▂█▃▄▃▃▂▂▃▂▂▂▂▂5589.04886.0606.02202.03434.03410.0-326.07684.05056.03889.0-383.04122.03879.03570.012289.02858.03078.03130.0866.01319.02035.03026.0-169.02139.02635.02381.01236.02672.02921.02338.02574.02599.014134.02765.06321.03214.03260.01803.01450.03749.02618.02234.0871.02485.02035.0
us-gaap:ShareBasedCompensation ▆▄▇▆▅▁▇▁▅▅▇█▅▄▆▅▄▆▄▃▆▃▄▃▅▄▄▃▃▃▂▃▂▅▃▂▃▃▁▂▃▃▂222.0172.0264.0234.0194.064.0270.064.0199.0185.0267.0303.0197.0182.0245.0207.0170.0218.0159.0145.0244.0143.0181.0141.0185.0162.0162.0143.0138.0143.0105.0126.0103.0189.0119.0115.0117.0130.072.0103.0122.0122.0108.0NA138.0
  2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
us-gaap:NetCashProvidedByUsedInInvestingActivities ▃▄█▅▁▅▄▃▄▇▅▄▅█▄▄▄▆▄▄▄▆▄▃▄▇▅▄▅▅▅▅▅▂▇▅▅▅▅▅▅▅▄-8137.0-1747.08330.0481.0-13011.0-71.0-2833.0-6760.0-1902.07550.0-764.0-2904.0-1474.09667.0-4779.0-2996.0-1738.04772.0-3107.0-4381.0-4678.04355.0-2224.0-5243.0-2105.06592.0-1514.0-2535.0-1507.0-98.080.0-611.0836.0-10930.06837.0-247.0-887.0451.0899.0215.0361.0725.0-3880.0NA9394.0
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment ▅▅█▅▄▄▇▅▄▄▇▅▄▃▇▄▄▃▇▄▃▂▆▂▂▁▃▂▂▂▄▂▂▁▅▂▂▂▆▄▃▂▂540.0554.0785.0525.0479.0463.0672.0565.0479.0460.0685.0547.0424.0386.0700.0450.0448.0358.0689.0432.0401.0301.0611.0289.0258.0239.0354.0275.0278.0292.0417.0278.0309.0202.0494.0285.0294.0254.0598.0454.0358.0250.0288.0NA305.0
  2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
us-gaap:NetCashProvidedByUsedInFinancingActivities ▄▄▁▄█▅▄▆▅▃▃▅▅▂▄▅▄▄▅▅▆▃▅▅▅▃▄▄▅▅▃▃▄▅▃▄▄▄▃▄▄▃▄-2557.0-2807.0-13787.0-2821.09159.0-2200.0-2440.03273.0-851.0-8467.0-6407.0-1406.0-1908.0-10720.0-3385.0-1728.0-3001.0-4921.0-2228.0-1624.01945.0-7014.0-1109.0-267.0-1875.0-6982.0-2926.0-2887.0-2040.0-2133.0-5744.0-5631.0-4034.0434.0-6233.0-3291.0-2968.0-3507.0-6250.0-4035.0-3918.0-6404.0-2523.0NA-3211.0
us-gaap:ProceedsFromIssuanceOfLongTermDebt NANA-11478.094.015365.01241.00.00.00.04942.00.04974.00.00.01.00.00.05273.05945.00.05031.00.00.00.0NANA0.00.04491.00.00.00.03994.02624.00.00.00.00.0NANANANANANANA
 us-gaap:ProceedsFromIssuanceOfLongTermDebt dei:LegalEntity,us-gaap:ConsolidatedEntities pfe:UpjohnInc,srt:SubsidiariesNANANA0.011400.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:RepaymentsOfLongTermDebt NANA1492.0330.00.02181.01000.0451.02351.03004.0462.00.02749.0355.01680.01.03220.01253.03372.00.02781.01536.00.01.00.03002.01318.034.00.0752.01750.02.02392.02.01499.07.04.03.03500.05.0-397.03878.02.0NA9.0
  2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04

Common Stock Value

us-gaap:CommonStockValue

us-gaap:CommonStockValue


Common
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value472472470470470470468468468468467466465465464463463463461461461460459459458458455455454454453452451450448447447446445445445444444443
Percentage of CommonStockValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.20.20.20.20.20.20.20.20.20.20.2

Shares Issued

us-gaap:SharesIssued us-gaap:StatementEquityComponents

us-gaap:SharesIssued

us-gaap:CommonStock


Shares
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-31
Value9450944594079397939493939369936693639358933293269303929992759230917891109051895689028876886988638850
Percentage of SharesIssued100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:TreasuryStock


Shares
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-31
Value3851385138403840384038413835-3835.0-3801.038013615-3484.0-3438.03437329631603003-2819.02652-1680.0-1327.0-864.0-799.0-2117.0-2089.0
Percentage of SharesIssued40.840.840.840.940.940.940.9-40.9-40.640.638.7-37.4-37.037.035.534.232.7-30.929.3-18.8-14.9-9.7-9.0-23.9-23.6

Common Stock Shares Issued

us-gaap:CommonStockSharesIssued

us-gaap:CommonStockSharesIssued


Common
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-31
Value940793699332927592309178911090518956890288768869
Percentage of CommonStockSharesIssued100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Preferred Stock Shares Issued

us-gaap:PreferredStockSharesIssued

us-gaap:PreferredStockSharesIssued


Preferred
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-31
Value0431.0478.0524.0597.0649.0717.0829.0967.01112.01279.01511.0
Percentage of PreferredStockSharesIssued0.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Weighted Average Number Of Diluted Shares Outstanding

us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding


Weighted
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value56785662563356195613564956725750598659526057604160376092613861376214624362436292640364446476665671177269750875377598781079358035805780728101
Percentage of WeightedAverageNumberOfDilutedSharesOutstanding100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Weighted Average Number Of Shares Outstanding Basic

us-gaap:WeightedAverageNumberOfSharesOutstandingBasic

us-gaap:WeightedAverageNumberOfSharesOutstandingBasic


Weighted
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value55985584555755545545554555625635587558665957595159586006606660686150616861596203633063686389658170427187743674767537777078757982802780468061
Percentage of WeightedAverageNumberOfSharesOutstandingBasic100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount


Antidilutive
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value5.02.07.06.03.03.01.04443434497180216223342280290419427366
Percentage of AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Earnings Per Share Basic

us-gaap:EarningsPerShareBasic

us-gaap:EarningsPerShareBasic


Earnings
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value0.990.870.110.390.620.61-0.061.380.910.69-0.060.70.660.62.060.480.520.520.140.220.330.49-0.020.350.430.380.20.420.460.360.430.392.00.380.860.430.440.240.190.480.330.280.110.310.25
Percentage of EarningsPerShareBasic100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:EarningsPerShareBasic us-gaap:Restatement

pfe:ScenarioChangeInAccountingPrincipleAdjustment


Earnings
Period End2021-07-042021-04-042020-06-282020-03-29
Value0.010.020.01-0.01
Percentage of EarningsPerShareBasic1.02.31.6-1.6

pfe:ScenarioPreviousAccountingPrinciple


Earnings
Period End2021-07-042021-04-042020-06-282020-03-29
Value0.980.850.620.61
Percentage of EarningsPerShareBasic99.097.7100.0100.0

Earnings Per Share Diluted

us-gaap:EarningsPerShareDiluted

us-gaap:EarningsPerShareDiluted


Earnings
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value0.980.860.110.390.610.61-0.051.360.890.68-0.050.690.650.592.030.470.510.510.140.210.330.49-0.030.340.420.380.190.420.450.360.420.391.980.380.850.430.430.240.190.480.330.280.110.310.25
Percentage of EarningsPerShareDiluted100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:EarningsPerShareDiluted us-gaap:Restatement

pfe:ScenarioChangeInAccountingPrincipleAdjustment


Earnings
Period End2021-07-042021-04-042020-06-282020-03-29
Value0.010.020.01-0.01
Percentage of EarningsPerShareDiluted1.02.31.6-1.6

pfe:ScenarioPreviousAccountingPrinciple


Earnings
Period End2021-07-042021-04-042020-06-282020-03-29
Value0.970.840.610.61
Percentage of EarningsPerShareDiluted99.097.7100.0100.0

Income Loss From Continuing Operations Per Basic Share

us-gaap:IncomeLossFromContinuingOperationsPerBasicShare

us-gaap:IncomeLossFromContinuingOperationsPerBasicShare


Income
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value0.990.87-0.360.390.620.61-0.061.380.910.69-0.060.70.660.62.060.480.520.520.140.220.330.49-0.020.340.430.380.20.420.460.350.410.390.510.380.20.420.430.240.190.310.330.280.110.30.25
Percentage of IncomeLossFromContinuingOperationsPerBasicShare100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncomeLossFromContinuingOperationsPerBasicShare us-gaap:Restatement

pfe:ScenarioChangeInAccountingPrincipleAdjustment


Income
Period End2021-07-042021-04-042020-06-28
Value0.010.020.01
Percentage of IncomeLossFromContinuingOperationsPerBasicShare1.02.31.6

pfe:ScenarioPreviousAccountingPrinciple


Income
Period End2021-07-042021-04-042020-06-282020-03-29
Value0.980.850.460.44
Percentage of IncomeLossFromContinuingOperationsPerBasicShare99.097.774.272.1

Income Loss From Continuing Operations Per Diluted Share

us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare

us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare


Income
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value0.980.86-0.360.390.610.61-0.051.360.890.68-0.060.690.650.592.030.470.510.510.140.220.330.49-0.030.340.420.380.190.420.450.350.40.390.50.380.20.410.420.240.20.310.330.280.110.30.25
Percentage of IncomeLossFromContinuingOperationsPerDilutedShare100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare us-gaap:Restatement

pfe:ScenarioChangeInAccountingPrincipleAdjustment


Income
Period End2021-07-042021-04-042020-06-28
Value0.010.020.01
Percentage of IncomeLossFromContinuingOperationsPerDilutedShare1.02.31.6

pfe:ScenarioPreviousAccountingPrinciple


Income
Period End2021-07-042021-04-042020-06-282020-03-29
Value0.970.840.450.44
Percentage of IncomeLossFromContinuingOperationsPerDilutedShare99.097.773.872.1

Comprehensive Income Net Of Tax

us-gaap:ComprehensiveIncomeNetOfTax

us-gaap:ComprehensiveIncomeNetOfTax


Comprehensive
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value546955231653276333121911-176.0741544344236-1252.037003270348012117385734863563-1963.0199726473019-523.0148126631134-2621.023513150221056532672137852548601535638672301-1474.0348037123602157410.0-468.0
Percentage of ComprehensiveIncomeNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax28.837.927.822.828.115.9-1.458.533.432.3-9.027.824.327.088.429.327.027.9-14.415.320.123.2-3.712.322.510.4-20.019.024.719.541.721.1106.318.956.025.55.814.9-8.820.221.921.89.80.1-2.8

Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest

us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest

us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest


Comprehensive
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value2810.01111-4.09.010.0-6.0121.0110.0-4.010.0141913154.00.0214.00.02.08.0-10.04.01.0247.09.0-32.01812185.0-10.08.0-40.07.012165.028-10.0
Percentage of ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.00.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.10.10.20.1-0.00.10.1-0.00.10.00.10.0-0.00.10.10.10.10.10.00.00.20.00.00.00.1-0.10.00.00.20.10.1-0.30.10.10.20.0-0.10.1-0.20.00.10.10.00.2-0.1

Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest

us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest

us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest


Comprehensive
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value549855331665277433071920-166.0740944464237-1241.037003266349012132387634993579-1959.0199726683022-523.0148326701124-2617.023523174221756622640138032560603335688572309-1512.0348737243618157938-478.0
Percentage of ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.037.928.022.928.016.0-1.358.433.532.3-8.927.824.327.088.529.427.128.0-14.415.320.323.2-3.712.322.510.3-19.919.024.819.541.820.9106.419.056.225.55.715.0-9.020.321.921.99.90.2-2.9

Cost Of Goods And Services Sold

us-gaap:CostOfGoodsAndServicesSold

us-gaap:CostOfGoodsAndServicesSold


Cost
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value704942111504252922812378260826022576243330752694291625633256284426602045279422872242265231722665275229743908367938053693379036844202
Percentage of CostOfGoodsAndServicesSold100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax37.128.925.320.819.319.820.620.519.418.522.020.321.719.923.821.620.618.020.618.117.319.629.519.118.319.323.321.422.422.423.721.525.3

Cost Of Revenue

us-gaap:CostOfRevenue us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

us-gaap:CostOfRevenue

pfe:ConsumerHealthcareJV


Cost
Period End2021-03-312020-12-312020-03-312019-12-31
Value1169118813941811
Percentage of CostOfRevenue100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ConsumerHealthcareJV0.00.00.00.0

pfe:GSKConsumerHealthcare


Cost
Period End2020-09-272020-06-302020-03-312019-09-29
Value117310611394803
Percentage of CostOfRevenue0.00.0100.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:GSKConsumerHealthcare0.00.00.00.0

Gains Losses On Extinguishment Of Debt

us-gaap:GainsLossesOnExtinguishmentOfDebt us-gaap:LongtermDebtType

us-gaap:GainsLossesOnExtinguishmentOfDebt

us-gaap:SeniorNotes


Gains
Period End2020-11-30
Value-36.0
Percentage of GainsLossesOnExtinguishmentOfDebt100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:SeniorNotes0.0

Gross Profit

us-gaap:GrossProfit us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

us-gaap:GrossProfit

pfe:ConsumerHealthcareJV


Gross
Period End2021-03-312020-12-312020-03-312019-12-31
Value2011190821091377
Percentage of GrossProfit100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ConsumerHealthcareJV0.00.00.00.0

pfe:GSKConsumerHealthcare


Gross
Period End2020-09-272020-06-302020-03-312019-09-29
Value1929186621091358
Percentage of GrossProfit0.00.0100.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:GSKConsumerHealthcare0.00.00.00.0

Income Loss From Continuing Operations

us-gaap:IncomeLossFromContinuingOperations

us-gaap:IncomeLossFromContinuingOperations


Income
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value55394868-2037.0219434263401-337.0767650463884-394.041033872356212274284030713121843132020193016-169.0212226262371124926692912225626262582356527381484310431871794148224232580221285124442005
Percentage of IncomeLossFromContinuingOperations100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.233.4-34.318.129.028.3-2.760.538.029.6-2.830.928.827.689.621.623.824.46.210.115.423.2-1.217.622.221.89.521.622.819.919.420.427.520.313.822.221.211.68.814.115.213.45.314.312.1

Income Loss From Continuing Operations Attributable To Noncontrolling Entity

us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity

us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity


Income
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302012-12-312012-09-302012-07-01
Value8.08.09.010.04.010.06.0118.07.09.015185.09.06.00.0169.03.09.09.06.07.06.09.09.05.06.010.06.06.07.0
Percentage of IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.10.10.10.10.00.10.00.10.10.10.10.10.10.00.10.00.00.10.10.00.10.10.10.10.00.10.10.00.00.10.10.00.0

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest


Income
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-04
Value66095683-2517.0217639533885-1508.01072741414323-946.0417745274127954358538153951776160424103561-354.0269735393082180335874003284730613573535739212170299144842553229336693682311814143926
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax34.839.0-42.317.933.532.3-11.984.631.233.0-6.831.433.632.07.027.229.630.95.712.318.327.4-2.522.329.928.413.729.031.325.122.628.341.329.020.221.429.816.613.721.321.718.98.822.9

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest pfe:OtherSegmentReconcilingItems, us-gaap:ConsolidationItems

pfe:BusinessCombinationsAcquisitionRelatedCosts, us-gaap:MaterialReconcilingItems


Income
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-28
Value-11.0-21.0-13.0-33.0-300.0176-28.0-97.0-112.0-62.0-48.0-109.0-155.0-68.0-124.0-187.0-280.0-202.0-116.0-263.0-541.0-68.0
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-0.5-0.5-0.32.2-2.84.3-0.610.3-2.7-1.4-1.2-11.4-4.3-1.8-3.1-24.1-17.5-8.4-3.374.3-20.1-1.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-0.1-0.2-0.1-0.3-2.41.3-0.2-0.7-0.8-0.5-0.4-0.8-1.2-0.5-1.0-1.4-2.1-1.5-0.9-1.9-4.5-0.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:BusinessCombinationsAcquisitionRelatedCosts us-gaap:MaterialReconcilingItems0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

pfe:CertainSignificantItems, us-gaap:MaterialReconcilingItems


Income
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-28
Value-1675.0-268.0-612.0-4014.07187-309.0-382.0-4297.0213-20.0-201.0-1850.0-449.0-191.0-157.0-1776.0-1969.0-1506.0-638.0-2952.0-837.0-305.0
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-77.0-6.8-15.8266.267.0-7.5-8.8454.25.1-0.4-4.9-193.9-12.5-5.0-4.0-228.9-122.8-62.5-17.9833.9-31.0-8.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-13.8-2.3-5.1-31.656.7-2.3-2.9-30.71.6-0.1-1.6-13.5-3.4-1.5-1.2-13.0-15.1-11.5-4.9-21.0-6.9-2.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:CertainSignificantItems us-gaap:MaterialReconcilingItems0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

pfe:PurchaseAccountingAdjustments, us-gaap:MaterialReconcilingItems


Income
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-28
Value-823.0-910.0-812.0-976.0-1141.0-1178.0-1038.0-1121.0-1309.0-1134.0-1221.0-1231.0-1154.0-1201.0-1172.0-1082.0-966.0-984.0-1153.0-1255.0-960.0-835.0
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-37.8-23.0-20.964.7-10.6-28.4-24.0118.5-31.3-25.0-29.6-129.0-32.2-31.5-29.7-139.4-60.2-40.8-32.4354.5-35.6-23.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-6.8-7.7-6.8-7.7-9.0-8.9-7.9-8.0-9.8-8.4-9.5-9.0-8.8-9.3-9.2-7.9-7.4-7.5-8.9-8.9-7.9-7.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:PurchaseAccountingAdjustments us-gaap:MaterialReconcilingItems0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest us-gaap:ConsolidationItems

us-gaap:CorporateNonSegment


Income
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-29
Value-1192.0-1136.0-1110.0-1751.0-1431.0-1399.0-1278.0-1463.0-1337.0-1144.0-1153.0-1574.0-1382.0-1222.0-1344.0-1203.0-1504.0-1256.0-1363.0-1481.0-1376.0-1286.0-1287.0-1406.0-1308.0-1287.0-1200.0-1580.0-1340.0
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-54.8-28.7-28.6116.1-13.3-33.8-29.6154.7-32.0-25.3-27.9-165.0-38.5-32.0-34.0-155.0-93.8-52.1-38.3418.4-51.0-36.3-41.8-78.0-36.5-32.2-42.1-51.6-37.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-9.8-9.6-9.2-13.8-11.3-10.5-9.7-10.5-10.1-8.5-8.9-11.5-10.5-9.5-10.5-8.8-11.5-9.6-10.5-10.5-11.4-10.8-11.8-10.7-10.6-10.1-10.6-11.7-10.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:CorporateNonSegment0.00.00.00.0-379.6-162.3-149.00.0-159.4-129.1-127.40.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:MaterialReconcilingItems


Income
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-28
Value-1939.0-1530.0-1489.0-1973.0-1443.0-1193.0-1113.0-847.0-736.0-669.0-725.0-932.0-759.0-758.0-688.0-994.0-786.0-708.0-668.0-964.0-715.0-715.0
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-89.1-38.7-38.3130.8-13.5-28.8-25.789.5-17.6-14.8-17.6-97.7-21.2-19.9-17.4-128.1-49.0-29.4-18.8272.3-26.5-20.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-16.0-13.0-12.4-15.6-11.4-9.0-8.5-6.1-5.5-5.0-5.6-6.8-5.8-5.9-5.4-7.3-6.0-5.4-5.1-6.9-5.9-6.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:MaterialReconcilingItems0.00.00.00.0-382.8-138.4-129.70.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:OperatingSegments


Income
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-29
Value78167818792072397856804481627418791579187719687776407453765562987315737776846778719969086190
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest359.2197.8203.9-480.073.2194.3188.8-784.1189.5174.9187.0720.9213.1195.4193.7811.6456.0306.1215.8-1914.7266.9195.2200.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax64.466.265.857.162.060.662.253.159.558.859.850.258.057.859.946.256.156.159.148.359.658.357.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:OperatingSegments64.466.265.80.063.964.966.60.059.558.864.30.058.057.859.90.056.156.159.10.059.658.357.0

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments

us-gaap:OperatingSegments, pfe:BiopharmaSegment


Income
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value68076650672960336503609358885751620659585823
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest312.8168.2173.2-400.160.6147.1136.2-607.9148.6131.6141.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax56.156.455.947.551.345.944.941.146.744.245.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:OperatingSegments pfe:BiopharmaSegment66.667.967.20.064.363.564.10.065.963.265.6

us-gaap:OperatingSegments, pfe:UpjohnSegment


Income
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value10091168119112081353195122742194205122222168
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest46.429.530.7-80.112.647.152.6-231.949.149.152.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax8.39.99.99.510.714.717.315.715.416.516.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:OperatingSegments pfe:UpjohnSegment52.758.258.90.061.669.574.00.067.670.669.5

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest us-gaap:Restatement

pfe:ScenarioChangeInAccountingPrincipleAdjustment


Income
Period End2021-07-042021-04-042020-06-282020-03-29
Value821468225
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest1.22.62.10.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.41.00.70.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ScenarioChangeInAccountingPrincipleAdjustment0.00.00.00.0

pfe:ScenarioPreviousAccountingPrinciple


Income
Period End2021-07-042021-04-042020-06-282020-03-29
Value6527553629442817
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest98.897.474.572.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax34.438.024.923.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ScenarioPreviousAccountingPrinciple0.00.00.00.0

Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest

us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest

us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest


Income
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value55654877-2025.0220234343410-327.0768050563889-383.041113879357112289285830773130849132020353026-166.0213026352376125726762921226526312588357527611490311031941803149324342588222485624542014
Percentage of IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.333.4-34.118.229.128.4-2.660.638.129.6-2.730.928.827.789.721.723.924.56.210.115.523.3-1.217.622.221.99.621.622.920.019.420.527.620.513.922.321.211.78.914.215.213.55.414.312.2

us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

pfe:ConsumerHealthcareJV


Income
Period End2021-03-312020-12-312020-03-312019-12-31
Value48323342546
Percentage of IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest0.0-11.50.0-14.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ConsumerHealthcareJV0.00.00.00.0

pfe:GSKConsumerHealthcare


Income
Period End2020-09-272020-06-302020-03-312019-09-29
Value355524425152
Percentage of IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest16.10.00.02.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:GSKConsumerHealthcare0.00.00.00.0

Income Tax Expense Benefit

us-gaap:IncomeTaxExpenseBenefit

us-gaap:IncomeTaxExpenseBenefit


Income
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value1043805-491.0-26.0519475-1182.03047-915.0433-564.066648556-11336.0727739821-71.0284375535-188.0567905706545911108258243098517821160680-119.012907508001235109489455814721135
Percentage of IncomeTaxExpenseBenefit100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.55.5-8.3-0.24.43.9-9.324.0-6.93.3-4.00.54.84.3-82.75.55.76.4-0.52.22.94.1-1.34.77.66.54.27.48.55.13.27.813.78.66.3-0.98.64.94.87.26.45.43.58.66.8

us-gaap:IncomeTaxExpenseBenefit us-gaap:Restatement

pfe:ScenarioChangeInAccountingPrincipleAdjustment


Income
Period End2021-07-042021-04-042020-06-282020-03-29
Value1832264.0
Percentage of IncomeTaxExpenseBenefit1.74.05.00.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.10.20.20.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ScenarioChangeInAccountingPrincipleAdjustment0.00.00.00.0

pfe:ScenarioPreviousAccountingPrinciple


Income
Period End2021-07-042021-04-042020-06-282020-03-29
Value1025773396355
Percentage of IncomeTaxExpenseBenefit98.396.076.374.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.45.33.43.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ScenarioPreviousAccountingPrinciple0.00.00.00.0

Income Taxes Paid Net

us-gaap:IncomeTaxesPaidNet

us-gaap:IncomeTaxesPaidNet


Income
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-04-04
Value1794394708115510512391028500190123519894699402571065303926195109131959351896929075237261641653253610754947515545357686764511399802871-134.020810547
Percentage of IncomeTaxesPaidNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax9.52.711.99.58.92.08.13.914.31.814.23.57.02.07.82.37.21.58.02.44.54.06.92.46.33.44.73.44.24.77.93.95.84.15.05.54.52.98.44.75.1-0.81.363.6

Interest Expense

us-gaap:InterestExpense

us-gaap:InterestExpense


Interest
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value316336271416372390416409389361370310326310330320312309297291292306335278278309353343343321347340356391373382379390396423404458427389522
Percentage of InterestExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.72.34.63.43.23.23.33.22.92.82.62.32.42.42.42.42.42.42.22.22.22.42.42.32.32.82.72.82.72.82.62.72.72.93.52.72.52.52.42.52.42.82.72.33.1

Interest Paid Net

us-gaap:InterestPaidNet

us-gaap:InterestPaidNet


Interest
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-03
Value353445344387438472341437424385343244465259417220665216274274521382140248582332221333635361217409670433198481686508213535650687
Percentage of InterestPaidNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.93.15.83.23.73.92.73.43.22.92.51.83.52.03.01.75.21.72.02.14.02.91.02.14.93.11.72.75.03.21.63.25.23.21.83.44.63.31.33.13.84.2

Net Income Loss

us-gaap:NetIncomeLoss

us-gaap:NetIncomeLoss


Net
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value55634877594219434263401-336.0768050463884-393.041143872356112274284030733121860132020193016-172.02130262623761228266629122329256825901409527506315320832531794143937382610222286624752026
Percentage of NetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.333.410.018.129.028.3-2.660.638.029.6-2.830.928.827.689.621.623.824.46.310.115.423.2-1.217.622.221.99.421.622.820.518.920.5108.620.458.823.021.611.68.621.715.413.55.414.412.2

us-gaap:NetIncomeLoss us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

pfe:ConsumerHealthcareJV


Net
Period End2021-03-312020-12-312020-03-312019-12-31
Value46122140537
Percentage of NetIncomeLoss0.037.20.0-11.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ConsumerHealthcareJV0.00.00.00.0

pfe:GSKConsumerHealthcare


Net
Period End2020-09-272020-06-302020-03-312019-09-29
Value348518405148
Percentage of NetIncomeLoss15.90.00.01.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:GSKConsumerHealthcare0.00.00.00.0

us-gaap:NetIncomeLoss us-gaap:Restatement

pfe:ScenarioChangeInAccountingPrincipleAdjustment


Net
Period End2021-07-042021-04-042020-06-282020-03-29
Value6311462-47.0
Percentage of NetIncomeLoss1.12.31.8-1.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.80.5-0.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ScenarioChangeInAccountingPrincipleAdjustment0.00.00.00.0

pfe:ScenarioPreviousAccountingPrinciple


Net
Period End2021-07-042021-04-042020-06-282020-03-29
Value5500476334263401
Percentage of NetIncomeLoss98.997.7100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.032.729.028.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ScenarioPreviousAccountingPrinciple0.00.00.00.0

Net Income Loss Attributable To Noncontrolling Interest

us-gaap:NetIncomeLossAttributableToNoncontrollingInterest

us-gaap:NetIncomeLossAttributableToNoncontrollingInterest


Net
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value269.0118.08.09.010.04.010.06.0118.07.09.015185.09.06.00.0169.03.09.09.06.07.06.09.09.06.09.039156.06.07.09.011118.0125.010.09.0
Percentage of NetIncomeLossAttributableToNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.10.10.20.10.10.10.10.00.10.00.10.10.10.10.10.10.00.10.00.00.10.10.00.10.10.10.10.00.10.10.00.10.30.10.10.00.00.10.10.10.00.10.00.10.1

Net Income Loss Available To Common Stockholders Basic

us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic

us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic


Net
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value55634877595219434263401-337.0768050453883-394.041143871356012274283930733121859131920193016-172.02130262623751228266629112329256825931409927426314320732531794143837382610222286524742025
Percentage of NetIncomeLossAvailableToCommonStockholdersBasic100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.333.410.018.129.028.3-2.760.638.029.6-2.830.928.727.689.621.623.824.46.310.115.423.2-1.217.622.221.99.421.622.820.518.920.5108.720.358.822.921.611.68.621.715.413.55.414.412.2

Net Income Loss Available To Common Stockholders Diluted

us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted

us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted


Net
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value55634877594219434263401-336.0768050463884-393.041143872356112274284030733121859132020193016-171.02130262623761227266629122329256925931409927426315320832531794143937382610222286624752026
Percentage of NetIncomeLossAvailableToCommonStockholdersDiluted100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.333.410.018.129.028.3-2.660.638.029.6-2.830.928.827.689.621.623.824.46.310.115.423.2-1.217.622.221.99.421.622.820.518.920.5108.720.358.823.021.611.68.621.715.413.55.414.412.2

Other Comprehensive Income Loss Net Of Tax

us-gaap:OtherComprehensiveIncomeLossNetOfTax

us-gaap:OtherComprehensiveIncomeLossNetOfTax


Other
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-03
Value-92.06471059572-127.0-1490.0160-275.0-610.0348-859.0-422.0-613.0-80.0-158.01018421449-2825.0678633-4.0-354.0-656.035-1257.0-3853.0-320.0253-121.0308841-331.0-205.0-288.0354-2403.0506-2962.0-262.01106
Percentage of OtherComprehensiveIncomeLossNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-0.54.417.84.7-1.1-12.41.3-2.2-4.62.7-6.1-3.2-4.6-0.6-1.27.73.33.5-20.75.24.8-0.0-2.5-5.40.3-11.6-29.4-2.62.0-1.122.80.3-2.6-1.5-2.72.5-16.03.3-17.7-1.56.7

us-gaap:OtherComprehensiveIncomeLossNetOfTax us-gaap:StatementEquityComponents

us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCredit


Other
Period End2021-07-042021-04-042014-12-31
Value-33.0-33.0445
Percentage of OtherComprehensiveIncomeLossNetOfTax35.9-5.1-11.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-0.2-0.23.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCredit0.00.00.0

us-gaap:AccumulatedGainLossNetCashFlowHedgeParent


Other
Period End2021-07-042021-04-04
Value-220.0380
Percentage of OtherComprehensiveIncomeLossNetOfTax239.158.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-1.22.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:AccumulatedGainLossNetCashFlowHedgeParent0.00.0

us-gaap:AccumulatedNetUnrealizedInvestmentGainLoss


Other
Period End2021-07-042021-04-042014-12-31
Value105-142.0-143.0
Percentage of OtherComprehensiveIncomeLossNetOfTax-114.1-21.93.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.6-1.0-1.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:AccumulatedNetUnrealizedInvestmentGainLoss0.00.00.0

us-gaap:AccumulatedOtherComprehensiveIncome


Other
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012014-12-31
Value-94.06461059569-115.0-1490.0160-265.0-613.0353-859.0-414.0-602.0-81.0-3849.0
Percentage of OtherComprehensiveIncomeLossNetOfTax102.299.8100.099.590.6100.0100.096.4100.5101.4100.098.198.2101.299.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-0.54.417.84.7-1.0-12.41.3-2.1-4.62.7-6.1-3.1-4.5-0.6-29.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:AccumulatedOtherComprehensiveIncome0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedTranslationAdjustment


Other
Period End2021-07-042021-04-042014-12-31
Value53442-1744.0
Percentage of OtherComprehensiveIncomeLossNetOfTax-57.668.345.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.33.0-13.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:AccumulatedTranslationAdjustment0.00.00.0

us-gaap:NoncontrollingInterest


Other
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value2.01.00.03.0-12.00.00.0-9.03.0-4.00.0-9.0-11.01.0
Percentage of OtherComprehensiveIncomeLossNetOfTax-2.20.20.00.59.4-0.00.03.3-0.5-1.1-0.02.11.8-1.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.0-0.10.00.0-0.10.0-0.00.0-0.1-0.10.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NoncontrollingInterest0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:Parent


Other
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value-94.06461059569-115.0-1490.0160-265.0-613.0353-859.0-414.0-602.0-81.0
Percentage of OtherComprehensiveIncomeLossNetOfTax102.299.8100.099.590.6100.0100.096.4100.5101.4100.098.198.2101.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-0.54.417.84.7-1.0-12.41.3-2.1-4.62.7-6.1-3.1-4.5-0.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:Parent0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Other Nonoperating Income Expense

us-gaap:OtherNonoperatingIncomeExpense

us-gaap:OtherNonoperatingIncomeExpense


Other
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value9981004-162.0-1148.0862-221.0-3041.0-319.0-126.0-92.0-3259.0414551178-1331.0-51.0661.0-840.0-1417.0-1068.0-330.0-2190.0-661.0-55.046-344.0-94.053-623.0556120-29.0-128.0-2.0-32.039-206.0-98.0-105.0251.0-3.0-18.0-52.0
Percentage of OtherNonoperatingIncomeExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.36.9-2.7-9.57.3-1.8-24.0-2.5-0.9-0.7-23.33.14.11.4-9.7-0.40.50.0-6.2-10.9-8.1-2.5-15.6-5.5-0.50.4-2.6-0.80.4-5.54.10.9-0.2-0.9-0.0-0.20.3-1.3-0.6-0.60.10.0-0.0-0.1-0.3

us-gaap:OtherNonoperatingIncomeExpense us-gaap:Restatement

pfe:ScenarioChangeInAccountingPrincipleAdjustment


Other
Period End2021-07-042021-04-042020-06-282020-03-29
Value821468225
Percentage of OtherNonoperatingIncomeExpense8.214.59.5-11.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.41.00.70.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ScenarioChangeInAccountingPrincipleAdjustment0.00.00.00.0

pfe:ScenarioPreviousAccountingPrinciple


Other
Period End2021-07-042021-04-042020-06-282020-03-29
Value916857873-216.0
Percentage of OtherNonoperatingIncomeExpense91.885.4101.397.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.85.97.4-1.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ScenarioPreviousAccountingPrinciple0.00.00.00.0

Profit Loss

us-gaap:ProfitLoss

us-gaap:ProfitLoss


Profit
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value55894886606220234343410-326.0768450563889-383.041223879357012289285830783130866131920353026-169.02139263523811236267229212338257425991413427656321321432601803145037492618223487124852035
Percentage of ProfitLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.533.510.218.229.128.4-2.660.638.129.6-2.731.028.827.789.721.723.924.56.410.115.523.3-1.217.722.221.99.421.622.920.619.020.6108.920.558.923.021.711.78.721.815.413.55.414.512.3

us-gaap:ProfitLoss us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

pfe:ConsumerHealthcareJV


Profit
Period End2021-03-312020-12-312020-03-312019-12-31
Value48323342546
Percentage of ProfitLoss0.038.40.0-14.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ConsumerHealthcareJV0.00.00.00.0

pfe:GSKConsumerHealthcare


Profit
Period End2020-09-272020-06-302020-03-312019-09-29
Value355524425152
Percentage of ProfitLoss16.10.00.02.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:GSKConsumerHealthcare0.00.00.00.0

us-gaap:ProfitLoss us-gaap:Restatement

pfe:ScenarioChangeInAccountingPrincipleAdjustment


Profit
Period End2021-07-042021-04-042020-06-282020-03-29
Value6311462-47.0
Percentage of ProfitLoss1.12.31.8-1.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.80.5-0.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ScenarioChangeInAccountingPrincipleAdjustment0.00.00.00.0

pfe:ScenarioPreviousAccountingPrinciple


Profit
Period End2021-07-042021-04-042020-06-282020-03-29
Value5526477234343410
Percentage of ProfitLoss98.997.7100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.132.729.128.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ScenarioPreviousAccountingPrinciple0.00.00.00.0

us-gaap:ProfitLoss us-gaap:StatementEquityComponents

us-gaap:NoncontrollingInterest


Profit
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value269.0118.08.09.010.04.010.06.0118.07.09.0
Percentage of ProfitLoss0.50.21.80.40.20.3-3.10.10.20.2-2.90.20.20.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.10.10.20.10.10.10.10.00.10.00.10.10.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NoncontrollingInterest0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:Parent


Profit
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value55634877594219434263401-336.0768050463884-393.0411438723561
Percentage of ProfitLoss99.599.898.099.699.899.7103.199.999.899.9102.699.899.899.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.333.410.018.129.028.3-2.660.638.029.6-2.830.928.827.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:Parent0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:RetainedEarnings


Profit
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value55634877594219434263401-336.0768050463884-393.0411438723561
Percentage of ProfitLoss99.599.898.099.699.899.7103.199.999.899.9102.699.899.899.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.333.410.018.129.028.3-2.660.638.029.6-2.830.928.827.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Research And Development Expense Excluding Acquired In Process Cost

us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost

us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost


Research
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value245920143189236021321724282322831842170324572008179717432311185917801708251218811748173123481722173418853209180217591623181116271530180021361981169920722596218822372091218821812221
Percentage of ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax13.013.853.619.518.114.322.218.013.913.017.615.113.313.516.914.113.813.418.414.413.313.316.714.214.617.424.514.613.814.313.412.911.813.319.914.211.313.515.512.713.212.713.712.713.4

us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

pfe:Myovant, us-gaap:CollaborativeArrangement


Research
Period End2020-12-26
Value151
Percentage of ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost0.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Myovant us-gaap:CollaborativeArrangement0.0

Revenue From Contract With Customer Excluding Assessed Tax

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax


Revenue
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value18977145825947121311180112028126881268013264131181397713298134661290613703131681289612779136281304513147130051404712087118531086413118123611277311353135581264312973135001073913976150571540516746171931698416502159951713216576
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ConsolidationItems

us-gaap:OperatingSegments


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-29
Value1213111801120281268912303124021225913977132981346612001137031316812896127791362813045131471300513541120871185310864
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.0100.0100.097.093.593.5100.0100.0100.093.0100.0100.0100.0100.0100.0100.0100.0100.096.4100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.0100.0100.097.093.593.5100.0100.0100.093.0100.0100.0100.0100.0100.0100.0100.0100.096.4100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:OperatingSegments100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments

us-gaap:OperatingSegments, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value102159795100071053210108959591859821942294348881
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax84.283.083.283.079.772.370.070.370.970.168.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax84.283.083.283.079.772.370.070.370.970.168.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:OperatingSegments pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, pfe:UpjohnSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value19162006202221562195280730753182303631473120
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax15.817.016.817.017.321.223.422.822.823.424.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax15.817.016.817.017.321.223.422.822.823.424.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:OperatingSegments pfe:UpjohnSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:Currency, us-gaap:StatementGeographical

currency:EUR, pfe:DevelopedEurope


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-31
Value1700170015001800170018001700200018001900170018001700170016001900170019001800200018001800180024002200230022002500210022002100
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax14.014.412.514.213.413.613.014.313.514.113.213.112.913.212.513.913.014.513.814.214.915.216.618.317.818.019.418.416.617.015.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax14.014.412.514.213.413.613.014.313.514.113.213.112.913.212.513.913.014.513.814.214.915.216.618.317.818.019.418.416.617.015.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax currency:EUR pfe:DevelopedEurope100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService

pfe:TotalAllianceBiopharmaceuticals


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value1880177014041382
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax9.912.111.911.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax9.912.111.911.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:TotalAllianceBiopharmaceuticals100.0100.0100.0100.0

pfe:TotalBiosimilars


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value559530289288
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.93.62.42.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.93.62.42.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:TotalBiosimilars100.0100.0100.0100.0

pfe:TotalSterileInjectablePharmaceuticals


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value1381148212331401
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax7.310.210.411.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax7.310.210.411.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:TotalSterileInjectablePharmaceuticals100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService, us-gaap:ReportingUnit

pfe:AllOtherInflammationandImmunologyProducts, pfe:InflammationandImmunology


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value33312622
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.20.20.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.20.20.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:AllOtherInflammationandImmunologyProducts pfe:InflammationandImmunology100.0100.0100.0100.0

pfe:AllOtherInternalMedicine, pfe:InternalMedicine


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value440474455509
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.33.33.94.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.33.33.94.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:AllOtherInternalMedicine pfe:InternalMedicine100.0100.0100.0100.0

pfe:AllOtherRareDiseaseProducts, pfe:RareDisease


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value29263131
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.20.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.20.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:AllOtherRareDiseaseProducts pfe:RareDisease100.0100.0100.0100.0

pfe:Aromasin, pfe:Oncology


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value51523934
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.40.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.40.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Aromasin pfe:Oncology100.0100.0100.0100.0

pfe:BMP2, pfe:InternalMedicine


Revenue
Period End2021-07-042020-06-28
Value6657
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:BMP2 pfe:InternalMedicine100.0100.0

pfe:BNT162b2, pfe:Vaccines


Revenue
Period End2021-07-042021-04-04
Value78383462
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax41.323.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax41.323.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:BNT162b2 pfe:Vaccines100.0100.0

pfe:BeneFIX, pfe:RareDisease


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value112112109121
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.80.91.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.80.91.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:BeneFIX pfe:RareDisease100.0100.0100.0100.0

pfe:Besponsa, pfe:Oncology


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value45504644
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.30.40.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.30.40.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Besponsa pfe:Oncology100.0100.0100.0100.0

pfe:Bosulif, pfe:Oncology


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value136123113100
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.81.00.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.81.00.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Bosulif pfe:Oncology100.0100.0100.0100.0

pfe:Braftovi, pfe:Oncology


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value42473637
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.30.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.30.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Braftovi pfe:Oncology100.0100.0100.0100.0

pfe:ChantixChampix, pfe:InternalMedicine


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value184217235270
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.01.52.02.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.01.52.02.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ChantixChampix pfe:InternalMedicine100.0100.0100.0100.0

pfe:Eliquis, pfe:InternalMedicine


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value1481164312721300
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax7.811.310.810.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax7.811.310.810.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Eliquis pfe:InternalMedicine100.0100.0100.0100.0

pfe:Enbrel, pfe:InflammationandImmunology


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value286319337347
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.52.22.92.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.52.22.92.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Enbrel pfe:InflammationandImmunology100.0100.0100.0100.0

pfe:EpiPen, pfe:Hospital


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value80667584
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.50.60.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.50.60.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:EpiPen pfe:Hospital100.0100.0100.0100.0

pfe:FSMEIMMUNTicoVac, pfe:Vaccines


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value61534548
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.40.40.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.40.40.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:FSMEIMMUNTicoVac pfe:Vaccines100.0100.0100.0100.0

pfe:Fragmin, pfe:Hospital


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value77715859
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.50.50.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.50.50.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Fragmin pfe:Hospital100.0100.0100.0100.0

pfe:Genotropin, pfe:RareDisease


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value10980106103
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.50.90.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.50.90.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Genotropin pfe:RareDisease100.0100.0100.0100.0

pfe:IVIgProducts, pfe:Hospital


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value1071058598
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.70.70.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.70.70.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:IVIgProducts pfe:Hospital100.0100.0100.0100.0

pfe:Ibrance, pfe:Oncology


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value1404125413491248
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax7.48.611.410.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax7.48.611.410.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Ibrance pfe:Oncology100.0100.0100.0100.0

pfe:InflectraRemsima, pfe:InflammationandImmunology


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value136177150158
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.71.21.31.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.71.21.31.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:InflectraRemsima pfe:InflammationandImmunology100.0100.0100.0100.0

pfe:Inlyta, pfe:Oncology


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value257229195169
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.41.61.71.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.41.61.71.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Inlyta pfe:Oncology100.0100.0100.0100.0

pfe:Lorbrena, pfe:Oncology


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value66604642
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.40.40.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.40.40.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Lorbrena pfe:Oncology100.0100.0100.0100.0

pfe:Medrol, pfe:Hospital


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value1129978129
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.70.71.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.70.71.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Medrol pfe:Hospital100.0100.0100.0100.0

pfe:Mektovi, pfe:Oncology


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value36353237
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.20.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.20.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Mektovi pfe:Oncology100.0100.0100.0100.0

pfe:Nimenrix, pfe:Vaccines


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value49465675
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.30.50.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.30.50.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Nimenrix pfe:Vaccines100.0100.0100.0100.0

pfe:OtherAntiinfectives, pfe:Hospital


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value425397321395
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.22.72.73.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.22.72.73.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:OtherAntiinfectives pfe:Hospital100.0100.0100.0100.0

pfe:OtherHospitalProducts, pfe:Hospital


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value569648574610
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.04.44.95.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.04.44.95.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:OtherHospitalProducts pfe:Hospital100.0100.0100.0100.0

pfe:OtherOncologyProducts, pfe:Oncology


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value1381196959
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.80.60.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.80.60.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:OtherOncologyProducts pfe:Oncology100.0100.0100.0100.0

pfe:OtherVaccinesProducts, pfe:Vaccines


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value46493038
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.30.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.30.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:OtherVaccinesProducts pfe:Vaccines100.0100.0100.0100.0

pfe:PfizerCentreOne, pfe:Hospital


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value437391224152
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.32.71.91.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.32.71.91.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:PfizerCentreOne pfe:Hospital100.0100.0100.0100.0

pfe:Precedex, pfe:Hospital


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value425511442
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.41.00.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.41.00.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Precedex pfe:Hospital100.0100.0100.0100.0

pfe:PremarinFamily, pfe:InternalMedicine


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value128143152152
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.71.01.31.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.71.01.31.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:PremarinFamily pfe:InternalMedicine100.0100.0100.0100.0

pfe:PrevnarPrevenarFamily, pfe:Vaccines


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value1241128411161450
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax6.58.89.512.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax6.58.89.512.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:PrevnarPrevenarFamily pfe:Vaccines100.0100.0100.0100.0

pfe:Pristiq, pfe:InternalMedicine


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value42604341
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.40.40.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.40.40.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Pristiq pfe:InternalMedicine100.0100.0100.0100.0

pfe:ReFactoAfXyntha, pfe:RareDisease


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value77899189
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.60.80.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.60.80.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ReFactoAfXyntha pfe:RareDisease100.0100.0100.0100.0

pfe:Retacrit, pfe:Oncology


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value1031098789
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.70.70.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.70.70.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Retacrit pfe:Oncology100.0100.0100.0100.0

pfe:Ruxience, pfe:Oncology


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value12098117.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.70.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.70.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Ruxience pfe:Oncology100.0100.0100.0100.0

pfe:Somavert, pfe:RareDisease


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value68656764
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.40.60.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.40.60.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Somavert pfe:RareDisease100.0100.0100.0100.0

pfe:Sulperazon, pfe:Hospital


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value141192102187
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.71.30.91.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.71.30.91.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Sulperazon pfe:Hospital100.0100.0100.0100.0

pfe:Sutent, pfe:Oncology


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value194200209205
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.01.41.81.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.01.41.81.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Sutent pfe:Oncology100.0100.0100.0100.0

pfe:Toviaz, pfe:InternalMedicine


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value62576460
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.40.50.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.40.50.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Toviaz pfe:InternalMedicine100.0100.0100.0100.0

pfe:Vfend, pfe:Hospital


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value72807574
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.50.60.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.50.60.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Vfend pfe:Hospital100.0100.0100.0100.0

pfe:Vyndaqel, pfe:RareDisease


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value501453277231
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.63.12.31.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.63.12.31.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Vyndaqel pfe:RareDisease100.0100.0100.0100.0

pfe:Xalkori, pfe:Oncology


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value120134138149
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.91.21.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.91.21.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Xalkori pfe:Oncology100.0100.0100.0100.0

pfe:Xeljanz, pfe:InflammationandImmunology


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value586538635451
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.13.75.43.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.13.75.43.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Xeljanz pfe:InflammationandImmunology100.0100.0100.0100.0

pfe:XtandiAllianceRevenues, pfe:Oncology


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value303267266209
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.61.82.31.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.61.82.31.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:XtandiAllianceRevenues pfe:Oncology100.0100.0100.0100.0

pfe:Zavicefta, pfe:Hospital


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value104944649
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.60.40.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.60.40.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Zavicefta pfe:Hospital100.0100.0100.0100.0

pfe:Zirabev, pfe:Oncology


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value129869.06.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.60.10.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.60.10.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Zirabev pfe:Oncology100.0100.0100.0100.0

pfe:ZithromaxZmax, pfe:Hospital


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value438955138
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.60.51.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.60.51.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ZithromaxZmax pfe:Hospital100.0100.0100.0100.0

pfe:Zyvox, pfe:Hospital


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value48555570
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.40.50.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.40.50.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Zyvox pfe:Hospital100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService, us-gaap:ReportingUnit, us-gaap:StatementBusinessSegments

pfe:AllOtherInflammationandImmunologyProducts, pfe:InflammationandImmunology, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value3526225.0156.03.09.0141111
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.20.20.00.10.00.00.10.10.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.20.20.00.10.00.00.10.10.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:AllOtherInflammationandImmunologyProducts pfe:InflammationandImmunology pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:AllOtherInternalMedicine, pfe:InternalMedicine, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value451498480654597631639761727750730
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.74.24.05.24.74.84.95.45.55.65.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.74.24.05.24.74.84.95.45.55.65.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:AllOtherInternalMedicine pfe:InternalMedicine pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:AllOtherRareDiseaseProducts, pfe:RareDisease, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value2731313528357247384376
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.30.30.30.20.30.50.30.30.30.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.30.30.30.20.30.50.30.30.30.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:AllOtherRareDiseaseProducts pfe:RareDisease pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:AllOtherUpjohnProducts, pfe:UpjohnReportingUnit, pfe:UpjohnSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-30
Value442476492405379587523400411
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.64.04.13.23.04.44.02.93.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.64.04.13.23.04.44.02.93.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:AllOtherUpjohnProducts pfe:UpjohnReportingUnit pfe:UpjohnSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:BMP2, pfe:InternalMedicine, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value7057697566796773548073
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.50.60.60.50.60.50.50.40.60.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.50.60.60.50.60.50.50.40.60.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:BMP2 pfe:InternalMedicine pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:BeneFIX, pfe:RareDisease, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value107109121116125121125134132141147
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.90.91.00.91.00.91.01.01.01.01.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.90.91.00.91.00.91.01.01.01.01.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:BeneFIX pfe:RareDisease pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Bosulif, pfe:Oncology, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value1111131009890978090697760
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.91.00.80.80.70.70.60.60.50.60.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.91.00.80.80.70.70.60.60.50.60.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Bosulif pfe:Oncology pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Braftovi, pfe:Oncology, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-31
Value42363730180.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.30.30.20.10.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.30.30.20.10.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Braftovi pfe:Oncology pfe:BiopharmaSegment100.0100.0100.0100.0100.00.00.0

pfe:Celebrex, pfe:UpjohnReportingUnit, pfe:UpjohnSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value133139156193179174174192188161145
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.11.21.31.51.41.31.31.41.41.21.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.11.21.31.51.41.31.31.41.41.21.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Celebrex pfe:UpjohnReportingUnit pfe:UpjohnSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:ChantixChampix, pfe:InternalMedicine, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value223235270282276276273296261277251
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.82.02.22.22.22.12.12.12.02.11.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.82.02.22.22.22.12.12.12.02.11.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ChantixChampix pfe:InternalMedicine pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Effexor, pfe:UpjohnReportingUnit, pfe:UpjohnSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value8086779480867783787971
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.70.60.70.60.60.60.60.60.60.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.70.60.70.60.60.60.60.60.60.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Effexor pfe:UpjohnReportingUnit pfe:UpjohnSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Eliquis, pfe:InternalMedicine, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value1114127213001099102510851011910870889765
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax9.210.810.88.78.18.27.76.56.56.65.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax9.210.810.88.78.18.27.76.56.56.65.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Eliquis pfe:InternalMedicine pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Enbrel, pfe:InflammationandImmunology, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value321337347414415420451523531551506
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.62.92.93.33.33.23.43.74.04.13.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.62.92.93.33.33.23.43.74.04.13.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Enbrel pfe:InflammationandImmunology pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:EpiPen, pfe:UpjohnReportingUnit, pfe:UpjohnSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-09-292019-06-302019-03-31
Value586472746756
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.50.60.60.50.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.50.60.60.50.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:EpiPen pfe:UpjohnReportingUnit pfe:UpjohnSegment100.0100.0100.0100.0100.0100.0

pfe:FSMEIMMUNTicoVac, pfe:Vaccines, pfe:BiopharmaSegment


Revenue
Period End2020-09-272019-12-312019-09-292019-06-302018-12-312018-09-302018-07-01
Value77236495225773
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.20.50.70.20.40.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.20.50.70.20.40.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:FSMEIMMUNTicoVac pfe:Vaccines pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0

pfe:Fragmin, pfe:Hospital, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value6058596862636072767470
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.50.50.50.50.50.50.50.60.50.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.50.50.50.50.50.50.50.60.50.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Fragmin pfe:Hospital pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Genotropin, pfe:RareDisease, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value107106103141124125107142143140132
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.90.90.91.11.00.90.81.01.11.01.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.90.90.91.11.00.90.81.01.11.01.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Genotropin pfe:RareDisease pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Ibrance, pfe:Oncology, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value1357134912481284128312611133113310251027933
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax11.211.410.410.110.19.58.68.17.77.67.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax11.211.410.410.110.19.58.68.17.77.67.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Ibrance pfe:Oncology pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:InflectraRemsima, pfe:InflammationandImmunology, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value162150158179155153138173166158145
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.31.31.31.41.21.21.11.21.21.21.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.31.31.31.41.21.21.11.21.21.21.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:InflectraRemsima pfe:InflammationandImmunology pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Inlyta, pfe:Oncology, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value1951951691611391047372718174
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.61.71.41.31.10.80.60.50.50.60.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.61.71.41.31.10.80.60.50.50.60.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Inlyta pfe:Oncology pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Lipitor, pfe:UpjohnReportingUnit, pfe:UpjohnSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value356431405467476407622523507521511
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.93.73.43.73.83.14.73.73.83.94.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.93.73.43.73.83.14.73.73.83.94.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Lipitor pfe:UpjohnReportingUnit pfe:UpjohnSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Lorbrena, pfe:Oncology, pfe:BiopharmaSegment


Revenue
Period End2020-09-272019-09-29
Value5532
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Lorbrena pfe:Oncology pfe:BiopharmaSegment100.0100.0

pfe:Lyrica, pfe:UpjohnReportingUnit, pfe:UpjohnSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value352349357433527117511861321121312231213
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.93.03.03.44.28.99.09.59.19.19.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.93.03.03.44.28.99.09.59.19.19.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Lyrica pfe:UpjohnReportingUnit pfe:UpjohnSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Medrol, pfe:Hospital, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value8778129121109120120124110123136
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.71.11.00.90.90.90.90.80.91.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.71.11.00.90.90.90.90.80.91.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Medrol pfe:Hospital pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Mektovi, pfe:Oncology, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-31
Value34323730190.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.30.30.20.10.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.30.30.20.10.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Mektovi pfe:Oncology pfe:BiopharmaSegment100.0100.0100.0100.0100.00.00.0

pfe:Nimenrix, pfe:Vaccines, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-01
Value50567571525850454630
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.50.60.60.40.40.40.30.30.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.50.60.60.40.40.40.30.30.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Nimenrix pfe:Vaccines pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Norvasc, pfe:UpjohnReportingUnit, pfe:UpjohnSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value183222197215219216300252248273256
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.51.91.61.71.71.62.31.81.92.02.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.51.91.61.71.71.62.31.81.92.02.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Norvasc pfe:UpjohnReportingUnit pfe:UpjohnSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:OtherAntiinfectives, pfe:Hospital, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value384367444153335367354112300362392
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.23.13.71.22.62.82.70.82.32.73.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.23.13.71.22.62.82.70.82.32.73.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:OtherAntiinfectives pfe:Hospital pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:OtherHospitalProducts, pfe:Hospital, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value568603684526656623631673669748708
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.75.15.74.15.24.74.84.85.05.65.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.75.15.74.15.24.74.84.85.05.65.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:OtherHospitalProducts pfe:Hospital pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:OtherOncologyProducts, pfe:Oncology, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value217221192129194140153104101100119
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.81.91.61.01.51.11.20.70.80.70.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.81.91.61.01.51.11.20.70.80.70.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:OtherOncologyProducts pfe:Oncology pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:OtherVaccinesProducts, pfe:Vaccines, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value56758619164312625214783
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.60.70.10.10.31.00.20.20.30.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.60.70.10.10.31.00.20.20.30.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:OtherVaccinesProducts pfe:Vaccines pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Panzyga, pfe:Hospital, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-31
Value62637476464417
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.50.60.60.40.30.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.50.60.60.40.30.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Panzyga pfe:Hospital pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0

pfe:PfizerCentreOne, pfe:Hospital, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-30
Value242224152254176204176216159
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.01.91.32.01.41.51.31.51.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.01.91.32.01.41.51.31.51.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:PfizerCentreOne pfe:Hospital pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Precedex, pfe:Hospital, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282019-09-292019-06-30
Value551143640
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.51.00.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.51.00.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Precedex pfe:Hospital pfe:BiopharmaSegment100.0100.0100.0100.0

pfe:PremarinFamily, pfe:InternalMedicine, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value168152152192182193168227204210191
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.41.31.31.51.41.51.31.61.51.61.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.41.31.31.51.41.51.31.61.51.61.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:PremarinFamily pfe:InternalMedicine pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:PrevnarPrevenarFamily, pfe:Vaccines, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value15341116145015791603117914861512166012501380
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax12.69.512.112.412.68.911.310.812.59.310.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax12.69.512.112.412.68.911.310.812.59.310.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:PrevnarPrevenarFamily pfe:Vaccines pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:ReFactoAfXyntha, pfe:RareDisease, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value929189107104108106126117141130
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.80.80.70.80.80.80.80.90.91.01.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.80.80.70.80.80.80.80.90.91.01.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ReFactoAfXyntha pfe:RareDisease pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Retacrit, pfe:Oncology, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-01
Value102878978645131271918
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.80.70.70.60.50.40.20.20.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.80.70.70.60.50.40.20.20.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Retacrit pfe:Oncology pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Ruxience, pfe:Oncology, pfe:BiopharmaSegment


Revenue
Period End2020-09-27
Value59
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Ruxience pfe:Oncology pfe:BiopharmaSegment100.0

pfe:Somavert, pfe:RareDisease, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value6767647264685972646863
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.60.50.60.50.50.40.50.50.50.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.60.50.60.50.50.40.50.50.50.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Somavert pfe:RareDisease pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Sulperazon, pfe:Hospital, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value143102187179163165177149145150168
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.20.91.61.41.31.21.31.11.11.11.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.20.91.61.41.31.21.31.11.11.11.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Sulperazon pfe:Hospital pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Sutent, pfe:Oncology, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value202209205232224248232264248275262
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.71.81.71.81.81.91.81.91.92.02.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.71.81.71.81.81.91.81.91.92.02.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Sutent pfe:Oncology pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Toviaz, pfe:InternalMedicine, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value5964606461656074677060
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.50.50.50.50.50.50.50.50.50.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.50.50.50.50.50.50.50.50.50.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Toviaz pfe:InternalMedicine pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Vfend, pfe:Hospital, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value52757481879485988711098
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.60.60.60.70.70.60.70.70.80.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.60.60.60.70.70.60.70.70.80.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Vfend pfe:Hospital pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Viagra, pfe:UpjohnReportingUnit, pfe:UpjohnSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value12194127118120114145127137185187
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.00.81.10.90.90.91.10.91.01.41.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.00.81.10.90.90.91.10.91.01.41.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Viagra pfe:UpjohnReportingUnit pfe:UpjohnSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Vyndaqel, pfe:RareDisease, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-01
Value3512772312141566341403738
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.92.31.91.71.20.50.30.30.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.92.31.91.71.20.50.30.30.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Vyndaqel pfe:RareDisease pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:XalatanXalacom, pfe:UpjohnReportingUnit, pfe:UpjohnSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value6265618068726285768572
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.60.50.60.50.50.50.60.60.60.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.60.50.60.50.50.50.60.60.60.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:XalatanXalacom pfe:UpjohnReportingUnit pfe:UpjohnSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Xalkori, pfe:Oncology, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value122138149145130133123107127137153
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.01.21.21.11.01.00.90.81.01.01.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.01.21.21.11.01.00.90.81.01.01.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Xalkori pfe:Oncology pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Xanax, pfe:UpjohnReportingUnit, pfe:UpjohnSegment


Revenue
Period End2020-09-272019-12-312019-09-292019-06-302018-12-312018-09-302018-07-01
Value55515052605256
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.40.40.40.40.40.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.40.40.40.40.40.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Xanax pfe:UpjohnReportingUnit pfe:UpjohnSegment100.0100.0100.0100.0100.0100.0100.0

pfe:Xeljanz, pfe:InflammationandImmunology, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value654635451608599613423553432463326
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.45.43.74.84.74.63.24.03.23.42.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.45.43.74.84.74.63.24.03.23.42.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Xeljanz pfe:InflammationandImmunology pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:XtandiAllianceRevenues, pfe:Oncology, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-30
Value266266209244225201168189180
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.22.31.71.91.81.51.31.41.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.22.31.71.91.81.51.31.41.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:XtandiAllianceRevenues pfe:Oncology pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:ZithromaxZmax, pfe:Hospital, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value2555138827773104836181101
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.51.10.60.60.60.80.60.50.60.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.51.10.60.60.60.80.60.50.60.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ZithromaxZmax pfe:Hospital pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Zoloft, pfe:UpjohnReportingUnit, pfe:UpjohnSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value7679787774736975727774
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.70.60.60.60.60.50.50.50.60.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.70.60.60.60.60.50.50.50.60.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Zoloft pfe:UpjohnReportingUnit pfe:UpjohnSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Zyvox, pfe:Hospital, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value5155705661716452506668
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.50.60.40.50.50.50.40.40.50.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.50.60.40.50.50.50.40.40.50.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Zyvox pfe:Hospital pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService, us-gaap:StatementBusinessSegments

pfe:TotalAllianceBiopharmaceuticals, pfe:BiopharmaUpjohnAndConsumerHealthcareSegments


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-30
Value12501404138212301141118710901018977
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax10.311.911.59.79.08.98.37.37.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax10.311.911.59.79.08.98.37.37.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:TotalAllianceBiopharmaceuticals pfe:BiopharmaUpjohnAndConsumerHealthcareSegments100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:TotalBiosimilars, pfe:BiopharmaUpjohnAndConsumerHealthcareSegments


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-30
Value424289288279236217179211197
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.52.42.42.21.91.61.41.51.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.52.42.42.21.91.61.41.51.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:TotalBiosimilars pfe:BiopharmaUpjohnAndConsumerHealthcareSegments100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:TotalSterileInjectablePharmaceuticals, pfe:BiopharmaUpjohnAndConsumerHealthcareSegments


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-30
Value119512371407133212481218123712861239
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax9.910.511.710.59.89.29.49.29.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax9.910.511.710.59.89.29.49.29.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:TotalSterileInjectablePharmaceuticals pfe:BiopharmaUpjohnAndConsumerHealthcareSegments100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ReportingUnit

pfe:Hospital


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value2259234318632088
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax11.916.115.817.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax11.916.115.817.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Hospital100.0100.0100.0100.0

pfe:InflammationandImmunology


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value104110651149978
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.57.39.78.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.57.39.78.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:InflammationandImmunology100.0100.0100.0100.0

pfe:InternalMedicine


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value2403259422792332
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax12.717.819.319.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax12.717.819.319.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:InternalMedicine100.0100.0100.0100.0

pfe:Oncology


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value3145286226472435
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax16.619.622.420.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax16.619.622.420.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Oncology100.0100.0100.0100.0

pfe:RareDisease


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value895824681639
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.75.75.85.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.75.75.85.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:RareDisease100.0100.0100.0100.0

pfe:Vaccines


Revenue
Period End2021-07-042021-04-042020-06-282020-03-29
Value9234489412471611
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax48.733.610.613.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax48.733.610.613.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Vaccines100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ReportingUnit, us-gaap:StatementBusinessSegments

pfe:Hospital, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value17281794201220551917191318872011184120772026
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax14.215.216.716.215.114.414.414.413.815.415.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax14.215.216.716.215.114.414.414.413.815.415.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Hospital pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:InflammationandImmunology, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value1173114997812511226121910371301118412221013
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax9.79.78.19.99.79.27.99.38.99.17.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax9.79.78.19.99.79.27.99.38.99.17.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:InflammationandImmunology pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:InternalMedicine, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value20852279233223652207233022172340218222762071
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax17.219.319.418.617.417.616.916.716.416.916.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax17.219.319.418.617.417.616.916.716.416.916.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:InternalMedicine pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Oncology, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value27612647243524672350223619611984184018881760
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax22.822.420.219.418.516.914.914.213.814.013.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax22.822.420.219.418.516.914.914.213.814.013.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Oncology pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:RareDisease, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value752681639686601521470560531571549
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax6.25.85.35.44.73.93.64.04.04.24.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax6.25.85.35.44.73.93.64.04.04.24.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:RareDisease pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:UpjohnReportingUnit, pfe:UpjohnSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value19162006202221562195280730753182303631473120
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax15.817.016.817.017.321.223.422.822.823.424.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax15.817.016.817.017.321.223.422.822.823.424.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:UpjohnReportingUnit pfe:UpjohnSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:Vaccines, pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value17171247161117091808137516121624184514001463
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax14.210.613.413.514.310.412.311.613.910.411.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax14.210.613.413.514.310.412.311.613.910.411.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:Vaccines pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementBusinessSegments

pfe:BiopharmaSegment


Revenue
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value102159795100071053210108959591859821942294348881
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax84.283.083.283.079.772.370.070.370.970.168.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax84.283.083.283.079.772.370.070.370.970.168.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:BiopharmaSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:BiopharmaUpjohnAndConsumerHealthcareSegments


Revenue
Period End2020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-01
Value121311180112028126801326413118132981346612906
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:BiopharmaUpjohnAndConsumerHealthcareSegments100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementGeographical

country:US


Revenue
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-03
Value759375974942571654025651549258506335617564686361622562756510653463456637680865306335662567115565499444335050484249064275508451865090536840105627572259546330687967007024
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax40.052.183.147.145.847.043.346.147.847.146.347.846.248.647.549.649.251.950.050.148.250.947.846.042.140.838.539.238.437.737.541.039.239.837.340.338.038.637.840.039.442.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax40.052.183.147.145.847.043.346.147.847.146.347.846.248.647.549.649.251.950.050.148.250.947.846.042.140.838.539.238.437.737.541.039.239.837.340.338.038.637.840.039.442.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:DevelopedEurope


Revenue
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-03
Value457730381693208720881921225121352228208624592231233420922199216321242021232422182440237027082315238023123078283730082795323727852913302925202976349735924219402741673884
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax24.120.828.517.217.716.017.716.816.815.917.616.817.316.216.016.416.515.817.117.018.618.219.319.220.121.323.523.023.524.623.922.022.522.423.521.323.223.325.223.424.523.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax24.120.828.517.217.716.017.716.816.815.917.616.817.316.216.016.416.515.817.117.018.618.219.319.220.121.323.523.023.524.623.922.022.522.423.521.323.223.325.223.424.523.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:DevelopedEurope100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:DevelopedRestOfWorld


Revenue
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-03
Value29971123-606.0163415521456170715851639153517561640169414611815163216111554178917111718152017361513155814931910181618611728220719922108217221262529269326353117280726212546
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax15.87.7-10.213.513.212.113.512.512.411.712.612.312.611.313.212.412.512.213.113.113.111.712.412.513.113.714.614.714.615.216.315.816.216.119.818.117.917.118.616.315.415.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax15.87.7-10.213.513.212.113.512.512.411.712.612.312.611.313.212.412.512.213.113.113.111.712.412.513.113.714.614.714.615.216.315.816.216.119.818.117.917.118.616.315.415.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:DevelopedRestOfWorld100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

pfe:EmergingMarkets


Revenue
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-03
Value38102824-81.0269427593001324031103062332232933066321430783177283928152567270625862655248928932694292126263080286629982555303026802862293120832844314532244641289625193048
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax20.119.4-1.422.223.425.025.524.523.125.323.623.123.923.823.221.621.820.119.919.820.219.120.622.324.624.223.523.223.522.522.321.222.121.719.420.320.920.927.716.814.818.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax20.119.4-1.422.223.425.025.524.523.125.323.623.123.923.823.221.621.820.119.919.820.219.120.622.324.624.223.523.223.522.522.321.222.121.719.420.320.920.927.716.814.818.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:EmergingMarkets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Revenues

us-gaap:Revenues us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

us-gaap:Revenues

pfe:ConsumerHealthcareJV


Revenuesus-gaap:
Period End2021-03-312020-12-312020-03-312019-12-31
Value3180309635033188
Percentage of Revenues100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ConsumerHealthcareJV0.00.00.00.0

pfe:GSKConsumerHealthcare


Revenuesus-gaap:
Period End2020-09-272020-06-302020-03-312019-09-29
Value3102292735032161
Percentage of Revenues0.00.0100.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:GSKConsumerHealthcare0.00.00.00.0

Selling General And Administrative Expense

us-gaap:SellingGeneralAndAdministrativeExpense

us-gaap:SellingGeneralAndAdministrativeExpense


Selling
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value292827832696301630302873424032603511333940073494354234124551350034253308442335593471338550483270338631043981355635203040415233953591358548153847397741335371462149734503459947744403
Percentage of SellingGeneralAndAdministrativeExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax15.419.145.324.925.723.933.425.726.525.528.726.326.326.433.226.626.625.932.527.326.426.035.927.128.628.630.328.827.626.830.626.927.726.644.827.526.426.832.126.929.327.328.827.926.6

Assets

us-gaap:Assets

us-gaap:Assets


Assets
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value169920158818154229178983177934166336167489170446156199155421159000167838165000164612172000172151168558168784171615178430170658162929167460170867160878160640169274171362172612171808172101175521179335187398185798182603182842185683188002196132195899194956195014212949
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:Assets us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

pfe:GSKConsumerHealthcare


Assetsus-gaap:
Period End2020-09-272020-06-302020-03-312019-09-29
Value44975442444584046081
Percentage of Assets25.10.00.027.0
Percentage of Assets25.10.00.027.0
Percentage of Assets pfe:GSKConsumerHealthcare100.0100.0100.0100.0

us-gaap:Assets us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency

us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring


Assetsus-gaap:
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312016-12-31
Value371130462776206320461581186315131467133312601594177315901523794
Percentage of Assets2.21.91.81.21.11.01.10.90.90.90.80.91.11.00.90.5
Percentage of Assets2.21.91.81.21.11.01.10.90.90.90.80.91.11.00.90.5
Percentage of Assets us-gaap:FairValueInputsLevel1 us-gaap:FairValueMeasurementsRecurring100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring


Assetsus-gaap:
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312016-12-31
Value17618111191150121504223559042931372901133410512183351727214668135972341421403
Percentage of Assets10.47.07.512.012.65.45.64.37.36.811.510.38.98.313.612.5
Percentage of Assets10.47.07.512.012.65.45.64.37.36.811.510.38.98.313.612.5
Percentage of Assets us-gaap:FairValueInputsLevel2 us-gaap:FairValueMeasurementsRecurring100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:Assets us-gaap:FairValueByMeasurementFrequency

us-gaap:FairValueMeasurementsRecurring


Assetsus-gaap:
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312016-12-31
Value2133014165142782356724402106231117688031280111845195951886616440151882493722197
Percentage of Assets12.68.99.313.213.76.46.75.28.27.612.311.210.09.214.512.9
Percentage of Assets12.68.99.313.213.76.46.75.28.27.612.311.210.09.214.512.9
Percentage of Assets us-gaap:FairValueMeasurementsRecurring100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:Assets us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

pfe:ViivHealthcareLimited, pfe:ViivHealthcareLimited


Assetsus-gaap:
Period End2020-12-312019-12-31
Value66647276
Percentage of Assets4.34.3
Percentage of Assets4.34.3
Percentage of Assets pfe:ViivHealthcareLimited pfe:ViivHealthcareLimited100.0100.0

Liabilities

us-gaap:Liabilities

us-gaap:Liabilities


Liabilities
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value996058995390756113487113370100998104042105051962749626395664961749485694071100141111041109863110038111776114829107592995821024631037439369893053976529305795656937409548197167100358104571104120100488102881102006105381105602106936104423106749122503
Percentage of Liabilities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets58.656.658.863.463.760.762.161.661.661.960.257.357.557.158.264.565.265.265.164.463.061.161.260.758.257.957.754.355.454.655.555.456.055.856.055.056.354.956.153.854.653.654.757.5

us-gaap:Liabilities us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

pfe:GSKConsumerHealthcare


Liabilitiesus-gaap:
Period End2020-09-272020-06-302020-03-312019-09-29
Value10576101871067710776
Percentage of Liabilities9.30.00.010.3
Percentage of Assets5.90.00.06.3
Percentage of Assets pfe:GSKConsumerHealthcare23.523.023.323.4

us-gaap:Liabilities us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

pfe:ViivHealthcareLimited, pfe:ViivHealthcareLimited


Liabilitiesus-gaap:
Period End2020-12-312019-12-31
Value93988765
Percentage of Liabilities10.48.4
Percentage of Assets6.15.2
Percentage of Assets pfe:ViivHealthcareLimited pfe:ViivHealthcareLimited141.0120.5

Liabilities And Stockholders Equity

us-gaap:LiabilitiesAndStockholdersEquity

us-gaap:LiabilitiesAndStockholdersEquity


Liabilities
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value169920158818154229178983177934166336167489170446156199155421159422167838164980164612171797172151168558168784171615178430170658162929167460170867160878160640169274171362172612171808172101175521179335187398185798182603182842185683188002196132195899194956195014212949
Percentage of LiabilitiesAndStockholdersEquity100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.3100.0100.0100.099.9100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Stockholders Equity

us-gaap:StockholdersEquity

us-gaap:StockholdersEquity


Stockholders
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value7004268620632386525964336650266314365103595685880663407713196977870184713086077058368584355954463306627696306864720668386689467304713017798876633777697630777969785478225081260817037954783256821909004788481900678781390014
Percentage of StockholdersEquity100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets41.243.241.036.536.239.137.738.238.137.839.942.542.342.641.535.334.634.634.735.536.838.738.639.141.641.942.145.544.445.344.344.443.843.943.744.743.544.843.745.945.246.245.042.3

us-gaap:StockholdersEquity us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

pfe:GSKConsumerHealthcare


Stockholders
Period End2020-09-272020-06-302020-03-312019-09-29
Value34154339193503135199
Percentage of StockholdersEquity52.30.00.054.1
Percentage of Assets19.10.00.020.7
Percentage of Assets pfe:GSKConsumerHealthcare75.976.776.476.4

us-gaap:StockholdersEquity us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

pfe:ViivHealthcareLimited, pfe:ViivHealthcareLimited


Stockholders
Period End2020-12-312019-12-31
Value-2734.0-1489.0
Percentage of StockholdersEquity-4.3-2.4
Percentage of Assets-1.8-0.9
Percentage of Assets pfe:ViivHealthcareLimited pfe:ViivHealthcareLimited-41.0-20.5

us-gaap:StockholdersEquity us-gaap:StatementEquityComponents

us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCredit


Stockholders
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312013-12-312012-12-31
Value482518549584591658693728776814855750783814847879919889855880960992703733313259
Percentage of StockholdersEquity0.70.80.80.90.91.11.21.11.11.21.21.11.31.41.41.51.51.41.41.41.41.51.01.00.40.3
Percentage of Assets0.30.30.30.30.30.40.40.50.50.50.50.40.50.50.50.50.50.50.50.50.60.60.40.40.20.1
Percentage of Assets us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCredit0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLoss


Stockholders
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312013-12-312012-12-31
Value-7074.0-6178.0-6296.0-6257.0-5933.0-5911.0-5986.0-6027.0-5538.0-5657.0-5764.0-5262.0-5210.0-5198.0-5278.0-5473.0-4423.0-4538.0-4585.0-4733.0-5303.0-5330.0-5398.0-5654.0-3223.0-6110.0
Percentage of StockholdersEquity-10.8-9.6-9.7-9.9-9.1-9.9-10.2-9.5-7.8-8.1-8.2-7.4-8.6-8.9-9.0-9.2-7.0-7.2-7.3-7.3-7.9-8.0-8.0-7.9-4.2-7.5
Percentage of Assets-4.0-3.5-3.8-3.7-3.5-3.8-3.9-3.8-3.3-3.4-3.5-3.1-3.0-3.1-3.1-3.2-2.5-2.7-2.8-2.8-3.1-3.3-3.4-3.3-1.9-3.3
Percentage of Assets us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLoss0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedGainLossNetCashFlowHedgeParent


Stockholders
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012017-12-312016-12-312015-12-31
Value-526.0-333.0-344.02060-33.0167167248267-30.0348421
Percentage of StockholdersEquity-0.8-0.5-0.50.00.1-0.10.30.30.30.4-0.00.60.7
Percentage of Assets-0.3-0.2-0.20.00.0-0.00.10.10.10.2-0.00.20.3
Percentage of Assets us-gaap:AccumulatedGainLossNetCashFlowHedgeParent0.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedNetUnrealizedInvestmentGainLoss


Stockholders
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312013-12-312012-12-31
Value1449.0-67.0-35.00.0-8.0-24.0-68.0-131.0-230.0-28.0401339221108-131.029517269-227.0913.0-271.0-222.0150236
Percentage of StockholdersEquity0.20.0-0.1-0.10.0-0.0-0.0-0.1-0.2-0.3-0.00.60.60.40.2-0.20.50.30.1-0.40.10.0-0.4-0.30.20.3
Percentage of Assets0.10.0-0.0-0.00.0-0.0-0.0-0.0-0.1-0.1-0.00.20.20.10.1-0.10.20.10.0-0.10.10.0-0.2-0.10.10.1
Percentage of Assets us-gaap:AccumulatedNetUnrealizedInvestmentGainLoss0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedOtherComprehensiveIncome


Stockholders
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312013-12-312012-12-31
Value-12676.0-13246.0-13131.0-11640.0-11801.0-11535.0-10923.0-11275.0-10417.0-10003.0-9402.0-9321.0-9164.0-10181.0-10594.0-11036.0-8214.0-8891.0-9520.0-9522.0-9170.0-8521.0-8557.0-7316.0-3271.0-5953.0
Percentage of StockholdersEquity-19.4-20.6-20.2-18.4-18.1-19.4-18.6-17.8-14.6-14.3-13.4-13.1-15.1-17.4-18.1-18.5-13.0-14.2-15.1-14.7-13.7-12.7-12.7-10.3-4.3-7.3
Percentage of Assets-7.1-7.4-7.9-6.9-6.9-7.4-7.0-7.1-6.2-6.1-5.7-5.4-5.3-6.0-6.3-6.4-4.6-5.2-5.8-5.7-5.4-5.3-5.3-4.3-1.9-3.2
Percentage of Assets us-gaap:AccumulatedOtherComprehensiveIncome0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedTranslationAdjustment


Stockholders
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312013-12-312012-12-31
Value-5703.0-7262.0-6973.0-5952.0-6519.0-6242.0-5772.0-6075.0-5772.0-5198.0-4375.0-5180.0-5021.0-5957.0-6417.0-6659.0-4847.0-5265.0-5776.0-5863.0-4926.0-4404.0-4067.0-2689.0-590.0-177.0
Percentage of StockholdersEquity-8.7-11.3-10.7-9.4-10.0-10.5-9.8-9.6-8.1-7.4-6.2-7.3-8.3-10.2-11.0-11.2-7.7-8.4-9.2-9.1-7.4-6.6-6.0-3.8-0.8-0.2
Percentage of Assets-3.2-4.1-4.2-3.6-3.8-4.0-3.7-3.8-3.4-3.2-2.7-3.0-2.9-3.5-3.8-3.9-2.7-3.1-3.5-3.5-2.9-2.7-2.5-1.6-0.3-0.1
Percentage of Assets us-gaap:AccumulatedTranslationAdjustment0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Assets Current

us-gaap:AssetsCurrent

us-gaap:AssetsCurrent


Assets
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value4881439533350674773946424347383280333459470734529049926415833730334835411414029136385358783894938501438454129843804450015171549443577025698758287577935624459500614356476361415571275876554863577286273260484582446046861670
Percentage of AssetsCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets28.724.922.726.726.120.919.619.630.129.131.424.822.621.223.923.421.621.322.721.625.725.326.226.332.130.834.133.333.833.632.733.934.334.633.131.332.129.530.732.030.929.931.029.0

us-gaap:AssetsCurrent us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

pfe:GSKConsumerHealthcare


Assets
Period End2020-09-272020-06-302020-03-312019-09-29
Value6614713682137505
Percentage of AssetsCurrent13.90.00.022.4
Percentage of Assets3.70.00.04.4
Percentage of Assets pfe:GSKConsumerHealthcare14.716.117.916.3

us-gaap:AssetsCurrent us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

pfe:ViivHealthcareLimited, pfe:ViivHealthcareLimited


Assets
Period End2020-12-312019-12-31
Value32833839
Percentage of AssetsCurrent9.411.7
Percentage of Assets2.12.3
Percentage of Assets pfe:ViivHealthcareLimited pfe:ViivHealthcareLimited49.352.8

Cash And Cash Equivalents At Carrying Value

us-gaap:CashAndCashEquivalentsAtCarryingValue

us-gaap:CashAndCashEquivalentsAtCarryingValue


Cash
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312010-10-032010-07-042010-04-042010-01-042009-12-312009-09-272008-12-312007-12-31
Value237217681784158718012151130527851784193711393559270423021342277925854057259520943411256136413099367035633343243734062862218320522436213410389450630312934353937063096730173521761877175919781978423421223406
Percentage of CashAndCashEquivalentsAtCarryingValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets1.41.11.20.91.01.30.81.61.11.20.72.11.61.40.81.61.52.41.51.22.01.62.21.82.32.22.01.42.01.71.31.21.41.15.62.51.71.61.91.91.60.40.90.00.00.00.00.90.00.00.0

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents


Cash
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312015-12-31
Value24181809182516271845219613502846183720181225365828112416143128582661413126663707
Percentage of CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets1.41.11.20.91.01.30.81.71.21.30.82.21.71.50.81.71.62.41.62.2

Short Term Investments

us-gaap:ShortTermInvestments

us-gaap:ShortTermInvestments


Short
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value19328118991043720325209938199852563021112896821769413680107279119186501414611748105031525512277175311688219649175592658624145327793100930648310193022531627312753321222319184622127521038232192525722388232792627723991
Percentage of ShortTermInvestments100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets11.47.56.811.411.84.95.13.77.16.211.18.26.55.510.88.27.06.28.96.910.310.411.710.316.515.019.418.117.818.117.618.017.417.712.010.111.611.312.412.911.411.913.511.3

Accounts Receivable Net Current

us-gaap:AccountsReceivableNetCurrent

us-gaap:AccountsReceivableNetCurrent


Accounts
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value10587986479301001291289881872494399793959980251002498739452822110002947688928225983691389033817695358951892086699955103889399935711371115231273512378125231288214182136081574915192151821461214645
Percentage of AccountsReceivableNetCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets6.26.25.15.65.15.95.25.56.36.25.06.06.05.74.85.85.65.34.85.55.45.54.95.65.65.65.15.86.05.55.46.56.46.86.76.97.07.67.28.07.87.87.56.9

Inventory Net

us-gaap:InventoryNet

us-gaap:InventoryNet


Inventory
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value894884938046929585648423828382228233802975088184807481487578792575847415678375077614757875137678579657865663635562496066616664826282703570637516700171897769842685978467840512403
Percentage of InventoryNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets5.35.35.25.24.85.14.94.85.35.24.74.94.94.94.44.64.54.44.04.24.54.74.54.53.63.63.33.73.63.53.63.73.53.83.84.13.83.94.14.34.44.34.35.8

Other Assets Current

us-gaap:OtherAssetsCurrent

us-gaap:OtherAssetsCurrent


Other
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312012-12-31
Value38184091343825192513273726002954253525672461245023432126228921581877221822492843302323552163224824492815275025452727347336133567
Percentage of OtherAssetsCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets2.22.62.21.41.41.61.61.71.61.71.51.51.41.31.31.31.11.31.31.61.81.41.31.31.51.81.61.51.62.02.11.9

Assets Noncurrent

us-gaap:AssetsNoncurrent us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

us-gaap:AssetsNoncurrent

pfe:GSKConsumerHealthcare


Assets
Period End2020-09-272020-06-302019-09-29
Value383613710838575
Percentage of AssetsNoncurrent100.0100.0100.0
Percentage of Assets21.40.022.6
Percentage of Assets pfe:GSKConsumerHealthcare85.383.983.7

us-gaap:AssetsNoncurrent us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

pfe:ViivHealthcareLimited, pfe:ViivHealthcareLimited


Assets
Period End2020-12-312019-12-31
Value33813437
Percentage of AssetsNoncurrent0.00.0
Percentage of Assets2.22.1
Percentage of Assets pfe:ViivHealthcareLimited pfe:ViivHealthcareLimited50.747.2

Property Plant And Equipment Gross

us-gaap:PropertyPlantAndEquipmentGross

us-gaap:PropertyPlantAndEquipmentGross


Property
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-31
Value287113075629977300372812527268249882567827882305223229833924
Percentage of PropertyPlantAndEquipmentGross100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets18.618.418.917.516.416.314.814.915.016.216.615.9

us-gaap:PropertyPlantAndEquipmentGross us-gaap:PropertyPlantAndEquipmentByType

us-gaap:Building


Property
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Value90221006899201025498109604935510055
Percentage of PropertyPlantAndEquipmentGross31.432.733.134.134.935.237.439.2
Percentage of Assets5.86.06.26.05.75.75.55.8
Percentage of Assets us-gaap:Building0.00.00.00.00.00.00.00.0

us-gaap:ConstructionInProgress


Property
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Value35522960299226802127179112711102
Percentage of PropertyPlantAndEquipmentGross12.49.610.08.97.66.65.14.3
Percentage of Assets2.31.81.91.61.21.10.80.6
Percentage of Assets us-gaap:ConstructionInProgress0.00.00.00.00.00.00.00.0

us-gaap:FurnitureAndFixtures


Property
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Value45414930469346614410435141623914
Percentage of PropertyPlantAndEquipmentGross15.816.015.715.515.716.016.715.2
Percentage of Assets2.92.93.02.72.62.62.52.3
Percentage of Assets us-gaap:FurnitureAndFixtures0.00.00.00.00.00.00.00.0

us-gaap:Land


Property
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Value444516500540530588529557
Percentage of PropertyPlantAndEquipmentGross1.51.71.71.81.92.22.12.2
Percentage of Assets0.30.30.30.30.30.40.30.3
Percentage of Assets us-gaap:Land0.00.00.00.00.00.00.00.0

us-gaap:MachineryAndEquipment


Property
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Value111531228111871119021124810933967110050
Percentage of PropertyPlantAndEquipmentGross38.839.939.639.640.040.138.739.1
Percentage of Assets7.27.37.56.96.66.55.75.8
Percentage of Assets us-gaap:MachineryAndEquipment0.00.00.00.00.00.00.00.0

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment


Accumulated
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-31
Value1532815105148121663616889169291678916728163891615816591170781684416665161721590615506150501480714838146371400213502132261328113421135841317511144
Percentage of AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets9.09.59.69.39.510.210.09.810.510.410.410.210.210.19.49.29.28.98.68.38.68.68.17.87.77.27.26.85.2

Amortization Of Intangible Assets

us-gaap:AmortizationOfIntangibleAssets us-gaap:FiniteLivedIntangibleAssetsByMajorClass

us-gaap:AmortizationOfIntangibleAssets

us-gaap:FiniteLivedIntangibleAssets


Amortization
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-09-292013-06-302013-03-31
Value-942.088380091091789711001200120012001300130012001200120012001200120011009889771000100095088410001000100010001100110012001300
Percentage of AmortizationOfIntangibleAssets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Percentage of Assets us-gaap:FiniteLivedIntangibleAssets0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Property Plant And Equipment Net

us-gaap:PropertyPlantAndEquipmentNet

us-gaap:PropertyPlantAndEquipmentNet


Property
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value1422414011139001440314113140401396713701135211346713385140361391913971138651350513386132381331813284136091358413766136951143211527117621203212179123471239712359124431395014461146061475616192169381772118281188331912322780
Percentage of PropertyPlantAndEquipmentNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets8.48.89.08.07.98.48.38.08.78.78.48.48.48.58.17.87.97.87.87.48.08.38.28.07.17.26.97.07.17.27.27.06.97.47.88.08.18.79.09.09.39.79.810.7

us-gaap:PropertyPlantAndEquipmentNet us-gaap:StatementGeographical

country:US


Property
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-31
Value78217606708969716649707255755885726278938537
Percentage of PropertyPlantAndEquipmentNet56.354.553.050.349.951.447.447.550.246.644.6
Percentage of Assets5.14.54.54.13.94.23.33.43.94.24.4
Percentage of Assets country:US0.00.00.00.00.00.00.00.00.00.00.0

pfe:DevelopedEurope


Property
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-31
Value47754304420443454228437646064845512160237159
Percentage of PropertyPlantAndEquipmentNet34.430.831.431.331.731.839.239.135.435.637.4
Percentage of Assets3.12.62.62.52.52.62.72.82.83.23.7
Percentage of Assets pfe:DevelopedEurope0.00.00.00.00.00.00.00.00.00.00.0

pfe:DevelopedRestOfWorld


Property
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-31
Value413453490632643660617696847904854
Percentage of PropertyPlantAndEquipmentNet3.03.23.74.64.84.85.25.65.95.34.5
Percentage of Assets0.30.30.30.40.40.40.40.40.50.50.4
Percentage of Assets pfe:DevelopedRestOfWorld0.00.00.00.00.00.00.00.00.00.00.0

pfe:EmergingMarkets


Property
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-31
Value89016031602191717971658963971123121182095
Percentage of PropertyPlantAndEquipmentNet6.411.512.013.813.512.08.27.88.512.511.0
Percentage of Assets0.61.01.01.11.01.00.60.60.71.11.1
Percentage of Assets pfe:EmergingMarkets0.00.00.00.00.00.00.00.00.00.00.0

Long Term Investments

us-gaap:LongTermInvestments

us-gaap:LongTermInvestments


Long
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-31
Value209422022820262190081872018220301427232905285927676444659569457015731170087346711695071312414146159991623317650182891751818451171681582216406157311610715392141491342910548106329814
Percentage of LongTermInvestments100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets12.312.713.110.610.511.01.81.61.91.81.73.84.04.24.14.24.24.44.15.37.78.79.69.511.011.410.310.89.99.29.59.09.08.27.67.45.85.75.2

Goodwill

us-gaap:Goodwill

us-gaap:Goodwill


Goodwill
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-312008-12-31
Value498674979149577599025844958502586535866553352534875341155614558365639355952560785501454656544495628150600485584824247217415714185442069427244266142467425194240042431437524467244370445684525245067454094510744853439474237621464
Percentage of Goodwill100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets29.331.432.133.532.835.235.034.434.234.433.633.133.834.332.532.632.632.431.731.529.629.828.827.625.826.124.924.924.724.724.724.223.723.324.024.324.424.424.023.223.023.022.519.90.0

us-gaap:Goodwill us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments

us-gaap:OperatingSegments, pfe:BiopharmaSegment


Goodwillus-gaap:
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312017-12-31
Value4934948047480814820248206428800.00.043359
Percentage of Goodwill82.482.282.282.282.280.40.00.077.5
Percentage of Assets27.627.028.928.828.327.50.00.025.2
Percentage of Assets us-gaap:OperatingSegments pfe:BiopharmaSegment0.00.00.00.00.00.00.00.00.0

us-gaap:OperatingSegments, pfe:UpjohnSegment


Goodwillus-gaap:
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312017-12-31
Value1055310401104211045110460104720.00.010600
Percentage of Goodwill17.617.817.817.817.819.60.00.018.9
Percentage of Assets5.95.86.36.26.16.70.00.06.2
Percentage of Assets us-gaap:OperatingSegments pfe:UpjohnSegment0.00.00.00.00.00.00.00.00.0

Indefinite Lived Intangible Assets Excluding Goodwill

us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill

us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill


Indefinite
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value453545354575578570328982898390233954407641659294120901215312179122291231512418169841748712631807281928522764276407660780577037692782778768065832485868972902611445112961369513724139521372918466
Percentage of IndefiniteLivedIntangibleAssetsExcludingGoodwill100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets2.72.93.03.24.05.45.45.32.52.62.65.57.37.47.17.17.37.49.99.87.45.04.95.04.84.84.54.64.54.54.54.54.54.44.64.94.96.26.07.07.07.27.08.7

us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill us-gaap:IndefiniteLivedIntangibleAssetsByMajorClass

pfe:LicensingAgreementsAndOther


Indefinite
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292018-12-31
Value5735735735735231073107310733.0
Percentage of IndefiniteLivedIntangibleAssetsExcludingGoodwill12.612.612.59.97.411.911.911.90.1
Percentage of Assets0.30.40.40.30.30.60.60.60.0
Percentage of Assets pfe:LicensingAgreementsAndOther0.00.00.00.00.00.00.00.00.0

us-gaap:InProcessResearchAndDevelopment


Indefinite
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312012-12-31
Value31343135317532214518591859195959196120822171238551635201524952925413552210101105695606117911711365434434387459329329443669
Percentage of IndefiniteLivedIntangibleAssetsExcludingGoodwill69.169.169.455.764.265.965.966.049.651.152.125.742.742.843.143.344.044.559.560.444.414.614.316.05.75.75.15.94.34.35.77.8
Percentage of Assets1.82.02.11.82.53.63.53.51.31.31.41.43.13.23.13.13.23.35.95.93.30.70.70.80.30.30.20.30.20.20.30.4
Percentage of Assets us-gaap:InProcessResearchAndDevelopment0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:TradeNames


Indefinite
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312012-12-31
Value82782782719911991199119911991199419941994690969276952692969376902689568836918702568937021715672087206727373467374736373817786
Percentage of IndefiniteLivedIntangibleAssetsExcludingGoodwill18.218.218.134.428.322.222.222.150.448.947.974.357.357.256.956.756.055.540.539.655.685.485.784.094.394.394.994.195.795.794.390.7
Percentage of Assets0.50.50.51.11.11.21.21.21.31.31.34.14.24.24.04.04.14.14.03.94.14.24.24.24.54.54.34.34.34.34.34.2
Percentage of Assets us-gaap:TradeNames0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Intangible Assets Net Excluding Goodwill

us-gaap:IntangibleAssetsNetExcludingGoodwill

us-gaap:IntangibleAssetsNetExcludingGoodwill


Intangible
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value2732327974284713092733541344643537038995330243403935211453064658447690487414972151348524275264854238430563960240356432973342434334351663637437360381223938540549417764410946013472094839952801538335559757059584975755868015
Percentage of IntangibleAssetsNetExcludingGoodwill100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets16.117.618.517.318.920.721.122.921.121.922.127.028.229.028.328.930.531.130.730.425.224.324.125.320.821.420.821.221.622.222.923.123.323.524.825.926.528.428.628.329.130.029.531.9

Finite Lived Intangible Assets Net

us-gaap:FiniteLivedIntangibleAssetsNet

us-gaap:FiniteLivedIntangibleAssetsNet


Finite
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value2278923439238962514226509254822638729972290702996331045360123449435537365623749239033400093566436750304253153032165347752578226694275062857029657304303155832673337113578537427382373937341356425374190243335445454382949549
Percentage of FiniteLivedIntangibleAssetsNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets13.414.815.514.014.915.315.817.618.619.319.521.520.921.621.321.823.223.720.820.617.819.419.220.416.016.616.216.717.217.718.318.618.819.120.120.921.522.322.621.422.122.822.523.3

us-gaap:FiniteLivedIntangibleAssetsNet us-gaap:FiniteLivedIntangibleAssetsByMajorClass

pfe:LicensingAgreementsAndOther


Finite
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282013-12-31
Value1042108211061146110157458260328129229677781884781585981884086481683984170174215216015916491
Percentage of FiniteLivedIntangibleAssetsNet4.64.64.64.64.22.32.22.01.01.01.02.22.42.42.22.32.12.12.42.22.82.72.22.10.60.60.60.60.3
Percentage of Assets0.60.70.70.60.60.30.30.40.20.20.20.50.50.50.50.50.50.50.50.50.50.50.40.40.10.10.10.10.1
Percentage of Assets pfe:LicensingAgreementsAndOther0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:DevelopedTechnologyRights


Finite
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value2161622217226432384025244247362562529180285902946530535343373275333726347653562537191381333374034830285692954330419330412461525493262522726028431293883049731593325863445336043367443781139680410754035641746429744220947647
Percentage of FiniteLivedIntangibleAssetsNet94.994.894.894.895.297.197.197.498.398.398.495.395.094.995.195.095.395.394.694.893.993.794.695.095.595.595.495.495.996.696.696.796.796.396.396.196.095.996.696.396.396.596.396.2
Percentage of Assets12.714.014.713.314.214.915.317.118.319.019.220.519.920.520.220.722.122.619.719.516.718.118.219.315.315.915.515.916.517.117.718.018.218.419.420.120.721.421.820.621.322.021.622.4
Percentage of Assets us-gaap:DevelopedTechnologyRights0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:TradeNames


Finite
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312012-12-31
Value1311401481561651731811901982062158989239649821008102510371060110410161147104499210151041109611461129949970964
Percentage of FiniteLivedIntangibleAssetsNet0.60.60.60.60.60.70.70.60.70.70.72.52.72.72.72.72.62.63.03.03.33.63.22.93.93.94.04.03.83.13.12.6
Percentage of Assets0.10.10.10.10.10.10.10.10.10.10.10.50.60.60.60.60.60.60.60.60.60.70.60.60.60.60.60.70.70.60.60.5
Percentage of Assets us-gaap:TradeNames0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Operating Lease Right Of Use Asset

us-gaap:OperatingLeaseRightOfUseAsset

us-gaap:OperatingLeaseRightOfUseAsset


Operating
Period End2020-12-312019-12-312019-09-292019-06-302019-03-31
Value13931313130612731280
Percentage of OperatingLeaseRightOfUseAsset100.0100.0100.0100.0100.0
Percentage of Assets0.90.80.80.80.8

Other Assets Noncurrent

us-gaap:OtherAssetsNoncurrent

us-gaap:OtherAssetsNoncurrent


Other
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312012-12-31
Value60564744456943554327416644504920438843332799298028962896322733883466332933234759461840033499391136353716351334213574375935963233
Percentage of OtherAssetsNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets3.63.03.02.42.42.52.72.92.82.81.81.81.81.81.92.02.12.01.92.72.72.52.12.32.32.32.12.02.12.22.11.7

us-gaap:OtherAssetsNoncurrent us-gaap:BalanceSheetLocation, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency

us-gaap:OtherNoncurrentAssets, us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring


Other
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312018-12-31
Value931853814857940102011021082
Percentage of OtherAssetsNoncurrent15.418.017.819.721.724.524.838.7
Percentage of Assets0.50.50.50.50.50.60.70.7
Percentage of Assets us-gaap:OtherNoncurrentAssets us-gaap:FairValueInputsLevel2 us-gaap:FairValueMeasurementsRecurring0.00.00.00.00.00.00.00.0

us-gaap:OtherAssetsNoncurrent us-gaap:BalanceSheetLocation, us-gaap:FairValueByMeasurementFrequency

us-gaap:OtherNoncurrentAssets, us-gaap:FairValueMeasurementsRecurring


Other
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312018-12-31
Value931853814857940102011021082
Percentage of OtherAssetsNoncurrent15.418.017.819.721.724.524.838.7
Percentage of Assets0.50.50.50.50.50.60.70.7
Percentage of Assets us-gaap:OtherNoncurrentAssets us-gaap:FairValueMeasurementsRecurring0.00.00.00.00.00.00.00.0

us-gaap:OtherAssetsNoncurrent us-gaap:Restatement

pfe:ScenarioChangeInAccountingPrincipleAdjustment


Other
Period End2021-07-042021-04-04
Value126.0
Percentage of OtherAssetsNoncurrent0.20.1
Percentage of Assets0.00.0
Percentage of Assets pfe:ScenarioChangeInAccountingPrincipleAdjustment0.00.0

pfe:ScenarioPreviousAccountingPrinciple


Other
Period End2021-07-042021-04-042020-12-31
Value604447384569
Percentage of OtherAssetsNoncurrent99.899.9100.0
Percentage of Assets3.63.03.0
Percentage of Assets pfe:ScenarioPreviousAccountingPrinciple0.00.00.0

Equity Securities Fv Ni

us-gaap:EquitySecuritiesFvNi

us-gaap:EquitySecuritiesFvNi


Equity
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012017-12-31
Value22841427567122731303341907051054475315971600121313322150
Percentage of EquitySecuritiesFvNi100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets1.30.90.46.97.32.50.40.63.01.01.00.70.81.2

us-gaap:EquitySecuritiesFvNi us-gaap:BalanceSheetLocation, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency

pfe:LongtermInvestments, us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring


Equity
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292018-12-312018-09-302018-07-012017-12-31
Value371130462776206320461581186315061243152717041398
Percentage of EquitySecuritiesFvNi162.5213.5489.616.815.737.7264.3142.977.7125.9127.965.0
Percentage of Assets2.21.91.81.21.11.01.10.90.80.91.00.8
Percentage of Assets pfe:LongtermInvestments us-gaap:FairValueInputsLevel1 us-gaap:FairValueMeasurementsRecurring0.00.00.00.00.00.00.00.00.00.00.00.0

pfe:LongtermInvestments, us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring


Equity
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292018-12-312018-09-302018-07-012017-12-31
Value257732282622392430363342
Percentage of EquitySecuritiesFvNi1.15.45.60.20.20.55.52.31.93.02.52.0
Percentage of Assets0.00.00.00.00.00.00.00.00.00.00.00.0
Percentage of Assets pfe:LongtermInvestments us-gaap:FairValueInputsLevel2 us-gaap:FairValueMeasurementsRecurring0.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:EquitySecuritiesFvNi us-gaap:BalanceSheetLocation, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

us-gaap:ShortTermInvestments, us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring, us-gaap:MoneyMarketFunds


Equity
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012017-12-31
Value22841427567122731303341907051035472715701571118413022115
Percentage of EquitySecuritiesFvNi100.0100.0100.0100.0100.0100.0100.098.299.598.398.297.697.798.4
Percentage of Assets1.30.90.46.97.32.50.40.63.01.01.00.70.81.2
Percentage of Assets us-gaap:ShortTermInvestments us-gaap:FairValueInputsLevel2 us-gaap:FairValueMeasurementsRecurring us-gaap:MoneyMarketFunds0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:EquitySecuritiesFvNi us-gaap:BalanceSheetLocation, us-gaap:FairValueByMeasurementFrequency

pfe:LongtermInvestments, us-gaap:FairValueMeasurementsRecurring


Equity
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292018-12-312018-09-302018-07-012017-12-31
Value373631232809209220721603190215301273156317371440
Percentage of EquitySecuritiesFvNi163.6218.9495.417.015.938.3269.8145.279.6128.9130.467.0
Percentage of Assets2.22.01.81.21.21.01.10.90.80.91.10.8
Percentage of Assets pfe:LongtermInvestments us-gaap:FairValueMeasurementsRecurring0.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:EquitySecuritiesFvNi us-gaap:BalanceSheetLocation, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

us-gaap:ShortTermInvestments, us-gaap:FairValueMeasurementsRecurring, us-gaap:MoneyMarketFunds


Equity
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012017-12-31
Value22841427567122731303341907051035472715701571118413022115
Percentage of EquitySecuritiesFvNi100.0100.0100.0100.0100.0100.0100.098.299.598.398.297.697.798.4
Percentage of Assets1.30.90.46.97.32.50.40.63.01.01.00.70.81.2
Percentage of Assets us-gaap:ShortTermInvestments us-gaap:FairValueMeasurementsRecurring us-gaap:MoneyMarketFunds0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Accounts Payable Current

us-gaap:AccountsPayableCurrent

us-gaap:AccountsPayableCurrent


Accounts
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value43274064430941413872397242203942400241564674429741963879465634803439339345363476326131253620329429302724344029732990254632342287197832794264296731653091383637653698375040264370
Percentage of AccountsPayableCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets2.52.62.82.32.22.42.52.32.62.72.92.62.52.42.72.02.02.02.61.91.91.92.21.91.81.72.01.71.71.51.91.31.11.72.31.61.71.72.01.91.91.92.12.1

Contract With Customer Liability Current

us-gaap:ContractWithCustomerLiabilityCurrent

us-gaap:ContractWithCustomerLiabilityCurrent


Contract
Period End2021-07-042021-04-042020-12-31
Value429120521113
Percentage of ContractWithCustomerLiabilityCurrent100.0100.0100.0
Percentage of Assets2.51.30.7

us-gaap:ContractWithCustomerLiabilityCurrent us-gaap:MajorCustomers, us-gaap:ProductOrService

pfe:GovernmentAndGovernmentSponsored, pfe:BNT162b2


Contract
Period End2021-07-042021-04-042020-12-31
Value43001900957
Percentage of ContractWithCustomerLiabilityCurrent100.292.686.0
Percentage of Assets2.51.20.6
Percentage of Assets pfe:GovernmentAndGovernmentSponsored pfe:BNT162b20.00.00.0

Debt Current

us-gaap:DebtCurrent

us-gaap:DebtCurrent


Debt
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value38884352270313363130841600716195166171050794108831738511583901099539448951476801068813633137241154610160981883946555514153895561931960274738521488966424777477035526401856375988609356235469
Percentage of DebtCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets2.32.71.87.57.49.69.79.76.76.15.64.47.05.55.85.55.64.66.27.68.07.16.15.75.24.13.03.13.25.43.52.72.94.73.54.34.23.02.12.93.13.12.92.6

Dividends Payable Current

us-gaap:DividendsPayableCurrent

us-gaap:DividendsPayableCurrent


Dividends
Period End2021-07-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312010-12-31
Value21842162211221110.02104199219910.02047196319800.02029190919040.01944182118200.01852172817260.017110.016501.016631.016855.017341.018261.017961601
Percentage of DividendsPayableCurrent100.0100.0100.0100.00.0100.0100.0100.00.0100.0100.0100.00.0100.0100.0100.00.0100.0100.0100.00.0100.0100.0100.00.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets1.31.41.21.20.01.31.21.30.01.31.21.20.01.21.11.10.01.11.01.10.01.11.01.10.01.00.01.00.01.00.00.90.00.90.01.00.01.00.8

Liabilities Current

us-gaap:LiabilitiesCurrent

us-gaap:LiabilitiesCurrent


Liabilities
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value3566426652259203415432723338903730436974320302942331858290133215627365304272821727182248643111534759320992873529399278452414320222216311992021938247902336620373234502754328619291313079827094280692785630471291712860937225
Percentage of LiabilitiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets21.016.816.819.118.420.422.321.720.518.920.017.319.516.617.716.416.114.718.119.518.817.617.616.315.012.612.811.612.714.413.611.613.114.715.416.016.814.614.914.215.615.014.717.5

us-gaap:LiabilitiesCurrent us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

pfe:GSKConsumerHealthcare


Liabilities
Period End2020-09-272020-06-302020-03-312019-09-29
Value5246499255245241
Percentage of LiabilitiesCurrent15.40.00.014.2
Percentage of Assets2.90.00.03.1
Percentage of Assets pfe:GSKConsumerHealthcare11.711.312.111.4

us-gaap:LiabilitiesCurrent us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

pfe:ViivHealthcareLimited, pfe:ViivHealthcareLimited


Liabilities
Period End2020-12-312019-12-31
Value30282904
Percentage of LiabilitiesCurrent11.77.8
Percentage of Assets2.01.7
Percentage of Assets pfe:ViivHealthcareLimited pfe:ViivHealthcareLimited45.439.9

Long Term Debt Current

us-gaap:LongTermDebtCurrent

us-gaap:LongTermDebtCurrent


Long
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-31
Value36873676200221491481337146224312139447147764255426247633546307230723292422537203011206024496.0350227
Percentage of LongTermDebtCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets2.22.31.31.20.80.20.91.41.42.93.02.52.62.92.11.81.82.02.52.21.81.21.30.01.80.0

us-gaap:LongTermDebtCurrent us-gaap:LongtermDebtType

us-gaap:UnsecuredDebt


Long
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312016-12-312015-12-312014-12-312013-12-31
Value368736762002214914813371462243121394471477642554262476335464225372030112060
Percentage of LongTermDebtCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets2.22.31.31.20.80.20.91.41.42.93.02.52.62.92.12.52.21.81.2
Percentage of Assets us-gaap:UnsecuredDebt0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Operating Lease Liability Current

us-gaap:OperatingLeaseLiabilityCurrent

us-gaap:OperatingLeaseLiabilityCurrent


Operating
Period End2020-12-312019-12-312019-09-292019-06-30
Value321276281263
Percentage of OperatingLeaseLiabilityCurrent100.0100.0100.0100.0
Percentage of Assets0.20.20.20.2

Other Liabilities Current

us-gaap:OtherLiabilitiesCurrent

us-gaap:OtherLiabilitiesCurrent


Other
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312012-12-31
Value172171279812640106831016810515110831016010110102761075310490101251095011115104461014811143110231262311053114191099096728390832090248824934610315995113812
Percentage of OtherLiabilitiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets10.18.18.26.05.76.36.66.06.56.66.86.36.16.76.56.16.06.66.47.16.57.06.65.75.25.25.35.15.46.05.87.4

us-gaap:OtherLiabilitiesCurrent us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement

pfe:BioNTech, pfe:BNT162b2, us-gaap:CollaborativeArrangement


Other
Period End2021-07-042021-04-042020-12-31
Value4500140025
Percentage of OtherLiabilitiesCurrent26.110.90.2
Percentage of Assets2.60.90.0
Percentage of Assets pfe:BioNTech pfe:BNT162b2 us-gaap:CollaborativeArrangement0.00.00.0

Taxes Payable Current

us-gaap:TaxesPayableCurrent

us-gaap:TaxesPayableCurrent


Taxes
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value1742140110491430144511509801892153618491265278124811614477100355279043711586479204181178105794453189276085167880290411581010178820981930101322151849195894610107
Percentage of TaxesPayableCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets1.00.90.70.80.80.70.61.11.01.20.81.71.51.00.30.60.30.50.30.60.40.60.20.70.70.60.30.50.40.50.40.50.50.60.51.01.11.00.51.10.91.00.54.7

Liabilities Noncurrent

us-gaap:LiabilitiesNoncurrent us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

us-gaap:LiabilitiesNoncurrent

pfe:GSKConsumerHealthcare


Liabilities
Period End2020-09-272020-06-302019-09-29
Value533051955536
Percentage of LiabilitiesNoncurrent100.0100.0100.0
Percentage of Assets3.00.03.2
Percentage of Assets pfe:GSKConsumerHealthcare11.911.712.0

us-gaap:LiabilitiesNoncurrent us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

pfe:ViivHealthcareLimited, pfe:ViivHealthcareLimited


Liabilities
Period End2020-12-312019-12-31
Value63705860
Percentage of LiabilitiesNoncurrent0.00.0
Percentage of Assets4.13.5
Percentage of Assets pfe:ViivHealthcareLimited pfe:ViivHealthcareLimited95.680.5

Long Term Debt

us-gaap:LongTermDebt

us-gaap:LongTermDebt


Long
Period End2020-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032015-12-312014-12-312014-09-282014-06-29
Value400034503341913633031398304373045728818315413166632267
Percentage of LongTermDebt100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets2.620.020.321.518.317.117.817.218.618.518.7

us-gaap:LongTermDebt us-gaap:DebtInstrument, us-gaap:LongtermDebtType

pfe:SeniorUnsecuredDebtDue2043, us-gaap:UnsecuredDebt


Long
Period End2020-12-31
Value1800
Percentage of LongTermDebt45.0
Percentage of Assets1.2
Percentage of Assets pfe:SeniorUnsecuredDebtDue2043 us-gaap:UnsecuredDebt0.0

pfe:SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030, us-gaap:SeniorNotes


Long
Period End2020-12-31
Value1000
Percentage of LongTermDebt25.0
Percentage of Assets0.6
Percentage of Assets pfe:SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030 us-gaap:SeniorNotes0.0

pfe:SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040, us-gaap:SeniorNotes


Long
Period End2020-12-31
Value1000
Percentage of LongTermDebt25.0
Percentage of Assets0.6
Percentage of Assets pfe:SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040 us-gaap:SeniorNotes0.0

pfe:SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050, us-gaap:SeniorNotes


Long
Period End2020-12-31
Value1250
Percentage of LongTermDebt31.2
Percentage of Assets0.8
Percentage of Assets pfe:SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050 us-gaap:SeniorNotes0.0

pfe:SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025, us-gaap:SeniorNotes


Long
Period End2020-12-31
Value750
Percentage of LongTermDebt18.8
Percentage of Assets0.5
Percentage of Assets pfe:SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025 us-gaap:SeniorNotes0.0

us-gaap:LongTermDebt us-gaap:DerivativeInstrumentRisk

pfe:ForeignCurrencyDebt


Long
Period End2021-07-042021-04-042020-12-31
Value8818722100
Percentage of LongTermDebt0.00.052.5
Percentage of Assets0.50.51.4
Percentage of Assets pfe:ForeignCurrencyDebt0.00.00.0

pfe:ForeignCurrencyLongTermDebt


Long
Period End2020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-31
Value2100200020001900200019002000200032003200320033004800
Percentage of LongTermDebt52.50.00.00.00.00.00.00.00.00.00.00.00.0
Percentage of Assets1.41.11.11.11.21.11.31.32.01.91.92.02.8
Percentage of Assets pfe:ForeignCurrencyLongTermDebt0.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:LongTermDebt us-gaap:LongtermDebtType

us-gaap:UnsecuredDebt


Long
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312015-12-312014-12-312014-09-282014-06-292013-12-31
Value180018001800180018001800180018001800180019001900200019001900190028818315414500450030462
Percentage of LongTermDebt0.00.00.00.00.00.00.00.00.00.00.00.05.85.65.26.1100.0100.014.213.90.0
Percentage of Assets1.01.01.11.11.11.21.21.11.11.11.21.11.21.11.11.117.218.62.62.617.7
Percentage of Assets us-gaap:UnsecuredDebt0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Long Term Debt Noncurrent

us-gaap:LongTermDebtNoncurrent

us-gaap:LongTermDebtNoncurrent


Long
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value3535435347371334978550529362813595536044361683573332909336522893531831335383450334191363303139830437304572782428818290792672929370315413166632267276493046231812315323148131036310833086833543349313539935723353083841043193
Percentage of LongTermDebtNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets20.822.324.127.828.421.821.521.123.223.020.720.117.519.319.520.020.321.518.317.117.817.117.217.016.618.318.618.518.716.117.718.117.616.816.717.016.918.118.618.018.218.119.720.3

us-gaap:LongTermDebtNoncurrent us-gaap:LongtermDebtType

us-gaap:UnsecuredDebt


Long
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312016-12-312016-10-022016-07-032016-04-03
Value35354353473713349785505293628135955360443616835733329093365228935318313353831398190020002100
Percentage of LongTermDebtNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.06.26.67.5
Percentage of Assets20.822.324.127.828.421.821.521.123.223.020.720.117.519.319.518.31.11.21.3
Percentage of Assets us-gaap:UnsecuredDebt0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Deferred Income Tax Liabilities Net

us-gaap:DeferredIncomeTaxLiabilitiesNet

us-gaap:DeferredIncomeTaxLiabilitiesNet


Deferred
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-31
Value41614355406345425409526855786724318035913700551257435967390030411308793085730753
Percentage of DeferredIncomeTaxLiabilitiesNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets2.42.72.62.53.03.23.33.92.02.32.33.33.53.62.317.718.318.317.9

Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent

us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanTaxStatus, us-gaap:RetirementPlanType

us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent

country:US, us-gaap:NonqualifiedPlan, us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefit


Pension
Period End2020-12-312019-12-312018-12-31
Value123911621113
Percentage of PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent100.0100.0100.0
Percentage of Assets0.80.70.7
Percentage of Assets country:US us-gaap:NonqualifiedPlan us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefit0.00.00.0

country:US, us-gaap:QualifiedPlan, us-gaap:PensionPlansDefinedBenefit


Pension
Period End2020-12-312019-12-312018-12-31
Value84519492088
Percentage of PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent68.2167.7187.6
Percentage of Assets0.51.21.3
Percentage of Assets country:US us-gaap:QualifiedPlan us-gaap:PensionPlansDefinedBenefit0.00.00.0

us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType

us-gaap:ForeignPlan, us-gaap:PensionPlansDefinedBenefit


Pension
Period End2020-12-312019-12-312018-12-312017-12-312016-12-31
Value26812526211121722279
Percentage of PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent216.4217.4189.70.00.0
Percentage of Assets1.71.51.31.31.3
Percentage of Assets us-gaap:ForeignPlan us-gaap:PensionPlansDefinedBenefit0.00.00.00.00.0

us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent us-gaap:RetirementPlanType

us-gaap:OtherPostretirementBenefitPlansDefinedBenefit


Pension
Period End2020-12-312019-12-312018-12-312017-12-312016-12-31
Value6451124137115041766
Percentage of PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent52.196.7123.20.00.0
Percentage of Assets0.40.70.90.91.0
Percentage of Assets us-gaap:OtherPostretirementBenefitPlansDefinedBenefit0.00.00.00.00.0

Minority Interest

us-gaap:MinorityInterest

us-gaap:MinorityInterest


Minority
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value273245235236228312303293357352351346346358348340326311296294297279278286286283321317323299313385430577418412414421431483482466452432
Percentage of MinorityInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.20.20.20.10.10.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.30.20.20.20.20.20.20.20.20.20.2

us-gaap:MinorityInterest us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

pfe:GSKConsumerHealthcare


Minority
Period End2020-09-272020-06-302020-03-312019-09-29
Value245138133105
Percentage of MinorityInterest103.80.00.035.8
Percentage of Assets0.10.00.00.1
Percentage of Assets pfe:GSKConsumerHealthcare0.50.30.30.2

Other Liabilities Noncurrent

us-gaap:OtherLiabilitiesNoncurrent

us-gaap:OtherLiabilitiesNoncurrent


Other
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value82286677666968516812681263176381618363465850636759475644614963886440691863376059551851805257498753105644488342664238441647674515523151384939526158365119619962394932497056015611
Percentage of OtherLiabilitiesNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets4.84.24.33.83.84.13.83.74.04.13.73.83.63.43.63.73.84.13.73.43.23.23.12.93.33.52.92.52.52.62.82.62.92.72.72.93.22.83.33.22.52.52.92.6

Operating Lease Liability Noncurrent

us-gaap:OperatingLeaseLiabilityNoncurrent

us-gaap:OperatingLeaseLiabilityNoncurrent


Operating
Period End2020-12-312019-12-312019-09-292019-06-302019-03-31
Value11141048103710261043
Percentage of OperatingLeaseLiabilityNoncurrent100.0100.0100.0100.0100.0
Percentage of Assets0.70.60.60.70.7

Operating Lease Liability

us-gaap:OperatingLeaseLiability

us-gaap:OperatingLeaseLiability


Operating
Period End2020-12-31
Value1435
Percentage of OperatingLeaseLiability100.0
Percentage of Assets0.9

Lessee Operating Lease Liability Payments Due

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue


Lessee
Period End2020-12-31
Value1618
Percentage of LesseeOperatingLeaseLiabilityPaymentsDue100.0
Percentage of Assets1.0

Lessee Operating Lease Liability Undiscounted Excess Amount

us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount


Lessee
Period End2020-12-31
Value183
Percentage of LesseeOperatingLeaseLiabilityUndiscountedExcessAmount100.0
Percentage of Assets0.1

Stockholders Equity

us-gaap:StockholdersEquity

us-gaap:StockholdersEquity


Stockholders
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value7004268620632386525964336650266314365103595685880663407713196977870184713086077058368584355954463306627696306864720668386689467304713017798876633777697630777969785478225081260817037954783256821909004788481900678781390014
Percentage of StockholdersEquity100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets41.243.241.036.536.239.137.738.238.137.839.942.542.342.641.535.334.634.634.735.536.838.738.639.141.641.942.145.544.445.344.344.443.843.943.744.743.544.843.745.945.246.245.042.3

us-gaap:StockholdersEquity us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

pfe:GSKConsumerHealthcare


Stockholders
Period End2020-09-272020-06-302020-03-312019-09-29
Value34154339193503135199
Percentage of StockholdersEquity52.30.00.054.1
Percentage of Assets19.10.00.020.7
Percentage of Assets pfe:GSKConsumerHealthcare75.976.776.476.4

us-gaap:StockholdersEquity us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

pfe:ViivHealthcareLimited, pfe:ViivHealthcareLimited


Stockholders
Period End2020-12-312019-12-31
Value-2734.0-1489.0
Percentage of StockholdersEquity-4.3-2.4
Percentage of Assets-1.8-0.9
Percentage of Assets pfe:ViivHealthcareLimited pfe:ViivHealthcareLimited-41.0-20.5

us-gaap:StockholdersEquity us-gaap:StatementEquityComponents

us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCredit


Stockholders
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312013-12-312012-12-31
Value482518549584591658693728776814855750783814847879919889855880960992703733313259
Percentage of StockholdersEquity0.70.80.80.90.91.11.21.11.11.21.21.11.31.41.41.51.51.41.41.41.41.51.01.00.40.3
Percentage of Assets0.30.30.30.30.30.40.40.50.50.50.50.40.50.50.50.50.50.50.50.50.60.60.40.40.20.1
Percentage of Assets us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCredit0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLoss


Stockholders
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312013-12-312012-12-31
Value-7074.0-6178.0-6296.0-6257.0-5933.0-5911.0-5986.0-6027.0-5538.0-5657.0-5764.0-5262.0-5210.0-5198.0-5278.0-5473.0-4423.0-4538.0-4585.0-4733.0-5303.0-5330.0-5398.0-5654.0-3223.0-6110.0
Percentage of StockholdersEquity-10.8-9.6-9.7-9.9-9.1-9.9-10.2-9.5-7.8-8.1-8.2-7.4-8.6-8.9-9.0-9.2-7.0-7.2-7.3-7.3-7.9-8.0-8.0-7.9-4.2-7.5
Percentage of Assets-4.0-3.5-3.8-3.7-3.5-3.8-3.9-3.8-3.3-3.4-3.5-3.1-3.0-3.1-3.1-3.2-2.5-2.7-2.8-2.8-3.1-3.3-3.4-3.3-1.9-3.3
Percentage of Assets us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLoss0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedGainLossNetCashFlowHedgeParent


Stockholders
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012017-12-312016-12-312015-12-31
Value-526.0-333.0-344.02060-33.0167167248267-30.0348421
Percentage of StockholdersEquity-0.8-0.5-0.50.00.1-0.10.30.30.30.4-0.00.60.7
Percentage of Assets-0.3-0.2-0.20.00.0-0.00.10.10.10.2-0.00.20.3
Percentage of Assets us-gaap:AccumulatedGainLossNetCashFlowHedgeParent0.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedNetUnrealizedInvestmentGainLoss


Stockholders
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312013-12-312012-12-31
Value1449.0-67.0-35.00.0-8.0-24.0-68.0-131.0-230.0-28.0401339221108-131.029517269-227.0913.0-271.0-222.0150236
Percentage of StockholdersEquity0.20.0-0.1-0.10.0-0.0-0.0-0.1-0.2-0.3-0.00.60.60.40.2-0.20.50.30.1-0.40.10.0-0.4-0.30.20.3
Percentage of Assets0.10.0-0.0-0.00.0-0.0-0.0-0.0-0.1-0.1-0.00.20.20.10.1-0.10.20.10.0-0.10.10.0-0.2-0.10.10.1
Percentage of Assets us-gaap:AccumulatedNetUnrealizedInvestmentGainLoss0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedOtherComprehensiveIncome


Stockholders
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312013-12-312012-12-31
Value-12676.0-13246.0-13131.0-11640.0-11801.0-11535.0-10923.0-11275.0-10417.0-10003.0-9402.0-9321.0-9164.0-10181.0-10594.0-11036.0-8214.0-8891.0-9520.0-9522.0-9170.0-8521.0-8557.0-7316.0-3271.0-5953.0
Percentage of StockholdersEquity-19.4-20.6-20.2-18.4-18.1-19.4-18.6-17.8-14.6-14.3-13.4-13.1-15.1-17.4-18.1-18.5-13.0-14.2-15.1-14.7-13.7-12.7-12.7-10.3-4.3-7.3
Percentage of Assets-7.1-7.4-7.9-6.9-6.9-7.4-7.0-7.1-6.2-6.1-5.7-5.4-5.3-6.0-6.3-6.4-4.6-5.2-5.8-5.7-5.4-5.3-5.3-4.3-1.9-3.2
Percentage of Assets us-gaap:AccumulatedOtherComprehensiveIncome0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedTranslationAdjustment


Stockholders
Period End2020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312013-12-312012-12-31
Value-5703.0-7262.0-6973.0-5952.0-6519.0-6242.0-5772.0-6075.0-5772.0-5198.0-4375.0-5180.0-5021.0-5957.0-6417.0-6659.0-4847.0-5265.0-5776.0-5863.0-4926.0-4404.0-4067.0-2689.0-590.0-177.0
Percentage of StockholdersEquity-8.7-11.3-10.7-9.4-10.0-10.5-9.8-9.6-8.1-7.4-6.2-7.3-8.3-10.2-11.0-11.2-7.7-8.4-9.2-9.1-7.4-6.6-6.0-3.8-0.8-0.2
Percentage of Assets-3.2-4.1-4.2-3.6-3.8-4.0-3.7-3.8-3.4-3.2-2.7-3.0-2.9-3.5-3.8-3.9-2.7-3.1-3.5-3.5-2.9-2.7-2.5-1.6-0.3-0.1
Percentage of Assets us-gaap:AccumulatedTranslationAdjustment0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest


Stockholders
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-312008-12-312007-12-31
Value70315688656347365495645646533863447653965992459158637587166470124705417165661110586945874659840636016306663347649986712467180675877162278305769567806876620783547897782827816788211579961836778262190530889639053388265904465774065124
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets41.443.441.236.636.339.337.938.438.438.140.142.742.542.941.735.534.834.834.935.637.038.938.839.341.842.142.345.744.645.444.544.644.044.244.045.043.745.143.946.245.446.445.342.50.00.0

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

pfe:GSKConsumerHealthcare


Stockholders
Period End2020-09-272020-06-302020-03-312019-09-29
Value34400340573516335304
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest52.50.00.054.0
Percentage of Assets19.20.00.020.7
Percentage of Assets pfe:GSKConsumerHealthcare76.577.076.776.6

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap:StatementEquityComponents

us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCredit


Stockholders
Period End2021-07-042021-04-042020-12-312019-12-312018-12-312017-12-31
Value386419452584728750
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest0.50.60.70.91.11.0
Percentage of Assets0.20.30.30.30.50.4
Percentage of Assets us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCredit0.00.00.00.00.00.0

us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLoss


Stockholders
Period End2020-12-312019-12-312018-12-312017-12-31
Value-6507.0-6257.0-6027.0-5262.0
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-10.3-9.9-9.5-7.3
Percentage of Assets-4.2-3.7-3.8-3.1
Percentage of Assets us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLoss0.00.00.00.0

us-gaap:AccumulatedGainLossNetCashFlowHedgeParent


Stockholders
Period End2021-07-042021-04-042020-12-312019-12-312018-12-312017-12-31
Value-268.0-48.0-428.020167-30.0
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-0.4-0.1-0.70.00.3-0.0
Percentage of Assets-0.2-0.0-0.30.00.1-0.0
Percentage of Assets us-gaap:AccumulatedGainLossNetCashFlowHedgeParent0.00.00.00.00.00.0

us-gaap:AccumulatedNetUnrealizedInvestmentGainLoss


Stockholders
Period End2021-07-042021-04-042020-12-312019-12-312018-12-312017-12-31
Value79-26.0116-35.0-68.0401
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest0.1-0.00.2-0.1-0.10.6
Percentage of Assets0.0-0.00.1-0.0-0.00.2
Percentage of Assets us-gaap:AccumulatedNetUnrealizedInvestmentGainLoss0.00.00.00.00.00.0

us-gaap:AccumulatedOtherComprehensiveIncome


Stockholders
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-31
Value-4758.0-4664.0-11688.0-12676.0-13246.0-13131.0-11640.0-11801.0-11535.0-10923.0-11275.0-10417.0-10003.0-9402.0-9321.0-11036.0-9522.0-7316.0-3271.0-5953.0-4129.0-3440.0552-4569.02299
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-6.8-6.8-18.4-19.4-20.5-20.1-18.3-18.0-19.2-18.5-17.7-14.5-14.3-13.3-13.0-18.4-14.6-10.2-4.3-7.3-5.0-3.90.6-7.93.5
Percentage of Assets-2.8-2.9-7.6-7.1-7.4-7.9-6.9-6.9-7.4-7.0-7.1-6.2-6.1-5.7-5.4-6.4-5.7-4.3-1.9-3.2-2.2-1.80.30.00.0
Percentage of Assets us-gaap:AccumulatedOtherComprehensiveIncome0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedTranslationAdjustment


Stockholders
Period End2021-07-042021-04-042020-12-312019-12-312018-12-312017-12-31
Value-4955.0-5008.0-5321.0-5952.0-6075.0-5180.0
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-7.0-7.3-8.4-9.4-9.5-7.2
Percentage of Assets-2.9-3.2-3.5-3.6-3.8-3.0
Percentage of Assets us-gaap:AccumulatedTranslationAdjustment0.00.00.00.00.00.0

us-gaap:AdditionalPaidInCapital


Stockholders
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-31
Value89336890028867488161878868768087428870998696386635862538582884898845998427882685810167897777283726087142370760704977028369913
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest127.1129.2139.7134.6136.1134.2137.8133.2145.1146.4135.3119.8121.1119.9117.6138.2124.6110.3100.988.986.480.277.9121.7107.4
Percentage of Assets52.656.057.549.349.452.752.251.155.755.754.251.151.551.449.048.248.446.744.939.138.036.333.10.00.0
Percentage of Assets us-gaap:AdditionalPaidInCapital0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:CommonStock


Stockholders
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-31
Value472472470470470470468468468468467466465465464461459455453448445444443443442
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest0.70.70.70.70.70.70.70.70.80.80.70.70.70.70.60.80.70.60.60.50.50.50.50.80.7
Percentage of Assets0.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.20.20.20.20.00.0
Percentage of Assets us-gaap:CommonStock0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:NoncontrollingInterest


Stockholders
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-31
Value273245235236228312303293357352351346346358348296278321313418431452432184114
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest0.40.40.40.40.40.50.50.40.60.60.60.50.50.50.50.50.40.40.40.50.50.50.50.30.2
Percentage of Assets0.20.20.20.10.10.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.00.0
Percentage of Assets us-gaap:NoncontrollingInterest0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:Parent


Stockholders
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-31
Value70042686206323865259643366502663143651035956858806634077131969778701847130859544647207130176307812608219087813900145755665010
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest99.699.699.699.699.699.599.599.699.499.499.499.599.599.599.599.599.699.699.699.599.599.599.599.799.8
Percentage of Assets41.243.241.036.536.239.137.738.238.137.839.942.542.342.641.534.738.642.144.343.743.745.042.30.00.0
Percentage of Assets us-gaap:Parent0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:RetainedEarnings


Stockholders
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-31
Value9634695158967701002841002031010009767010011394440933888955491995898608996185291717747199372176697325424046210-42716.0404264914249660
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest137.0138.2152.5153.1155.2154.6153.9153.1157.6157.9140.5128.4128.1127.5119.0119.9110.8100.891.066.455.9-48.444.785.176.3
Percentage of Assets56.759.962.756.056.360.758.358.760.560.156.354.854.554.749.641.843.042.640.529.224.6-21.919.00.00.0
Percentage of Assets us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:TreasuryStock


Stockholders
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-31
Value-111356.0-111349.0-110988.0-110980.0-110978.0-111010.0-110801.0-110795.0-110786.0-110781.0-101610.0-96574.0-95463.0-95460.0-89425.0-84364.0-79252.0-73021.0-67923.0-40121.0-31801.0-22712.0-21632.0-57391.0-56847.0
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-158.4-161.7-174.9-169.4-171.9-169.9-174.6-169.4-184.9-187.3-159.4-134.8-136.1-135.3-124.8-141.0-121.9-102.0-88.6-49.1-38.5-25.7-23.9-99.4-87.3
Percentage of Assets-65.5-70.1-72.0-62.0-62.4-66.7-66.2-65.0-70.9-71.3-63.9-57.5-57.9-58.0-52.0-49.2-47.3-43.1-39.5-21.6-16.9-11.6-10.20.00.0
Percentage of Assets us-gaap:TreasuryStock0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Common Stock Value

us-gaap:CommonStockValue

us-gaap:CommonStockValue


Common
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value472472470470470470468468468468467466465465464463463463461461461460459459458458455455454454453452451450448447447446445445445444444443
Percentage of CommonStockValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.30.20.20.20.20.20.20.20.20.20.20.2

Additional Paid In Capital

us-gaap:AdditionalPaidInCapital

us-gaap:AdditionalPaidInCapital


Additional
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value8933689002886748816187886876808742887099869638663586253858288489884599842788382783373831118268582534821388144381016807638040780004789777849878208778497728376756764127577872608723177202771786714237123571095709257076070497
Percentage of AdditionalPaidInCapital100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets52.656.057.549.349.452.752.251.155.755.754.251.151.551.449.048.749.549.248.246.348.150.048.447.350.049.846.745.845.345.344.943.742.640.439.139.639.438.738.036.336.336.436.333.1

Retained Earnings Accumulated Deficit

us-gaap:RetainedEarningsAccumulatedDeficit

us-gaap:RetainedEarningsAccumulatedDeficit


Retained
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value96346951589677010028410020310100097670100113944409338889554919958986089961852917504374107748477177472846733507497171993740197362074471721767429271627720286973270381676285697254240512564790448124462104812144320449264271640426
Percentage of RetainedEarningsAccumulatedDeficit100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets56.759.962.756.056.360.758.358.760.560.156.354.854.554.749.643.644.044.341.840.843.046.043.043.345.846.442.643.441.541.940.540.137.730.429.228.126.225.924.624.522.623.021.919.0

us-gaap:RetainedEarningsAccumulatedDeficit us-gaap:DisposalGroupClassification, us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperations

us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoff, pfe:UpjohnInc


Retained
Period End2020-11-16
Value-1900.0
Percentage of RetainedEarningsAccumulatedDeficit0.0
Percentage of Assets0.0
Percentage of Assets us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoff pfe:UpjohnInc0.0

us-gaap:RetainedEarningsAccumulatedDeficit us-gaap:Restatement

pfe:ScenarioChangeInAccountingPrincipleAdjustment


Retained
Period End2021-07-042021-04-042020-12-31
Value177114-6378.0
Percentage of RetainedEarningsAccumulatedDeficit0.20.1-6.6
Percentage of Assets0.10.1-4.1
Percentage of Assets pfe:ScenarioChangeInAccountingPrincipleAdjustment0.00.00.0

pfe:ScenarioPreviousAccountingPrinciple


Retained
Period End2021-07-042021-04-042020-12-31
Value961699504496770
Percentage of RetainedEarningsAccumulatedDeficit99.899.9100.0
Percentage of Assets56.659.862.7
Percentage of Assets pfe:ScenarioPreviousAccountingPrinciple0.00.00.0

Accumulated Other Comprehensive Income Loss Net Of Tax

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax


Accumulated
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value-4758.0-4664.0-11688.0-12676.0-13246.0-13131.0-11640.0-11801.0-11535.0-10923.0-11275.0-10417.0-10003.0-9402.0-9321.0-9164.0-10181.0-10594.0-11036.0-8214.0-8891.0-9520.0-9522.0-9170.0-8521.0-8557.0-7316.0-3467.0-3152.0-3390.0-3271.0-6383.0-6465.0-6155.0-5953.0-5653.0-6008.0-3622.0-4129.0-1211.0-952.0-2056.0-3440.0552
Percentage of AccumulatedOtherComprehensiveIncomeLossNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets-2.8-2.9-7.6-7.1-7.4-7.9-6.9-6.9-7.4-7.0-7.1-6.2-6.1-5.7-5.4-5.3-6.0-6.3-6.4-4.6-5.2-5.8-5.7-5.4-5.3-5.3-4.3-2.0-1.8-2.0-1.9-3.6-3.6-3.3-3.2-3.1-3.3-2.0-2.2-0.6-0.5-1.1-1.80.3

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax us-gaap:Restatement

pfe:ScenarioChangeInAccountingPrincipleAdjustment


Accumulated
Period End2021-07-042021-04-042020-12-31
Value-168.0-141.06378
Percentage of AccumulatedOtherComprehensiveIncomeLossNetOfTax3.53.0-54.6
Percentage of Assets-0.1-0.14.1
Percentage of Assets pfe:ScenarioChangeInAccountingPrincipleAdjustment0.00.00.0

pfe:ScenarioPreviousAccountingPrinciple


Accumulated
Period End2021-07-042021-04-042020-12-31
Value-4589.0-4523.0-11688.0
Percentage of AccumulatedOtherComprehensiveIncomeLossNetOfTax96.497.0100.0
Percentage of Assets-2.7-2.8-7.6
Percentage of Assets pfe:ScenarioPreviousAccountingPrinciple0.00.00.0

Treasury Stock Value

us-gaap:TreasuryStockValue

us-gaap:TreasuryStockValue


Treasury
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value111356111349110988110980110978111010110801110795110786110781101610965749546395460894258942189416894148436484346843138431379252792597909879100730217182070535692046792363272595154483240121367033486333519318012858626471242152271221632
Percentage of TreasuryStockValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets65.570.172.062.062.466.766.265.070.971.363.957.557.958.052.051.953.053.049.247.349.451.747.346.449.249.243.141.940.940.339.536.033.223.921.620.119.118.116.914.613.512.411.610.2

Minority Interest

us-gaap:MinorityInterest

us-gaap:MinorityInterest


Minority
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-12-312009-12-31
Value273245235236228312303293357352351346346358348340326311296294297279278286286283321317323299313385430577418412414421431483482466452432
Percentage of MinorityInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.20.20.20.10.10.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.30.20.20.20.20.20.20.20.20.20.2

us-gaap:MinorityInterest us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

pfe:GSKConsumerHealthcare


Minority
Period End2020-09-272020-06-302020-03-312019-09-29
Value245138133105
Percentage of MinorityInterest103.80.00.035.8
Percentage of Assets0.10.00.00.1
Percentage of Assets pfe:GSKConsumerHealthcare0.50.30.30.2

Minority Interest Decrease From Distributions To Noncontrolling Interest Holders

us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders

us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders


Minority
Period End2020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value10.01.0800.01.0-2.08.00.05.00.07.00.0
Percentage of MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders100.0100.0100.00.0100.0100.0100.00.0100.00.0100.00.0
Percentage of Assets0.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders us-gaap:StatementEquityComponents

us-gaap:NoncontrollingInterest


Minority
Period End2020-12-312020-09-272020-06-282019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value10.01.0801.0-2.08.00.05.00.07.00.0
Percentage of MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders100.0100.0100.0100.0100.0100.00.0100.00.0100.00.0
Percentage of Assets0.00.00.00.00.00.00.00.00.00.00.0
Percentage of Assets us-gaap:NoncontrollingInterest0.00.00.00.00.00.00.00.00.00.00.0

Net Cash Provided By Used In Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetCashProvidedByUsedInOperatingActivities


Net
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-04-04
Value1129945385625209035553133376945102611169847385259384719836742488732521589597246993579165147135024409068553984463408729355786590838302241525650034021277452614439589846426683-6360.0
Percentage of NetCashProvidedByUsedInOperatingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax59.531.194.617.230.126.029.735.619.712.933.939.528.615.449.237.125.212.443.836.027.212.733.641.634.56.341.136.132.025.942.746.729.516.648.935.826.718.031.425.834.728.141.8-38.4

Net Cash Provided By Used In Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:NetCashProvidedByUsedInInvestingActivities


Net
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-04-04
Value-8137.0-1747.08330481-13011.0-71.0-2833.0-6760.0-1902.07550-764.0-2904.0-1474.09667-4779.0-2996.0-1738.04772-3107.0-4381.0-4678.04355-2224.0-5243.0-2105.06592-1514.0-2535.0-1507.0-98.080-611.0836-10930.06837-247.0-887.0451899215361725-3880.09394
Percentage of NetCashProvidedByUsedInInvestingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-42.9-12.0140.14.0-110.3-0.6-22.3-53.3-14.357.6-5.5-21.8-10.974.9-34.9-22.8-13.537.3-22.8-33.6-35.633.5-15.8-43.4-17.860.7-11.5-20.5-11.8-0.90.6-4.86.4-81.063.7-1.8-5.92.95.41.32.14.4-24.356.7

Net Cash Provided By Used In Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:NetCashProvidedByUsedInFinancingActivities


Net
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-04-04
Value-2557.0-2807.0-13787.0-2821.09159-2200.0-2440.03273-851.0-8467.0-6407.0-1406.0-1908.0-10720.0-3385.0-1728.0-3001.0-4921.0-2228.0-1624.01945-7014.0-1109.0-267.0-1875.0-6982.0-2926.0-2887.0-2040.0-2133.0-5744.0-5631.0-4034.0434-6233.0-3291.0-2968.0-3507.0-6250.0-4035.0-3918.0-6404.0-2523.0-3211.0
Percentage of NetCashProvidedByUsedInFinancingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-13.5-19.2-231.8-23.377.6-18.3-19.225.8-6.4-64.5-45.8-10.6-14.2-83.1-24.7-13.1-23.3-38.5-16.3-12.414.8-53.9-7.9-2.2-15.8-64.3-22.3-23.4-16.0-18.8-42.4-44.5-31.13.2-58.0-23.5-19.7-22.8-37.3-23.5-23.1-38.8-15.8-19.4

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect


Cash
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value608-15.0198-218.0-351.0846-1495.01008-180.0792-2432.0846396985-1428.0198-1470.01465
Percentage of CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.2-0.13.3-1.8-3.07.0-11.87.9-1.46.0-17.46.42.97.6-10.41.5-11.411.5

Deferred Income Tax Expense Benefit

us-gaap:DeferredIncomeTaxExpenseBenefit

us-gaap:DeferredIncomeTaxExpenseBenefit


Deferred
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-04-04
Value-152.0199-871.0-668.0-38.0109-1453.02227-100.0-60.0-1231.0-474.0-794.0294-2651.0-79.028238635-1325.0194-204.014518-142.0-41.0-446.0-87.050834559413327927642217284-404.0-429.0188625-120.0-333.0840
Percentage of DeferredIncomeTaxExpenseBenefit100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DeferredIncomeTaxExpenseBenefit us-gaap:Restatement

pfe:ScenarioChangeInAccountingPrincipleAdjustment


Deferred
Period End2021-07-042021-04-042020-06-282020-03-29
Value1932264.0
Percentage of DeferredIncomeTaxExpenseBenefit-12.516.1-68.43.7

pfe:ScenarioPreviousAccountingPrinciple


Deferred
Period End2021-07-042021-04-042020-06-282020-03-29
Value-171.0167-74.077
Percentage of DeferredIncomeTaxExpenseBenefit112.583.9194.770.6

Net Cash Provided By Used In Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetCashProvidedByUsedInOperatingActivities


Net
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-04-04
Value1129945385625209035553133376945102611169847385259384719836742488732521589597246993579165147135024409068553984463408729355786590838302241525650034021277452614439589846426683-6360.0
Percentage of NetCashProvidedByUsedInOperatingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax59.531.194.617.230.126.029.735.619.712.933.939.528.615.449.237.125.212.443.836.027.212.733.641.634.56.341.136.132.025.942.746.729.516.648.935.826.718.031.425.834.728.141.8-38.4

Net Income Loss

us-gaap:NetIncomeLoss

us-gaap:NetIncomeLoss


Net
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value55634877594219434263401-336.0768050463884-393.041143872356112274284030733121860132020193016-172.02130262623761228266629122329256825901409527506315320832531794143937382610222286624752026
Percentage of NetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.333.410.018.129.028.3-2.660.638.029.6-2.830.928.827.689.621.623.824.46.310.115.423.2-1.217.622.221.99.421.622.820.518.920.5108.620.458.823.021.611.68.621.715.413.55.414.412.2

us-gaap:NetIncomeLoss us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

pfe:ConsumerHealthcareJV


Net
Period End2021-03-312020-12-312020-03-312019-12-31
Value46122140537
Percentage of NetIncomeLoss0.037.20.0-11.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ConsumerHealthcareJV0.00.00.00.0

pfe:GSKConsumerHealthcare


Net
Period End2020-09-272020-06-302020-03-312019-09-29
Value348518405148
Percentage of NetIncomeLoss15.90.00.01.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:GSKConsumerHealthcare0.00.00.00.0

us-gaap:NetIncomeLoss us-gaap:Restatement

pfe:ScenarioChangeInAccountingPrincipleAdjustment


Net
Period End2021-07-042021-04-042020-06-282020-03-29
Value6311462-47.0
Percentage of NetIncomeLoss1.12.31.8-1.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.80.5-0.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ScenarioChangeInAccountingPrincipleAdjustment0.00.00.00.0

pfe:ScenarioPreviousAccountingPrinciple


Net
Period End2021-07-042021-04-042020-06-282020-03-29
Value5500476334263401
Percentage of NetIncomeLoss98.997.7100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.032.729.028.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ScenarioPreviousAccountingPrinciple0.00.00.00.0

Profit Loss

us-gaap:ProfitLoss

us-gaap:ProfitLoss


Profit
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value55894886606220234343410-326.0768450563889-383.041223879357012289285830783130866131920353026-169.02139263523811236267229212338257425991413427656321321432601803145037492618223487124852035
Percentage of ProfitLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.533.510.218.229.128.4-2.660.638.129.6-2.731.028.827.789.721.723.924.56.410.115.523.3-1.217.722.221.99.421.622.920.619.020.6108.920.558.923.021.711.78.721.815.413.55.414.512.3

us-gaap:ProfitLoss us-gaap:EquityMethodInvestmentNonconsolidatedInvestee

pfe:ConsumerHealthcareJV


Profit
Period End2021-03-312020-12-312020-03-312019-12-31
Value48323342546
Percentage of ProfitLoss0.038.40.0-14.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ConsumerHealthcareJV0.00.00.00.0

pfe:GSKConsumerHealthcare


Profit
Period End2020-09-272020-06-302020-03-312019-09-29
Value355524425152
Percentage of ProfitLoss16.10.00.02.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:GSKConsumerHealthcare0.00.00.00.0

us-gaap:ProfitLoss us-gaap:Restatement

pfe:ScenarioChangeInAccountingPrincipleAdjustment


Profit
Period End2021-07-042021-04-042020-06-282020-03-29
Value6311462-47.0
Percentage of ProfitLoss1.12.31.8-1.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.80.5-0.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ScenarioChangeInAccountingPrincipleAdjustment0.00.00.00.0

pfe:ScenarioPreviousAccountingPrinciple


Profit
Period End2021-07-042021-04-042020-06-282020-03-29
Value5526477234343410
Percentage of ProfitLoss98.997.7100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.132.729.128.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax pfe:ScenarioPreviousAccountingPrinciple0.00.00.00.0

us-gaap:ProfitLoss us-gaap:StatementEquityComponents

us-gaap:NoncontrollingInterest


Profit
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value269.0118.08.09.010.04.010.06.0118.07.09.0
Percentage of ProfitLoss0.50.21.80.40.20.3-3.10.10.20.2-2.90.20.20.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.10.10.20.10.10.10.10.00.10.00.10.10.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NoncontrollingInterest0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:Parent


Profit
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value55634877594219434263401-336.0768050463884-393.0411438723561
Percentage of ProfitLoss99.599.898.099.699.899.7103.199.999.899.9102.699.899.899.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.333.410.018.129.028.3-2.660.638.029.6-2.830.928.827.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:Parent0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:RetainedEarnings


Profit
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-01
Value55634877594219434263401-336.0768050463884-393.0411438723561
Percentage of ProfitLoss99.599.898.099.699.899.7103.199.999.899.9102.699.899.899.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.333.410.018.129.028.3-2.660.638.029.6-2.830.928.827.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Share Based Compensation

us-gaap:ShareBasedCompensation

us-gaap:ShareBasedCompensation


Share
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-04-04
Value222172264234194642706419918526730319718224520717021815914524414318114118516216214313814310512610318911911511713072103122122108138
Percentage of ShareBasedCompensation100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Net Cash Provided By Used In Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:NetCashProvidedByUsedInInvestingActivities


Net
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-04-04
Value-8137.0-1747.08330481-13011.0-71.0-2833.0-6760.0-1902.07550-764.0-2904.0-1474.09667-4779.0-2996.0-1738.04772-3107.0-4381.0-4678.04355-2224.0-5243.0-2105.06592-1514.0-2535.0-1507.0-98.080-611.0836-10930.06837-247.0-887.0451899215361725-3880.09394
Percentage of NetCashProvidedByUsedInInvestingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-42.9-12.0140.14.0-110.3-0.6-22.3-53.3-14.357.6-5.5-21.8-10.974.9-34.9-22.8-13.537.3-22.8-33.6-35.633.5-15.8-43.4-17.860.7-11.5-20.5-11.8-0.90.6-4.86.4-81.063.7-1.8-5.92.95.41.32.14.4-24.356.7

Payments To Acquire Property Plant And Equipment

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment


Payments
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-04-04
Value540554785525479463672565479460685547424386700450448358689432401301611289258239354275278292417278309202494285294254598454358250288305
Percentage of PaymentsToAcquirePropertyPlantAndEquipment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Net Cash Provided By Used In Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:NetCashProvidedByUsedInFinancingActivities


Net
Period End2021-07-042021-04-042020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272015-06-282015-03-292014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-012011-12-312011-10-022011-07-032011-04-032010-10-032010-04-04
Value-2557.0-2807.0-13787.0-2821.09159-2200.0-2440.03273-851.0-8467.0-6407.0-1406.0-1908.0-10720.0-3385.0-1728.0-3001.0-4921.0-2228.0-1624.01945-7014.0-1109.0-267.0-1875.0-6982.0-2926.0-2887.0-2040.0-2133.0-5744.0-5631.0-4034.0434-6233.0-3291.0-2968.0-3507.0-6250.0-4035.0-3918.0-6404.0-2523.0-3211.0
Percentage of NetCashProvidedByUsedInFinancingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-13.5-19.2-231.8-23.377.6-18.3-19.225.8-6.4-64.5-45.8-10.6-14.2-83.1-24.7-13.1-23.3-38.5-16.3-12.414.8-53.9-7.9-2.2-15.8-64.3-22.3-23.4-16.0-18.8-42.4-44.5-31.13.2-58.0-23.5-19.7-22.8-37.3-23.5-23.1-38.8-15.8-19.4

Proceeds From Issuance Of Long Term Debt

us-gaap:ProceedsFromIssuanceOfLongTermDebt

us-gaap:ProceedsFromIssuanceOfLongTermDebt


Proceeds
Period End2020-12-312020-09-272020-06-282020-03-292019-12-312019-09-292019-06-302019-03-312018-12-312018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-12-312016-10-022016-07-032016-04-032015-12-312015-09-272014-12-312014-09-282014-06-292014-03-302013-12-312013-09-292013-06-302013-03-312012-12-312012-09-302012-07-012012-04-01